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ABSTRACT 
Applications of Functional Carbon Nanomaterials 
from Hydrogen Storage to Drug Delivery 
by 
Ashley Dawn Leonard 
This dissertation describes the modification and functionalization of single-walled 
carbon nanotubes (SWCNTs). These SWCNTs were then investigated for their use in 
medical applications and for the storage of hydrogen. 
A technique was developed that leads to highly customized, individually 
suspended aqueous solutions of SWCNTs. These newly generated water-soluble 
SWCNTs were then functionalized further in water, thereby permitting the second 
functionalization addends to be chemically sensitive functional groups, for example drugs, 
that would not withstand the strongly acidic conditions of the first functionalization. 
The radical scavenging properties of nanovectors derived from SWCNTs were 
investigated and it was found that even the poorest SWCNT nanovector studied was 
nearly 40 times more effective at scavenging radicals than dendrite-fullerene DF-1, which 
has been shown to be a radioprotective to zebrafish via an antioxidant mechanism. This 
was used as the base to investigate using SWCNTs as protectors and mitigators of 
radiation exposure. 
SWCNTs were then explored for their use as drug delivery agents, in particular, 
the water insoluble chemotherapy drug, paclitaxel. SWCNTs showed promising in vivo 
and in vitro efficacy in the delivery of paclitaxel. Toxicity and biodistribution studies of 
the SWCNTs as drug delivery agents were performed in vivo using SWCNTs 
functionalized with radiolabeled indium. 
It was found that SWCNTs could be used for hydrogen storage by chemically 
crosslinking 3-dimensional frameworks of SWCNT fibers. These frameworks were 
shown to physisorb twice as much hydrogen, at low pressures, with respect to their 
surface areas, than typical macroporous carbon materials. This makes these SWCNT 
frameworks attractive materials for the development of a hydrogen vehicle fuel tank. 
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Introduction 
2 
Single-Walled Carbon Nanotubes 
Since their discovery in 1993,12 single-walled carbon nanotubes (SWCNTs) have 
attracted the attention of scientists for a multitude of different applications from materials 
science3'4 to medicinal chemistry5'6 because of their many unique properties. SWCNTs 
are 1 nm in diameter and can be microns in length; they are stronger than steel,7"10 have 
the chemistry of carbon and the thermal conductivity of diamond,11 and can have the 
electrical conductivity of either copper or silicon,12'13 leading to a plethora of 
applications.11 
Multifunctional Nanovector 
Of particular interest to us is the use of multi-functional SWCNTs as drug 
delivery agents. This multi-functional nano-sized particle would have a combination of 
features including the ability to transport drugs, to target specific cells or areas of the 
body, the ability to traverse specific membranes and barriers, and to fluoresce or act as a 
contrast agent, while remaining soluble in a biological system; this is depicted in Figure 
l.14 A multi-functional SWCNT could contain some or all of these features. 
Therapeutic or Biological surface 
imaging payload modifier 
C Z 3 Drug A ( j & P E G 
O Drug B Y ^Target ing moieties 
Contrast enhancer 
Permeation enhancer 
Core constituent 
material 
Figure l.14 Multi-functional nanomaterial containing solubilizing agents, targeting 
moieties, imaging agents, permeation enhancers, and drugs. 
3 
A) Solubilization of SWCNTs 
One down fall of SWCNTs is that they tend to bundle together due to their strong 
van der Waals attractions of 0.5 eV/nm between adjacent nanotubes.15'16 In this bundled 
form the SWCNTs are not soluble in water nor phosphate buffered saline (PBS), which is 
a necessity for the creation of a multifunctional SWCNT. This solubility problem can be 
overcome by functionalizing the SWCNTs. 
Many different functionalization and solublization methods have been developed 
from simply wrapping the SWCNTs with polymers,17 to covalent functionalization of the 
sidewalls of the SWCNTs.18"23 Figure 2 depicts a few of the functionalization/ 
solubilization methods developed to date. 
/TS 
RH 
R =CH,(ChL)1 J 
CI-fyCI-Qxl 
CH3(CH2)3Br 
CH3CH3CHICH3 
THP O (CH2)3I HjNCOCHJT 
NaNO. 
AIBN 
a. R = H, X=H to b. R=S03H, X=H oleum 
a. R=N02, X=Hto b. R=ND2, X=SO,H 
a. R=CI, X=H to b. R=CI, X=SO,H 
a. R=t-butyl, X=H to b. t-butyl, X=H and S03H 
a. R=CH2CH2OH, X=H to b. R=CH2CH2OH, X=S03H 
a. R=SO,H, X=H to b. R=SO ' ' ' " 
Figure 2. Different functionalization/solubilization methods for SWCNTs. A. Oleum 
functionalization.19 B. Reductive alkylation.21 C. Surfactant wrapping.17 D. Solvent free 
i x • functionalization. E. Fluorination. F. Noncovalent funcationalization. 18 24 
Many of the techniques described above require high-powered sonication or 
centrifugation, or for bulk preparation, require oleum (fuming sulfuric acid; H2SO4 with 
dissolved SO3) to disperse the SWCNTs as individuals followed by functionalization via 
5 
diazonium chemistry. We developed a technique that leads to highly customized, 
individually suspended aqueous SWCNT systems. These newly generated water-soluble 
SWCNTs were then functionalized further in water as the only solvent, thereby 
permitting the second functionalization addends to be chemically sensitive functional 
groups that would not withstand the strongly acidic conditions of the first 
functionalization. This allows for the synthesis of SWCNTs containing functional groups 
that are not accessible via the oleum method alone, such as biologically important 
molecules that would decompose under the oleum conditions described above. 
With this new repetitive functionalization method, we were able to take 
previously developed water-soluble US-SWCNTs that have highly defective sidewalls, 
bearing many carboxylic acids, and render them soluble in PBS by covalent attachment 
of polyethylene glycol (PEG). These new PEGylated US-SWCNTs became the base 
material of the multifunctional nanovector described above. 
B) Drug attachment 
Once the core of the multifunctional nanovector is developed, payloads can be 
attached. Many methods have been developed to attach active moieties or payloads to 
nanomaterials. Some of the more common methods are covalent attachment through 
either a cleavable or non-cleavable linker; wrapping the nanomaterial with the payload, 
or more commonly wrapping the nanomaterial and payload with dendrimers or polymers, 
in effect, sequestrating the payload. 
For the research discussed here, the PEG groups in PEG-SWCNTs act as 
solubilizing tentacles that can absorb a hydrophobic molecule in an unfavorable, aqueous 
6 
environment and into a more favorable, organic PEG-SWCNT matrix, thereby lowering 
the free energy of the system. The PEG-SWCNT matrix can then deliver the payload to 
the site, organ, or cell of interest. Thus, PEG-SWCNTs are an attractive material to be 
used as a vector to deliver hydrophobic molecular cargo, such as paclitaxel, a water 
insoluble anti-cancer drug. In addition, PEG-SWCNTs could serve as a protective 
barrier, theoretically sheltering the drug or payload from premature destruction within the 
body before it reaches the final destination of the cell. 
C) Imaging 
In order to track the newly developed multi-functional nanovector, several 
different imaging methods have been employed. SWCNTs have an inherent fluorescence 
because of their extended conjugation which allows for direct imaging using a fluorescent 
97 
microscope. But, once the SWCNTs are covalently functionalized, their fluorescence 
"3 
quickly diminishes due to disruption of the extended conjugation with sp bonds, thereby 
eliminating this option for functionalized SWCNTs. Fluorescent tags can also be 
covalently attached to the SWCNTs, but the SWCNTs quench much of their fluorescence 
making imaging difficult. Another method of imaging SWCNTs is loading the SWCNTs 
with contrast agents such as gadolinium, which has been shown to be the best contrast 
agent system to date, but this is currently limited to SWCNTs that have been cut using 
fluorine followed by heating. 
We chose to radiolabel the PEGylated US-SWCNTs with l u In , which has been 
studied previously in SWCNT research.29'30 Indium has a long half life of 2.8 days 
making it a good candidate for biodistribution and imaging of the PEG-HCCs. 
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D) Radical Scavenging 
Another interesting property of SWCNTs that could be an attractive property of 
o 1 10 
the multifunctional nanovector is their ability to behave as radical scavengers. 
Radical scavenging may occur via radical addition to the curved, sp2-hybridized carbon 
nanotube framework.3435 We were able to show that SWCNT vectors are potent 
antioxidants, even the poorest SWCNT nanovector studied was nearly 40 times more 
effective at scavenging radicals than dendrite-fullerene DF-1, which was shown to be a 
radioprotective to zebrafish via an antioxidant mechanism. Taking advantage of the 
radical scavenging ability of SWCNTs has paved the way for many medicinal 
applications. 
E) Medicinal Applications 
Multifunctional nanovectors have a broad range of applications within the field of 
•yn 
medicine with some nanomaterials already close to clinical trials. We are currently 
using the described nanovector for applications in radiation protection and mitigation, 
traumatic brain injury,38 radiation exposure sickness,39'40 Alzheimer's disease,41 cancer 
therapy, tissue reinforcement, and spinal cord injury. We are already seeing promising 
results in some of these applications. 
Other SWCNT Applications: Hydrogen Storage 
Growing concerns regarding the accessibility of hydrocarbon fuels and their 
environmental impact have led to global interest in developing hydrogen-fueled 
vehicles.42 Problematically, compressed hydrogen gas tanks are heavy and 
8 
volumetrically large if they are to provide the equivalent energy content derivable from 
conventional liquid gasoline tanks, and the use of high pressure hydrogen tanks in 
consumer automobiles lessens their attractiveness. But hydrogen that is reversibly bound 
to a light-weight solid phase support provides an attractive alternative to the large volume, 
weight and pressure tanks currently being explored.43 
The use of physisorption rather than chemisorption of hydrogen atoms to a 
surface eliminates the need for high heating to desorb the hydrogen from the solid phase, 
thereby providing for faster kinetics of release making SWCNTs attractive materials for 
hydrogen storage. SWCNTs would be stable upon cycling, and can provide good thermal 
conductivity to dissipate the heat of adsorption. Chemically crosslinked 3-dimensional 
(3-D) frameworks of SWCNT fibers were fabricated. They physisorb twice as much 
hydrogen, at low pressures, with respect to their surface areas, than typical macroporous 
carbon materials, making them attractive materials for developing a hydrogen vehicle 
adsorption bed. 
Conclusions 
SWCNTs have promise in many different areas from materials science to 
medicinal chemistry because of their unique properties. The work herein focuses on their 
use for medical applications and for the storage of hydrogen. 
References 
1. Iijima, S.; Ichihashi, T. Nature 1993, 363, 603-605. 
9 
2. Bethune, D. S.; Kiang, C. H.; de Vries, M. S.; Gorman, G.; Savoy, R.; Vazquez, 
J.; Beyers, R. Nature 1993, 363, 605-607. 
3. Bellucci, S. Phys. Status Solidi C 2005, 2, 34-47. 
4. Dyke, C. A.; Tour, J. M. J. Phys. Chem. A FIELD Full Journal Title:Journal of 
Physical Chemistry A 2004, 70S, 11151 -11159. 
5. Mishra, L.; Dwivedi, S.; Pandey, D.; Dwivedi, A.; Tomar, G. S. PharmaChem 
2008, 7, 16-20. 
6. Singh, I.; Rehni, A. K.; Kumar, P.; Kumar, M.; Aboul-Enein, H. Y. Fullerenes, 
Nanotubes, Carbon Nanostruct. FIELD Full Journal Title:Fullerenes, Nanotubes, 
and Carbon Nanostructures 2009,17, 361-377. 
7. Ajayan, P. M.; Schadler, L. S.; Giannaris, C.; Rubio, A. Adv. Mater. 2000, 12, 
750-753. 
8. Gao, G.; Cagin, T.; Goddard, W. A., Ill Nanotech 1998, 9, 184-191. 
9. Yu, M.-F.; Files, B. S.; Arepalli, S.; Ruoff, R. S. Phys. Rev. Lett. 2000, 84, 5552-
5555. 
10. Wong, E. W.; Sheehan, P. E.; Lieber, C. M. Science 1997, 277, 1971-1975. 
11. Baughman, R. H.; Zakhidov, A. A.; de Heer, W. A. Science 2002, 297, 787-792. 
12. Avouris, P. Chem. Phys. 2002, 281, 429-445. 
13. Louie, S. G. Top. Appl. Phys. 2001, 80, 113-145. 
14. Ferrari, M. Nat. Rev. Cancer 2005, 5,161-171. 
15. O'Connell, M. J.; Boul, P.; Ericson, L. M.; Huffman, C.; Wang, Y.; Haroz, E.; 
Kuper, C.; Tour, J.; Ausman, K. D.; Smalley, R. E. Chem. Phys. Lett. 2001, 342, 
265-271. 
16. Thess, A.; Lee, R.; Nikolaev, P.; Dai, H.; Petit, P.; Robert, J.; Xu, C.; Lee, Y. H.; 
Kim, S. G.; et al. Science 1996, 275, 483-487. 
17. Moore, V. C.; Strano, M. S.; Haroz, E. H.; Hauge, R. H.; Smalley, R. E.; Schmidt, 
J.; Talmon, Y. Nano Lett. 2003, 3, 1379-1382. 
18. Mickelson, E. T.; Huffman, C. B.; Rinzler, A. G.; Smalley, R. E.; Hauge, R. H.; 
Margrave, J. L. Chem. Phys. Lett. 1998, 296, 188-194. 
19. Hudson, J. L.; Casavant, M. J.; Tour, J. M. J. Am. Chem. Soc. 2004, 126, 11158-
11159. 
20. Liang, F.; Beach, J. M.; Rai, P. K.; Guo, W.; Hauge, R. H.; Pasquali, M.; Smalley, 
R. E.; Billups, W. E. Chem. Mater. 2006,18, 1520-1524. 
21. Liang, F.; Sadana, A. K.; Peera, A.; Chattopadhyay, J.; Gu, Z.; Hauge, R. H.; 
Billups, W. E. Nano Lett. 2004, 4, 1257-1260. 
22. Dyke, C. A.; Tour, J. M. J. Am. Chem. Soc. 2003,125, 1156-1157. 
23. Stephenson, J. J.; Hudson, J. L.; Leonard, A. D.; Price, B. K.; Tour, J. M. Chem. 
Mater. 2007,19, 3491-3498. 
24. Chen, R. J.; Zhang, Y.; Wang, D.; Dai, H. J. Am. Chem. Soc. 2001, 123, 3838-
3839. 
25. Hudson, J. L.; Jian, H.; Leonard, A. D.; Stephenson, J. J.; Tour, J. M. Chem. 
Mater. 2006,18, 2766-2770. 
26. Stinchcombe, T. E. Nanomedicine 2007, 2, 415-423. 
27. Cherukuri, P.; Gannon, C. J.; Leeuw, T. K.; Schmidt, H. K.; Smalley, R. E.; 
Curley, S. A.; Weisman, R. B. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 18882-
18886. 
11 
28. Hartman, K. B.; Laus, S.; Bolskar, R. D.; Muthupillai, R.; Helm, L.; Toth, E.; 
Merbach, A. E.; Wilson, L. J. Nano Lett. 2008, 8, 415-419. 
29. Villa, C. H.; McDevitt, M. R.; Escorcia, F. E.; Rey, D. A.; Bergkvist, M.; Batt, C. 
A.; Scheinberg, D. A. Nano Lett. 2008, 8, 4221-4228. 
30. Liu, Z.; Cai, W.; He, L.; Nakayama, N.; Chen, K.; Sun, X.; Chen, X.; Dai, H. Nat. 
Nanotechnol. 2007, 2, 47-52. 
31. Watts, P. C. P.; Fearon, P. K.; Hsu, W. K.; Billingham, N. C.; Kroto, H. W.; 
Walton, D. R. M. J. Mater. Chem. 2003,13, 491-495. 
32. Fenoglio, I.; Tomatis, M.; Lison, D.; Muller, J.; Fonseca, A.; Nagy Janos, B.; 
Fubini, B. Free Radic Biol Med 2006, 40, 1227-1233. 
33. Galano, A. J. Phys. Chem. C 2008,112, 8922-8927. 
34. Ying, Y.; Saini, R. K.; Liang, F.; Sadana, A. K.; Billups, W. E. Org. Lett. 2003, 5, 
1471-1473. 
35. Engel, P. S.; Billups, W. E.; Abmayr, D. W., Jr.; Tsvaygboym, K.; Wang, R. J. 
Phys. Chem. C2008,112, 695-700. 
36. Daroczi, B.; Kari, G.; McAleer, M. F.; Wolf, J. C.; Rodeck, U.; Dicker, A. P. Clin. 
Cancer Res. 2006,12, 7086-7091. 
37. Lai, S.; Clare, S. E.; Halas, N. J. Acc. Chem. Res. 2008, 41, 1842-1851. 
38. Rigg John, L.; Elovic Elie, P.; Greenwald Brian, D. J Head Trauma Rehabil 2005, 
20, 389-391. 
39. Milas, L.; Hunter, N.; Reid, B. O. Int. J. Radiat. Oncol., Biol. Phys. 1982, 8, 535-
538. 
12 
40. Korkina, L. G.; Afanas'ef, I. B.; Diplock, A. T. Biochem. Soc. Trans. 1993, 21, 
314S. 
41. Reddy, P. H. J. Biomed. Biotechnol 2006, No pp given. 
42. Hefner, R. A., Ill Int. J. Hydrogen Energy 2002, 27, 1-9. 
43. Morris, R. E.; Wheatley, P. S. Angew. Chem. Int. Ed. 2008, 47, 4966-4981. 
13 
Chapter 1 
Repetitive Functionalization of Water-Soluble Single-Walled Carbon Nanotubes. 
Addition of Acid-Sensitive Addends 
14 
1.1 Introduction 
The preparation of water-soluble single walled carbon nanotubes (SWCNTs) in 
1 8 
bulk quantities has been addressed in the literature. " Many of these techniques require 
high-powered sonication or centrifugation, or for bulk preparation, require oleum (fuming 
sulfuric acid; H2SO4 with dissolved SO3) to disperse the SWCNTs as individuals 
followed by functionalization via diazonium chemistry. There are many limitations with 
these previous methods for generating individual SWCNTs. We have developed a 
technique which leads to highly customized, individually suspended aqueous SWCNT 
systems. We then take those newly generated water-soluble SWCNTs and functionalize 
them further in water as the only solvent; thereby permitting the second functionalization 
addends to be chemically sensitive9 functional groups that are not able to withstand 
strongly acidic conditions. This allows for the synthesis of SWCNTs containing 
functional groups that are not accessible via the oleum method alone, such as biologically 
important molecules that would decompose under the oleum conditions described 
above.10 By using the oleum procedure as the source for individualized SWCNTs, and 
following this with aqueous aryldiazonium chemistry, it is possible to obtain water-
soluble SWCNTs with a variety of functional groups that can be customized to fit a 
desired application. 
Of particular interest to us, is the application of multi-functional SWCNTs as drug 
delivery agents. One way to overcome the adverse effects of some drug treatments is to 
mask the drug, or make it inactive, until it reaches the location of action. Once the 
masked drug has reached its destination it can then be unmasked to reveal the active 
compound only in the targeted disease area. Masked drugs are commonly known as 
15 
prodrugs and have been used extensively in medicine to treat a number of conditions.11 A 
further extension of this concept is to use a multi-functional nano-sized particle that has a 
combination of features including the ability to transport drugs, to target specific cells or 
areas of the body, the ability to traverse specific membranes and barriers, and to fluoresce 
or act as a contrast agent, while remaining soluble in a biological system; this is depicted 
in Figure 1.1.12 A multi-functional SWCNT could contain some or all of these features, 
using this newly developed chemistry. 
a tkr 
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Figure 1.1.12 Multi-functional nanomaterial containing solubilizing agents, targeting 
moieties, imaging agents, permeation enhancers, and drugs. 
1.2 Results and Discussion 
To produce water-soluble SWCNTs we used an oleum functionalization method1 to 
add sulfonated 4-chlorophenyl moieties to the sidewalls of the SWCNTs to give 1. 
Scheme 1.1 shows the general method for the repetitive functionalization of SWCNTs. 
After initial functionalization, 1 was dispersed in water by homogenization and treated 
with a variety of diazonium salts. The diazonium salts functionalized the tubes and 
provided a bi-modal functionality to the sidewall of the SWCNTs. Note that some arene 
radical addition to the existing pendants will occur with the addition of the diazonium salt. 
16 
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2-9 
H 2 0 
pH 10 
2 R = ferf-butyl 
3 R = COOH 
4 R = COOCH3 
5 R = N0 2 
6 R = F 
7 R = CI 
8 R = Br 
9 R = I 
10 R = ferf-butyl 
11 R = COOH 
12 R = COOCH3 
13 R = N0 2 
14 R = F 
15 R = CI 
16 R = Br 
17 R = I 
Scheme 1.1. The repetitive functionalization protocol. Water-soluble SWCNTs (1) are 
reacted with a variety of diazonium salts (2-9) to produce multi-functional SWCNTs 10-
17. 
The second technique for providing water-soluble SWCNTs was to make 
carboxylated ultrashort-SWCNTs (US-SWCNTs) by cutting the nanotubes in a mixture 
of oleum and nitric acid;13 shorter lengths of cut SWCNTs can be obtained by increasing 
the cutting temperature (from 30 °C yielding 98 nm average length to 70 °C yielding 32 
nm average length).13'14 These tubes contain defect sites with carboxylic acids that can be 
17 
exploited for further functionalization. The US-SWCNTs were then treated with 
poly(ethylene glycol) (PEG)-amine and iV,yV-dicyclohexylcarbodiimide (DCC) in dry 
DMF to covalently bind the PEG chains to the carboxylic acids located at the defect sites 
(Scheme 1.2).15'16 
Scheme 1.2. US-SWCNTs 18-22 that are produced by chemically cutting and oxidizing 
SWCNTs at varying reaction temperatures are coupled with PEG-amine to make 
PEGylated US-SWCNTs 23-27, respectively. 
After this process was complete, the material was transferred to a dialysis bag (50,000 
MWCO) and dialyzed in water for 5 d to remove any unbound PEG-amine. This process 
yielded material that is soluble in water, irrigation saline, and phosphate buffered saline 
C0 2H 
CONH-PEG 
'CONH-PEG 
CONH-PEG 
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(PBS). To test solubility in PBS and irrigation saline, the concentrated PEGylated US-
SWCNTs or US-SWCNTs, in water, were diluted with PBS or saline, see Figure 1.2. 
A B 
Figure 1.2. PBS solubility test showing that A) US-SWCNTs flocculate while in PBS 
whereas B) PEGylated US-SWCNTs are soluble in PBS. 
The water-soluble PEGylated US-SWCNTs that were cut at room temperature 
(23) then underwent diazonium salt functionalization using a variety of diazonium salts 
(5-7, 9) as shown in Scheme 1.3. This again gives multi-functionality to the SWCNTs 
28-31. These PEGylated US-SWCNTs remained soluble in water after the repetitive 
functionalization. 
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28 R = NO. 
29 R = F ' 
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Scheme 1.3. Water-soluble PEGylated US- SWCNTs (23) are functionalized with a 
variety of diazonium salts (5-7, 9) to produce PEGylated US-SWCNTs 28-31 that are 
multi-functional. 
To demonstrate a possible biological application of this system, the PEGylated US-
SWCNTs were then functionalized with acid sensitive moieties, such as biotin. Other 
molecules besides biotin could be attached which could be used as imaging, targeting, or 
drug delivery agents. Once biotin was attached, the SWCNTs still maintained solubility 
in water and PBS as shown in Scheme 4. 
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Scheme 1.4. Water-soluble PEGylated US-SWCNTs (23) are functionalized with an 
acid sensitive moiety, biotin, to produce a water soluble multifunctional SWCNT (32). 
1.3 Characterization 
Each of the SWCNT products from repetitive functionalizations (10-17) showed 
an increase in the D/G ratio in the Raman spectrum compared to arylsulfonic acid 
SWCNT 1. The D/G ratio is the ratio of the disorder mode (diamondoid or D-band, 1290 
1 1 
cm"), characteristic of the sp -hybridized carbons, compared to the tangential mode 
(graphitic or G-band, 1594 cm"1), characteristic of the sp2-hybridized carbons remaining 
21 
on the nanotube.9a Figure 1.3 is a representative Raman spectrum showing an increase in 
the functionalization of 15 compared to 1 by the increase of the D band. 
Figure 1.3. Representative Raman spectrum (633 nm excitation) showing starting 
material 1 and repetitive functionalization product 15. The increase of the D band in 15 
is indicative of an increase in sidewall functionalization. 
Table 1.1 shows the Raman D/G value for each functionalized product and a 
calculation for the functional groups per nanotube carbon based on thermogravimetric 
analysis (TGA) weight loss. 
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Cmpd Raman D/G TGA wt loss (%) Functional Group 
Coverage 
1 0.38 29 1/30 
10 0.55 35 1/20 
11 0.58 31 1/20 
12 0.76 40 1/25 
13 0.65 36 1/21 
14 0.65 23 1/27 
15 0.58 34 1/18 
16 0.62 43 1/17 
17 0.63 53 1/15 
Table 1.1. Raman D/G ratio and TGA-determined weight loss for functionalized 
SWCNTs 1, 10-17. Representative Raman (633 nm excitation) D/G values were 
averaged over five scans per sample. TGA results show total mass loss. Total mass loss 
was attributed to functional groups covalently attached to the sidewall. Using the mass 
loss and the molecular weight of the functional group fragment, the number of moles of 
functional group present was calculated. With the moles of both functional groups 
present and SWCNT carbons, the functional group to SWCNT carbon ratio was 
calculated. 
X-ray photoelectron spectroscopy (XPS) analysis (Table 1.2) was used in conjunction 
with Raman and TGA to confirm the presence of added functional groups to the sidewall 
of 1. TGA weight loss was not significant in some cases (11, 14) compared to the 
starting material (1), but the Raman and XPS data strongly support the conclusion that 
functionalization did occur. Increased functionalization of these SWCNT products was 
noted due to increased halogen (14-17) and nitro (13) signals in the XPS analysis. The 
hydrocarbon and carboxy SWCNTs (10-12) are more difficult to distinguish by XPS due 
to the inability to distinguish between the SWCNT carbon and the addend carbon. 
23 
Cmpd C (%) 0 (%) N (%) Br (%) S (%) I (%) F (%) CI (%) 
1 76.6 15.8 2.9 - - 2.69 — - - 2.27 
10 86.1 9.1 1.7 1.6 1.4 
11 72.0 20.1 2.3 — 3.7 — — 1.8 
12 77.3 18.2 1.3 — 1.6 — — 1.5 
13 76.4 15.0 5.5 — 1.6 — 1.5 
14 67.6 24.2 4.0 — 1.2 — 3.1 — 
15 80.6 10.5 1.7 1.3 0 6/0 
16 82.1 10.7 0.9 3.6 1.2 0.03 1.3 
17 78.5 10.8 5.1 0.8 4.12 0 0.7 
Table 1.2. XPS data for compounds 1, and 10-17. 
Figure 1.4 shows an XPS analysis of 1 with aryl chloride functionalization. There was no 
bromine detected whereas Figure 1.5 shows an XPS analysis of 16 revealing the bromine 
from the addend attached through the repetitive functionalization method. 
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Figure 1.4. XPS analysis of SWCNT 1 bearing chloroarylsulfonic acid addends; no 
bromine was detected. 
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Figure 1.5. XPS analysis of SWCNT 16 bearing aryl bromide addends. The XPS result 
indicates the presence of both chloride and bromide addends. 
Transmission electron microscopy (TEM) indicated that the SWCNTs were individuals 
after functionalization of 1 using aryldiazonium salts (2-9) in water. A representative 
TEM of 11 (Figure 1.6) indicates the presence of individual SWCNTs with a roughened 
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sidewall surface, which has been attributed to the aryl moieties attached to the tube 
Figure 1.6. TEM of 11 deposited from a solution in water onto a holey lacey carbon grid. 
This image shows an individual SWCNT functionalized first with arylchlorosulfonic acid 
followed by functionalization with benzoic acid diazonium salt. The bumps on the 
sidewall are from the aryl functionalities on the SWCNT. The scalebar is 20 nm. 
Repetitive functionalization of PEGylated US-SWCNTs 
The PEGylated US-SWCNTs that underwent repetitive functionalization (28-31) showed 
an increase in the D/G ratio compared to the starting PEGylated US-SWCNTs (23) as 
indicated in Table 1.3, which confirms that repetitive functionalization did occur. This is 
wall.10 
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further confirmed using XPS, Table 1.3, which shows an increase in the corresponding 
halogen content for diazonium salt functionalization in comparison to the starting 
PEGylated US-SWCNTs (23). The nitrogen present in the sample can be attributed to 
the presence of aryldiazo moieties and N2 surface contamination. 
Cmpd Raman D/G C(%) O (%) N (%) Br (%) S (%) I(%) F(%) CI (%) 
23 0.44 65.9 30.3 3.4 0.2 0.2 0.0 0.0 0.0 
28 0.53 67.7 24.8 7.0 0.0 0.2 0.0 0.2 0.0 
29 0.62 72.2 17.4 6.3 0.0 0.1 0.0 4.0 0.0 
30 0.75 71.9 19.4 4.1 0.0 0.4 0.0 0.0 4.1 
31 0.82 61.4 28.1 8.4 0.2 0.1 0.7 0.0 1.1 
Table 1.3. Raman D/G ratio and XPS analysis of products 23 and 28-31. 
1.4 Conclusion 
A method for the bulk preparation of water-soluble SWCNTs which does not use 
high powered sonication nor centrifugation has been developed. This allows for 
repetitive functionalization with aryl groups that would not be stable under oleum 
functionalization conditions. We have also shown that water and PBS-soluble US-
SWCNTs can be made by first cutting the SWCNTs with oleum and nitric acid followed 
by PEGylation. These PEGylated US-SWCNTs then undergo repetitive functionalization 
in water using diazonium salt chemistry to produce multi-functional water and PBS-
soluble US-SWCNTs. 
1.5 Experimental 
General Methods. Amine terminated poly(ethylene glycol) was obtained from 
Nektar (5000 MW). Purified SWCNTs17 were obtained from Rice University HiPco 
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laboratory. All other starting compounds were purchased from Sigma-Aldrich and used 
without further purification unless otherwise stated. Thermogravimetric analysis was 
performed from room temperature to 850 °C at 10 °C/min under argon. Raman 
spectroscopy was performed on a Renishaw Raman scope using a 633 nm He-Ne laser, 
taking the median of five scans. XPS was carried out on a PHI Quantera SXM Scanning 
X-ray Microprobe with a pass energy of 26.00 eV, 45° takeoff angle and a 100 jam beam 
size. AFM samples were prepared by deposition from DMF onto a freshly cleaved mica 
surface. AFM images were obtained using tapping mode. Length analysis of the 
SWCNTs was performed with the AFM images using SIMAGIS Nanotechnology 
software version 3.0. TEM samples were prepared by deposition from water onto a 
Pelco200 lacey carbon grid. Sonication was carried out using a Cole-Palmer ultrasonic 
cleaner. 
Repetitive Functionalization General Method. To a 500 mL flask was added 
200 mL of a solution of 1 at a concentration of 60 mg/L (0.012 g, 1 meq C). The mixture 
was stirred at room temperature while the aryl diazonium salt (2.0 mmol) was added as a 
solid. The solution was then adjusted to pH 10 using 1 M NaOH. Once the solution was 
at pH 10, it was allowed to stir at room temperature for 1 h. Workup involved diluting 
with acetone and filtering over a 1 jim polycarbonate filter. The resulting bucky paper 
was then washed with water and acetone to remove any impurities. Diazonium salts 2-9 
1 8 
were prepared as previously described from the appropriate aniline. 
General US-SWCNT Formation Process.13 To 0.100 g of purified HiPco 
SWCNTs in a 100 mL round bottom flask equipped with a stir bar under an N2 
atmosphere was added oleum (20% free SO3, 25 mL). The material was stirred overnight 
29 
to achieve a good dispersion. After dispersion, a mixture of oleum (25 mL) and 
concentrated nitric acid (18 mL) was slowly added. After complete addition the flask was 
transferred to an oil bath preheated to the desired temperature and heated for 2 h. The 
solution was carefully poured over ice (200 g) and filtered over a 1 |xm polycarbonate 
filter. The resultant cake was washed on the filter thoroughly with water followed by 
ether. The cake was then dried in vacuum. This process uses a highly reactive mixture of 
acids; strong exothermic reactions are possible. Extreme caution should be used during 
the procedure. All cutting reactions should be done in a fume hood and appropriate 
safety equipment should be worn, including a lab coat, thick rubber gloves, safety glasses 
and a full face and neck shield. An alternative workup consisted of first vacuum filtering 
over a 0.22 jam polycarbonate membrane, and rinsing the filter cake thoroughly with 
water. The vacuum was then disconnected from the side arm and a minimal amount of 
methanol was added to the glass funnel to re-suspend the SWCNTs. Ether was added to 
the SWCNT/methanol suspension to cause the SWCNTs to precipitate. The vacuum was 
again applied and ether was continually added until the pH of the filtrate was neutral, at 
which point the filter cake was dried. 
PEGylation General Procedure. US-SWCNTs (0.050 g, 4.0 meq C) were 
added to a 100 mL round bottom flask equipped with a stir bar. To this was added dry 
DMF (50 mL) and the mixture was sonicated for 15 min to achieve a good dispersion. 
After dispersion, DCC (0.87 g, 4.2 mmol) was added and the mixture allowed to stir 5 
min before amine terminated PEG (5000 MW, 1.04 g) was added. The mixture was 
allowed to stir 24 h at which point it was transferred to a dialysis bag (50,000 MWCO) 
and dialyzed in flowing water for 5 d to remove any unbound PEG. After dialysis, the 
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material was filtered through glass wool to remove precipitated DCU. The concentration 
of the resultant material was then determined by Beer's law analysis using an extinction 
coefficient of 0.043. 
Dialysis Continuous Flow Setup. A deionized water spout was split into five 
separate lines using polypropylene T-joints and Nalgene tubing (5/16" ID). Each line 
was fed to the bottom of five separate 5 L beakers and the beakers were placed in a 
plastic tray (40" x 24" x 3") fitted with three drains at one end. The tray was slightly 
elevated at one end to promote drainage. The water source was turned on and the beakers 
were allowed to continually overflow. The flow rate was adjusted to prevent overflowing 
the tray. 
4-Chloro-3-sulfonylphenyl SWCNTs (l).1 Purified SWCNTs (0.250 g, 20.8 
meq C) were dispersed in oleum (250 mL, 20% free SO3) with magnetic stirring for 3 h. 
Sodium nitrite (2.87 g, 41.6 mmol) was added followed by 4-chloroaniline (5.31 g, 41.6 
mmol) and azobisisobutyronitrile (AIBN) (0.69 g, 4.2 mmol). The mixture was stirred at 
80 °C for 1 h, and then carefully poured over ice (250 g) and the suspension filtered 
through a polycarbonate membrane (1 |j.m). The filter cake was washed with water and 
acetone. The resultant solid was then dispersed in dimethylformamide (DMF) and 
filtered over a polytetrafluoroethylene (PTFE) membrane (1 |im). The filter cake was 
washed with a copious amount of acetone until a colorless filtrate was obtained and then 
dried to yield 1 (0.41 g, 320 mg/L). Raman D/G ratio 0.38; TGA mass loss 29%; XPS 
atomic concentration C l s 76.30%, N l s 2.94%, Ols 15.81%, S2p 2.69%, C12p 2.27%. 
4-fe/"f-Butylphenyl/4-chloro-3-sulfonylphenyl SWCNTs (10). The general 
method for repetitive functionalization was followed. 4-?er/-Butylbenzenediazonium 
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tetrafluoroborate (0.50 g, 2.0 mmol) was added to the SWCNT solution. The final bucky 
paper (13 mg) was formed by filtering over a 0.2 |a,m PTFE filter and drying in vacuum. 
Raman D/G 0.55, TGA mass loss 35%. TGA analysis estimates 1/20 SWCNT carbons 
functionalized. C l s 86.1%, N l s 1.7%, Ols 9.1%, S2p 1.6%, C12p 1.4%. 
4-Benzoic acid/4-chloro-3-sulfonylphenyl SWCNTs (11). The general method 
for repetitive functionalization was followed. 4-Benzoic acid diazonium 
tetrafluoroborate (0.47 g, 2.0 mmol) was added to the SWCNT solution. The final bucky 
paper (15 mg) was formed by filtering over 0.2 jam PTFE filter and was dried in vacuum. 
Raman D/G 0.58, TGA mass loss 31%. TGA analysis estimates 1/20 SWCNT carbons 
functionalized. C l s 72.0%, N l s 2.3%, Ols 20.1%, S2p 3.7%, C12p 1.8%. 
4-Methylbenzoate/4-chloro-3-sulfonylphenyl SWCNTs (12). The general 
method for repetitive functionalization was followed. 4-Methyl benzoatediazonium 
tetrafluoroborate (0.50 g, 2.0 mmol) was added to the SWCNT solution. The final bucky 
paper (10 mg) was formed by filtering over 0.2 |j,m PTFE filter and dried in vacuum. 
Raman D/G 0.76, TGA mass loss 40%. TGA analysis estimates 1/25 SWCNT carbons 
functionalized. C l s 77.3%, N l s 1.3%, Ols 18.23%, S2p 1.6%, C12p 1.5%. 
4-Nitrophenyl/4-chloro-3-sulfonylphenyl SWCNTs (13). The general method 
for repetitive functionalization was followed. 4-Nitrobenzenediazonium tetrafluoroborate 
(0.50 g, 2.0 mmol) was added to the SWCNT solution. The final bucky paper (13 mg) 
was formed by filtering over a 0.2 fim PTFE filter and was dried in vacuum. Raman D/G 
0.65, TGA mass loss 36%. TGA analysis estimates 1/21 SWCNT carbons 
functionalized; XPS atomic concentration Cls 76.4%, N l s 5.5%, Ols 15.0%, S2p 1.6%, 
C12p 1.5%. 
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4-Fluorophenyl/4-chloro-3-sulfonyIphenyl SWCNTs (14). The general method 
for repetitive functionalization was followed. The final bucky paper (14 mg) was formed 
by filtering over a 0.2 |jm PTFE filter and was dried in vacuum. Raman D/G ratio 0.65; 
TGA mass loss 23%; TGA analysis estimates 1/27 SWCNT carbons functionalized; XPS 
atomic concentration C l s 67.59%, N l s 4.00%, O l s 24.15%, S2p 1.17%, F ls 3.09%. 
4-ChlorophenyI/4-chloro-3-sulfonylphenyl SWCNTs (15). The general method 
for repetitive functionalization was followed. The final bucky paper (12.4 mg) was 
formed by filtering over a 0.2 jj.ni PTFE filter and was dried in vacuum. Raman D/G 
ratio 0.58; TGA mass loss 34%; TGA analysis estimates 1/18 SWCNT carbons 
functionalized; XPS atomic concentration Cls 80.55%, N l s 1.65%, Ols 10.48%, S2p 
1.26%, C12p 5.95%, F ls 0.00%. 
4-Bromophenyl/4-chloro-3-sulfonylphenyl SWCNTs (16). The general method 
for repetitive functionalization was followed. The final bucky paper (14 mg) was formed 
by filtering over a 0.2 jim PTFE filter and was dried in vacuum. Raman D/G ratio 0.62; 
TGA mass loss 43%; TGA analysis estimates 1/17 SWCNT carbons functionalized; XPS 
atomic concentration C l s 82.11%, N l s 0.93%, Ols 10.74%, S2p 1.24%, C12p 1.32%, 
Br3d 3.63%, F ls 0.03%. 
4-Iodophenyl/4-chloro-3-sulfonylphenyl SWCNTs (17). The general method 
for repetitive functionalization was followed. The final bucky paper (22.2 mg) was 
formed by filtering over a 0.2 pm PTFE filter and was dried in vacuum. Raman D/G 
ratio 0.63; TGA mass loss 53%. TGA analysis estimates 1/15 SWCNT carbons 
functionalized; XPS atomic concentration Cls 78.53%, N l s 5.09%, Ols 10.79%, S2p 
0.75%, C12p 0.72%, 14.12%, F ls 0.00%. 
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US-SWCNTs (18).13'14 The general SWCNT cutting procedure was followed with 
heating at 30 °C to yield 18 (0.110 g). Raman D/G ratio 0.65; TGA mass loss 49%. 
Average SWCNT length 98 nm, as determined by AFM. 
US-SWCNTs (19). The general SWCNT cutting procedure was followed with 
heating at 40 °C to yield 19 (0.094 g). Raman D/G ratio 0.58; TGA mass loss 49%. 
Average SWCNT length 33 nm, as determined by AFM. 
US-SWCNTs (20). The general SWCNT cutting procedure was followed with 
heating at 50 °C to yield 20 (0.102 g). Raman D/G ratio 0.89; TGA mass loss 55%. 
Average SWCNT length 33 nm, as determined by AFM. 
US-SWCNTs (21). The general SWCNT cutting procedure was followed with 
heating at 60 °C to yield 21 (0.202 g). Raman D/G ratio 0.92; TGA mass loss 54%. 
Average SWCNT length 34 nm, as determined by AFM. 
US-SWCNTs (22). The general SWCNT cutting procedure was followed with 
heating at 70 °C to yield 22 (0.203 g). Raman D/G ratio 0.94; TGA mass loss 63%. 
Average SWCNT length 32 nm, as determined by AFM. 
PEGylated US-SWCNTs (23). The PEGylation general procedure was followed 
using 18 as starting SWCNT material to yield 23 (conc. 160 mg/L); Raman D/G 0.44; 
TGA mass loss 71%; XPS atomic concentration Cls 65.9%, N l s 3.4%, Ols 30.3%, S2p 
0.2%, Br3d 0.2%, I3d5 0.0%, F l s 0.0%, C12p 0.0%. 
PEGylated US-SWCNTs (24). The PEGylation general procedure was followed 
using 19 as starting SWCNT material to yield 24 (conc. 77 mg/L). 
PEGylated US-SWCNTs (25). The PEGylation general procedure was followed 
using 20 as starting SWCNT material to yield 25 (conc. 32 mg/L). 
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PEGylated US-SWCNTs (26). The PEGylation general procedure was followed 
using 21 as starting SWCNT material to yield 26 (conc. 19 mg/L). 
PEGylated US-SWCNTs (27). The PEGylation general procedure was followed 
using 22 as starting SWCNT material to yield 27 (conc. 14 mg/L). 
4-Nitrophenyl PEGylated US-SWCNTs (28). The general method for repetitive 
functionalization was followed using 23 as the starting PEGylated SWCNTs material to 
give 28. Raman D/G 0.53; TGA mass loss 51%;19 XPS atomic concentration Cls 67.7%, 
N l s 7.0%, Ols 24.8%, S2p 0.2%. 
4-Fluorophenyl PEGylated US-SWCNTs (29). The general method for 
repetitive functionalization was followed using 23 as the starting PEGylated SWCNTs 
material to give 29. Raman D/G 0.62; TGA mass loss 53%;19 XPS atomic concentration 
C l s 72.2%, N l s 6.3%, Ols 17.4%, S2p 0.1%, F l s 4.0%. 
4-Chlorophenyl PEGylated US-SWCNTs (30). The general method for 
repetitive functionalization was followed using 23 as the starting PEGylated SWCNTs 
material to give 30. Raman D/G 0.75; TGA mass loss 59%;19XPS atomic concentration 
C l s 71.9%, N l s 4.1%, Ols 19.4%, S2p 0.4%, C12p 4.1%. 
4-Iodophenyl PEGylated US-SWCNTs (31). The general method for repetitive 
functionalization was followed using 23 as the starting PEGylated SWCNTs material to 
give 31. Raman D/G 0.82; TGA mass loss 58%.12 XPS atomic concentration Cls 61.4%, 
N l s 8.4%, Ols 28.1%, S2p 0.1%, I3d5 0.7%. 
Biotin [4-(2-aminoethoxy)phenyl](3,3-diethyl)triazene amide (32). A 
previously published procedure was used.10 
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Biotin [4-(2-aminoethoxy)phenyl](3,3-diethyl)triazene amide PEGylated US-
SWCNTs (33). The general method for repetitive functionalization was followed by 
adding 32 to the PEGylated SWCNT 23 (a different lot of 23 was used with a D/G of 
0.26. and adjusting the pH to 2 with 6 M HC1. After stirring for 5 min the pH was 
adjusted to 10 with 6 M NaOH. The reaction was stirred for 12 h at room temperature to 
give 33. Raman D/G 0.43; TGA mass loss 65%. XPS atomic concentration Cls 83.8%, 
N l s 1.0%, Ols 15.1%. 
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1.7 Experimental Contributions 
My contributions to the experimental work in this chapter are as follows: 
synthesis and characterization (including XPS, TGA, Raman) of PEGylated SWCNTs 
and the repetitive functionalization of these materials. Jason Stephenson synthesized and 
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characterized the bimodal SWCNTs first with an aniline, followed by functionalization 
with a diazonium salt. Jared Hudson synthesized and characterized the biotin SWCNTs 
and the US-SWCNTs. Katherine Price determined the lengths of the US-SWCNTs using 
AFM. 
Chapter 2 
Antioxidant Single-Walled Carbon Nanotubes 
2.1. Introduction 
As discussed in Chapter 1, the development of water-soluble single-walled carbon 
nanotubes (SWCNTs)1"9 has opened the door for the exploitation of these materials in 
biological settings. In particular, their notable aspect ratio renders them ideal scaffolds 
for the attachment of payloads and other entities to the sidewalls, and their ability to 
undergo rapid cellular uptake10"16 makes them attractive nanomaterials in biological 
settings. Another interesting property of SWCNTs that has been scarcely exploited to 
date is their ability to behave as radical scavengers.17 
Radical scavenging may occur via radical addition to the curved, sp -hybridized 
carbon nanotube framework.18'19 It is known that C6o-derivatives are efficient radical 
scavengers,20 and several studies utilizing functionalized, water-soluble C6o-derivatives 
have accounted for this effect in vivo.21'25 SWCNTs, having similar electron affinity as 
their fullerene counterparts, have been added to polymer matrices to retard oxidation.26 
Indeed, new generations of potent radical scavenging scaffolds could be important in 
materials technologies which often suffer from oxidative decomposition pathways. 
Additionally, antioxidant chemotherapy has been shown to be an essential component in 
the treatment of numerous disorders including strokes,27 traumatic brain injury,28 
radiation exposure sickness,29'30Alzheimer's disease,31 and coronary artery disease32 to 
name a few, thus generating a new series of potent radical scavenging scaffolds could 
prove to be important in medicine if the scaffolds could be shown to be nontoxic, 
deliverable to the site of interest, and then cleared so as not to disrupt the favorable 
biological radical cascades. Here we show that SWCNTs act as antioxidants in biological 
settings in both their pristine forms and in phenolic-functionalized structures. 
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Since we and others have shown SWCNTs to be multifunctional, " it is possible 
to functionalize individual SWCNTs with solubility enhancers, targeting agents, 
fluorescent tags, and/or therapeutic payloads, for example, towards the goal of a SWCNT 
nanovector. In this work, two types of SWCNTs have been functionalized with analogs 
of the phenolic antioxidant, butylated hydroxytoluene (BHT). The sidewalls of long 
10 
Pluronic-wrapped pristine SWCNTs were directly studied along with their BHT-
derivative functionalized forms. Pluronic (BASF) is a triblock copolymer of 
poly(ethyelene glycol)/poly(propylene glycol)/polyethylene glycol (PEG/PPG/PEG). 
Another SWCNT type studied were ultra-short SWCNTs (US-SWCNTs)39 which bare 
many carboxylic acids located along the sidewalls and ends of the structures, giving a 
handle to append BHT-derivatives. Using the total oxygen-radical absorbance capacity 
(ORAC) assay,40'41 we showed that both types of SWCNTs are extremely effective 
antioxidants. Two contrasting trends in the antioxidant potential of SWCNTs were noted, 
apparently as a consequence of the type of functionalization employed. When 
functionalization with the BHT-derivative occurred via carboxylic acids sites already 
present on the US-SWNTs, the antioxidant activity increased with increasing BHT-
derivative groups. However, when functionalization occurred directly on the sidewalls of 
the pristine SWCNTs through diazonium chemistry, the radical scavenging activity 
decreased with increasing BHT-derivative functionality. The latter case indicates that the 
radical scavenging activity of the SWCNT sidewalls was greater than the scavenging 
activity of the BHT-derivative appended system. Therefore, SWCNTs are themselves 
1 7h 
powerful antioxidants as recently suggested by ab initio studies. Since the SWCNTs in 
this study were soluble in biologically relevant salts, we demonstrated that concentrations 
of SWCNTs up to 330 nM or 83 mg/L had little to no cytotoxicity on the cell line 
studied, making these SWCNTs attractive agents for antioxidant therapy research. 
2.2. Results and Discussion 
2.2.1 Binding of amine-BHT ionically and covalently to PEG-US-SWCNTs. In order 
to provide an appropriate scaffold for the ionic, acid/base attachment of amine-BHT 1 
(Scheme 2.1), US-SWCNTs 2 were made by cutting purified SWCNTs in a mixture of 
oleum and nitric acid.39 Carboxylic acid groups located at the functionalized sites provide 
a handle for further functionalization of the SWCNTs49'50 with PEG to produce 3. 
Following this process, the PEG-US-SWCNTs 3 were combined with amine-BHT 1 to 
yield 4 via an acid/base ionic interaction.51 
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Scheme 2.1. SWCNTs were cut using oleum and nitric acid to give US-SWCNT 2. The 
US-SWCNTs were then PEGylated to afford PEG-US-SWCNT 3 followed by acid-base 
binding of amine BHT 1 to the PEG-US-SWCNTs to give 4. 
For the covalent derivatization of PEG-US-SWCNTs (Scheme 2.2), DCC, 
methoxy polyethylene glycol amine, and DMAP were added to US-SWCNTs. After 12 h 
amine-BHT 1, DCC, and DMAP were added to afford 4. PEG was added first to the US-
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SWCNTs in order to occupy enough acid groups needed for PBS solubility followed by 
addition of excess amine-BHT for maximal reaction with the remaining acid moieties. 
)H 
Scheme 2.2. US-SWCNTs 2 were PEGylated followed by covalent attachment of 
amine-BHT 1 to the carboxylic acids to afford amine-BHT derivatized PEG-US-
SWCNTs 5. 
Determination of the loading of amine-BHT on the PEG-US-SWCNTs was not 
feasible by a direct TGA determination. The number of PEG groups per nanotube could 
easily be determined through TGA by heating the PEG-US-SWCNT at a rate of 10 
°C/min under argon and recording the weight loss. Under these conditions the nanotube 
itself will not lose any weight and the weight loss will be attributed to functionalities on 
the SWCNT. The weight loss from the US-SWCNT (done in the same manner as 
previously described) was subtracted from this value in order to determine the amount of 
PEG attached to the SWCNTs. Due to the small size of the amine-BHT molecule relative 
HN 
2 5 
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to the 5000 MW PEG groups, TGA is not sensitive enough to discern the relatively small 
amount of weight loss due to amine-BHT when over 95% weight loss is already observed 
for the precursor 3. Therefore, to estimate the upper limit of amine-BHT groups that can 
be bound to the PEG-US-SWCNTs, the number of open acid groups after attachment of 
PEG was estimated from the TGA thermogram. According to the calculation (see 
Section 2.4.5), the upper limit for amine-BHT binding is 900 molecules per PEG-US-
SWCNT. 
2.2.2 OPE-BHT Derivatized SWCNTs 
An alternative approach to functionalize SWCNTs with BHT-derivatives was taken. For 
this purpose, in-situ diazonium formation and functionalization via the triazene moiety 
was utilized.52 Briefly, triazene-OPE-BHT 10 (Scheme 2.3) was added to Pluronic-
wrapped SWCNT solution 11. The pH of the solution was adjusted to pH 2 in order to 
convert the triazene to the diazonium salt, and then the pH subsequently adjusted to pH 
10 to complete the reaction (Scheme 2.4). Here, this step was repeated three more times 
to maximize the functionalization of SWCNTs with BHT moieties. OPE-derivatized 
SWCNTs 12 were subsequently dialyzed in 1 wt% Pluronic to remove impurities and 
excess reagent, but after dialysis the mixture still remained rusty brown in color, an 
appearance that is atypical of the SWCNT alone. When OPE-BHT-derivatized SWCNTs 
were washed with organic solvents to achieve a clean bucky paper for analysis, a clear 
orange filtrate consisting of organic byproducts was observed. NMR analysis of the 
filtrate revealed that there was no excess OPE-BHT in solution. The bucky paper was 
washed repeatedly until the filtrate was colorless. 
Scheme 2.3. Synthesis of triazene OPE-BHT 10. 
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Scheme 2.4. Triazene OPE-BHT 10 was covalently attached to pluronic-wrapped 
SWCNTs 11 to give OPE-BHT-derivatized SWCNTs 12. 
2.2.3 ORAC of SWCNT Formulations. The ORAC assay40'41 monitors a fluorescent 
probe's loss of fluorescent intensity in the presence of oxygen radicals. When oxygen 
radical scavengers are added to the system, the fluorescent intensity persists until the 
radical scavenger is consumed. The assay readout compares the radical scavenging 
ability of test compounds to a known radical scavenger, trolox, a water-soluble vitamin E 
derivative. For these experiments, fluorescein sodium salt (FL) and a,a '-
axodiisobutyramidine dihydrochloride (AAPH) were used as the fluorescent probe and 
thermally-activated radical initiator, respectively. The trolox mass equivalent (TME) 
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value is a unit that expresses the tested antioxidant's radical scavenging ability relative to 
a given mass of trolox. Trolox is given a TME of 1 and through calculation of TMEs, one 
can compare results to other radical scavengers throughout the literature. Trolox 
equivalents (TE) are calculated using molarity instead of mass. We chose to use TME 
instead of TE for a more accurate and fair comparison between SWCNTs and the free 
molecule trolox, because precise determination of SWCNT moles is not possible due to 
their polydispersity and if based on moles, SWCNTs are grossly off-scale in their radical 
sequestration ability. 
Figure 2.1 depicts the ORAC results of all SWCNT samples assayed. Even the 
poorest SWCNT antioxidant, PEG-US-SWCNTs without BHT-derivative addends, is 
nearly 40 times more effective at scavenging radicals than dendrite-fullerene DF-1, which 
was shown to be a radioprotective to zebrafish via an antioxidant mechanism.21 In a 
related plot from which Figure 2.1 is determined, Figure 2.2 illustrates the effectiveness 
of the US-SWCNT series 3, 4, and 5 versus trolox and DF-1; the relative persistence of 
fluorescence intensity observed with the SWCNTs over the other samples is indicative of 
their powerful antioxidant capability. 
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Figure 2.1. TME for DF-1, PEG-US-SWCNTs 3-5, Pluronic-wrapped SWCNT 11 and 
OPE-BHT derivatized 12. TME values for US-SWCNT and SWCNT samples in Figure 
1 were adjusted to account for the contribution of the corresponding solubilizer controls 6 
and 13, respectively, by subtracting the TME value found for each solubility control. In 
this way, the TME values listed on the plot are independent of the solubility enhancing 
addend. Error range is 15%. 
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Figure 2.2. Relative fluorescein intensity versus time. Fluorescein intensity persistence 
is proportional to the strength of the antioxidant. 
Contrary to what we expected, increased loading of BHT-derivatives was not 
directly proportional to the antioxidant capacity of the SWCNTs in all cases. Our 
original goal was to load as many BHT-derivatives as possible onto the SWCNT or US-
SWCNT scaffolds in order to produce large local concentrations of the BHT-derived 
antioxidants, using the SWCNT primarily as a scaffold. It is important to note that BHT 
and its derivatives used here are water-insoluble. Through the various associations of 
BHT-derivatives with SWCNTs and US-SWCNTs, the hydrophobic molecules were 
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solubilized in water, permitting the application of the antioxidant derivatives to the future 
in vitro studies. 
For the US-SWCNT series, the results were as expected: the amount of BHT-
derivative functionalization was proportional to the antioxidant activity as assessed by the 
TME values. Because ionic binding upon these scaffolds is more efficient than covalent 
binding,51'53 it is not surprising that amine-BHT ionically bound to PEG-US-SWCNTs as 
in 4 is a more effective antioxidant than amine-BHT covalently bound to PEG-US-
SWCNTs as in 5. In contrast, it was found that the antioxidant activity of the Pluronic-
wrapped SWCNTs was inversely proportional to the amount of BHT-derivative present. 
These findings are attributed to the mode of functionalization used for each series. In the 
case of the US-SWCNTs, the amine-BHT moieties were appended to carboxylic acids 
already present on the nanotube; the addition of amine-BHT did not alter the sidewall of 
the SWCNT itself. However, in the case of the Pluronic-wrapped SWCNTs, triazene-
OPE-BHT was used to directly functionalize the sidewall of the Pluronic-wrapped 
SWCNTs. That is, with every addition of OPE-BHT, a new defect site was introduced on 
the sidewall. It is known that functionalization decreases the radical scavenging ability of 
fullerenes, because the amount of pristine conjugation available for radical addition is in 
turn decreased and the bandgap of the structure is commensurately raised.54'55 In spite of 
this, we hypothesized that the antioxidant potential afforded by each additional BHT-
derivatives would be the largest determinant in the overall radical scavenging activity of 
the SWCNT. However, according to the data, the BHT-derivatives were not potent 
enough antioxidants to counter the antioxidant activity that was lost with each defect 
introduced to the sidewall of the SWCNTs through the covalent functionalization. This is 
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evidenced by the TME values of the SWCNT samples 11 and 12 in Figure 2.1. Even 
though SWCNT 12 is functionalized with many OPE-BHT moieties, pristine SWCNT 11 
has a higher total antioxidant capacity. 
To glean the radical scavenging ability attributable to the US-SWCNT itself and 
not from the attached solubilizing PEG moieties, the antioxidant contribution of the PEG 
was calculated (see Section 2.4.7). Briefly, this was done by calculating the amount of 
PEG attached to the US-SWCNT, dissolving that amount of PEG in water (6), and testing 
it side-by-side in the ORAC assay. As can be seen in Figure 2.2, the area under the curve 
is enhanced for PEG-US-SWNTs 3 relative to that of the PEG control 6. This means 
that all additional radical scavenging observed with PEG-US-SWCNTs 3 over PEG 
control 6 can be attributed to the US-SWCNT itself; therefore, even US-SWCNTs with 
heavily compromised sidewalls are still able to sequester oxygen radicals. The same 
treatment outlined above was done to determine what contribution the Pluronic medium 
has toward the TME of Pluronic-wrapped SWCNTs by also testing a solution of 1 wt % 
Pluronic in water (13) in the ORAC assay. Although the TME for Pluronic was higher 
than the PEG control 6, the radical scavenging contribution was still small relative to that 
of the Pluronic-wrapped SWCNT. 
Cytotoxicity of SWCNT Formulations. To assess an acute cytotoxic response of the 
various SWCNT solutions, HRE and HepG2 liver cells were exposed to the samples for 
24 h. Renal and liver cells were chosen for the in vitro assays because the kidney and 
liver play an important role in the in vivo clearance of SWCNTs.16'56"58 Figure 3 shows 
that no SWCNT solutions cause acute toxicity to HepG2 cells. No agglomeration of the 
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SWCNTs was seen in any of the samples after being exposed to the cells for 24 h. OPE-
BHT-SWCNT 12 shows some slight toxicity to HRE cells. This may be due to a minor 
organic59 byproduct of the reaction of triazene-OPE-BHT 10 with Pluronic-wrapped 
SWCNTs 11 that yielded 12. As noted earlier, the byproduct gave 12 a rust-colored tint 
and was not completely removed from the functionalized SWCNTs after dialysis in 1 wt 
% Pluronic solution. 
120 
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3 4 13 DF-1 Triton-X 
Figure 2.3. Cytotoxicity of SWCNT solutions 3, 4, 5, 11, and 12 as compared to that of 
DF-1. Trition-X, the toxicity control, is a standard surfactant known to be cytotoxic. 
PEG and Pluronic controls 6 and 13, respectively, are also shown. 
2.3. Conclusion 
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Through use of the ORAC assay, SWCNTs were shown to be potent antioxidants. 
When functionalized with the radical scavenging BHT-derivatives through existing 
functionalities on the sidewall, the antioxidant activity of the system is increased. If, 
however, the BHT-derivative functionalization occurs through covalent addition to the 
sidewall, the antioxidant activity of the system is decreased. These observations confirm 
the radical scavenging activity of the pristine SWCNTs. The solubilized SWCNTs tested 
here induced little cytotoxic response, hence application of SWCNTs towards 
antioxidants in materials and medical therapeutics warrants further studies. 
2.4. Experimental 
Materials. THF was freshly distilled over sodium/benzophenone in a nitrogen 
atmosphere. Other solvents were distilled over calcium hydride under a nitrogen 
atmosphere. All other chemicals including Anhydrous Af/V-dimethylformamide were 
purchased from Sigma-Aldrich and used without further purification unless otherwise 
stated. NANOPure water was obtained from a Barnstead water purification system and 
had a resistivity of 18 megaQ-cm or greater. SWCNTs were obtained from the HiPco 
laboratory at Rice University.42'43 2,6-Di-/er/-butyl-4-(2-aminoethyl)phenol (amine-BHT) 
l 4 4 was synthesized using known procedures. US-SWCNTs 239 were synthesized using a 
modified procedure where the moist filter cake of US-SWCNTs was transferred to a 
scintillation vial and pulverized with a Teflon stir rod over light heat on a hot plate 
resulting in a fine, dry powder that was dried in a vacuum desiccator overnight. The 
Raman diamondoid-to-graphitic (D/G) ratio was 0.8 and the thermogravimetric analysis 
(TGA, 10 °C/min, Ar, up to 900 °C) mass loss was 43%. From the TGA, it was 
estimated that 1/5 of the SWCNT carbons45 were functionalized with a carboxylic acid 
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group, as described previously.39 The average US-SWCNT length of 60 nm was 
determined by atomic force microscopy (AFM) as described previouly.39'46 The X-ray 
photoelectron spectroscopy (XPS) atomic concentrations were: Cls 68%, Ols 31%, N l s 
1%, S2p 0.4% as previously described for these heavily carboxylated nanotubes. 
Continuous Flow Setup for Aqueous Dialysis.46 A deionized (DI) water supply 
was split into five separate lines using polypropylene T-joints and Nalgene tubing (80 
mm. i.d.). Each line was fed to the bottom of five separate 1 L beakers and the beakers 
were placed in a plastic tray (102 cm x 61 cm x 7.6 cm) fitted with three drains at one 
end; the other end was slightly elevated to promote drainage. The water source was 
turned on and the beakers were allowed to continually overflow. The flow rate was 
adjusted to prevent overflowing the tray. 
PEGylation of US-SWCNTs (PEG-US-SWCNTs) (3). An oven dried 100 mL 
round bottom flask equipped with a stir bar was charged with 2 (0.063 g, 5.2 mequiv C) 
and anhydrous DMF (50 mL). The mixture was vigorously stirred for 15 min under a 
nitrogen atmosphere. A^,A^'-dicyclohexylcarbodiimide (DCC, 1.08 g, 5.2 mmol) was 
added followed by methoxy polyethylene glycol amine (0.50 g, 0.1 mmol, MW 5000) 
and 4-dimethylaminopyridine (DMAP, 11 mg, 0.09 mmol). The mixture was stirred 
overnight and purified by dialysis (dialysis bag MWCO 50000) first in DMF for 1 d to 
remove water-insoluble organic byproducts, then for 4 d in flowing deionized water for 
further purification and replacement of the organic solvent by water. Product 3 was 
repeatedly filtered through several layers of Kimwipes™ to remove remaining 
particulates. The concentration of the resultant material, determined by Beer's law 
analysis, using an extinction coefficient of 0.0104 L/mg at Xmax 763 nm, was 572 mg/L. 
The material was further diluted to 83 mg/L using DI water for ORAC and cell toxicity 
assays. The TGA mass loss was 95%. TGA analysis estimates 1/21 SWCNT carbons 
functionalized with PEG. 
Ionically bound amine-BHT derivatized PEG-US-SWCNTs (4). Compound 3 
(0.6 mg, 0.05 mequiv C) was added to a 50 mL round bottom flask equipped with a stir 
bar. Amine-BHT 1 (0.012 g, 0.05 mmol) was dissolved in DMF (1 mL) and added. The 
mixture was stirred overnight. No film was visible on top of the reaction solution 
indicating that the lipophilic amine-BHT had been solubilized through ionic association 
with the carboxylic acid groups on 3. The material was purified by dialysis (dialysis bag 
MWCO 50000) in flowing DI water for 5 d to afford 4. The concentration of the 
resultant material, determined by Beer's law analysis, using an extinction coefficient of 
0.0104 L/mg at X,max 763 nm, was 450 mg/L. The material was further diluted to 83 mg/L 
using DI water for ORAC and cell toxicity assays. 
Calculation for the upper limit of amine-BHT binding via TGA 
Assuming 100 carbon atoms per nm of SWCNT, 6000 carbon atoms compose a US-
SWCNT based on a 60 nm average length from AFM. From the TGA thermogram of 
US-SWCNTs 2, about 1 out of every 5 carbon atoms has a carboxylic acid group, 
assuming all weight loss is due to carboxylic acid groups. This corroborated with the 
literature values for the carboxylic acid content on US-SWNTs which further used XPS 
and titrations to determine this number. This means there are 1200 acid groups per US-
SWCNT. From the TGA of PEG-US-SWCNTs 3, 1 out of 21 carbons on the US-
SWCNT are bound to a PEG group. This means that 1 out of every 4 carboxylic acids 
(300 on the entire US-SWCNT) are being occupied by PEG groups, and 3 out of 4 (900 
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on the entire US-SWCNT) are free. If every free acid is being bound to an amine-BHT 
group, this translates to 900 amine-BHT molecules per PEG-US-SWCNT as an upper 
limit. 
Covalently bound amine-BHT derivatized PEG-US-SWCNTs (5). DCC (26 
mg, 0.13 mmol) was quickly added to a stirring solution of 3 mg PEG-US-SWCNT 3 
(prepared as above yet further reacted in the same pot prior to purification for this 
specific process) under a nitrogen atmosphere in dry DMF (6 mL). After 10 min, 1 (16 
mg, 0.064 mmol) was added, followed by DMAP (3 mg, 0.03 mmol). The mixture was 
left stirring overnight at room temperature. The mixture was purified in the same way as 
4. The concentration of the resultant material, determined by Beer's law analysis, using 
an extinction coefficient of 0.0104 L/mg at Amax 763 nm, was 210 mg/L. The material 
was further diluted to 83 mg/L using DI water for ORAC and cell toxicity assays 
PEG control (6). 14.0 mg of 5000 MW methoxy polyethylene glycol was 
dissolved in 61.4 mL of DI water. The resulting solution was 0.228 mg/mL and 
represents the amount of PEG attached to an 83 mg/L concentration of US-SWCNTs. 
To compensate for the amount of radical scavenging activity that may be due to the 5000 
MW PEG groups on the US-SWCNTs, the amount of bound PEG for a known volume 
(12 mL) of PEG-US-SWCNTs at a known concentration (128 mg/L) was determined by 
TGA weight loss to be 4.22 mg; this means that for 1 mL of 128 mg/L PEG-US-
SWCNTs 3, there is 0.352 mg of PEG. A ratio was then set up to solve for the amount of 
PEG that must be attached to a PEG-US-SWCNT solution at 83 mg/L (eq 1). 
Mass PEG in 128 mg/L ( m g ) MaSSPEG in 83 mg/L ( m g ) 
128 mg/L 83
 mg/L (1) 
From this calculation, it was found that there is 0.288 mg of PEG per 1 mL of 83 mg/L 
solution of PEG-US-SWCNTs. A stock solution of 5000 MW PEG was made (14 mg 
PEG in 61.4 mL of DI water) to achieve a solution with a concentration of 0.228 mg 
PEG/mL. An aliquot of this stock solution was tested alongside the PEG-US-SWCNT 
samples as sample 6. The TME value was subsequently calculated using the mass 
calculated from the concentration of the PEG-US-SWCNT solution to experimentally 
determine how much of the radical scavenging activity is due to the PEG itself without 
the US-SWCNTs. 
2.4.8 (2,6-Di-tert-butyl-4-bromophenoxy)trimethylsilane (7).47 An oven dried 
100 mL round bottom flask equipped with a stir bar was charged with 2,6-di-tert-butyl-4-
bromophenol (2.85 g, 10.0 mmol) and THF (50 mL) and then cooled to -78 °C. n-
Butyllithium (6.00 mL, 15 mmol, 2.5 M in hexane) was slowly added and the mixture 
was stirred for 1 h. After 1 h, chlorotrimethylsilane (1.84 g, 16.9 mmol) was added to the 
mixture. The reaction was allowed to stir for 1 h while warming to room temperature, 
and was then poured into water. The product was extracted with hexanes 2x and the 
combined organic layers were washed with water. The organic layer was dried over 
MgSC>4, filtered, and the solvent was removed from the filtrate under reduced pressure. 
The product was purified by column chromatography (silica gel, hexanes as eluent) to 
provide 3.39 g 7 (95%). 'H NMR (400 MHz, CDC13, ppm) 7.32 (s, 2H), 1.38 (s, 18H), 
0.38 (s, 9H). 
2.4.9 (2,6-Di-tert-butyl-4-iodophenoxy)trimethylsilane (8). An oven dried 100 
mL round bottom flask equipped with a stir bar was charged with compound 7 (3.40 g, 
9.5 mmol) and 50 mL ether. The mixture was cooled to -78 °C and fer/-butyllithium 
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(1.83 g, 28.5 mmol, 17.8 mL of a 1.6 M solution in pentane) was slowly added. The 
resulting solution was stirred for 1 h and 1,2-diiodoethane (5.36 g, 19 mmol) was added. 
The mixture was stirred at -78 °C for 1 h and then allowed to warm to room temperature. 
The solution was poured into water and extracted with hexanes. The combined organic 
layers were washed with water and dried with MgS04. The product was filtered and the 
solvent was removed from the filtrate under reduced pressure. The resulting material 
(1.47 g) was a mixture of 7 and the desired product 8 (51%) and it was used without 
purification. NMR (400 MHz, CDC13, ppm) 7.34 (s, 2H), 1.38 (s, 18H), 0.38 (s, 9H). 
2.4.10 l-[(2,6-Di-/ert-butyl-4-phenoxy)trimethylsilane]phenylethyne(3,3-
diethyl)triazene (9). An oven dried 100 mL round bottom flask equipped with a stir bar 
was charged with compound 8 (1.47 g of the above mixture), l-acetylenephenyl(3,3-
diethyl)triazene48 (0.40 g, 2.0 mmol), PdCl2(PPh3)2 (0.042 g, 0.6 mmol), Cul (0.025 g, 
1.3 mmol), triethylamine (2 mL) and well-degassed THF (30 mL). The contents were 
stirred at 60 °C until TLC analysis showed conversion of 8. The mixture was filtered and 
poured into saturated NH4CI and extracted with dichloromethane. The combined organic 
layers were washed with water and dried with MgSC>4. The product was filtered and the 
solvent was removed from the filtrate under reduced pressure. The product was purified 
by column chromatography (silica gel, 1:3 dichloromethane to hexanes as eluent) to yield 
0.83 g (78%) of the desired product 9. FTIR (cm-1) 2955, 2872, 1495, 1467, 1421, 1397, 
1326, 1269, 1255, 1236, 1200, 1165, 1123, 1108, 1079. 'H NMR (400 MHz, CDC13, 
ppm) 7.41 (d, J= 8.4, 2H), 7.34 (s, 2H), 7.29 (d, J= 8.4, 2H), 3.78 (q, J= 14.3, 4H), 1.45 
(s, 18H), 1.27 (t, J = 14.3, 6H), 0.38 (s, 9H). 13C NMR (100 MHz, CDC13, ppm) 153.9, 
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150.9, 141.3, 132.4, 129.5, 120,5, 120.2, 115.5, 90.3, 88.3, 35.4, 31.4, 4.0. HRMS (EIS) 
C29H44N3OSi (+1 H) calc'd: 478.3254 found: 478.3245. 
l-(2,6-Di-ter/-butyl-4-phenol)phenylethyne(3,3-diethyl)triazene (triazene 
OPE-BHT) (10). To a 100 mL round bottom flask equipped with a magnetic stir bar, 
compound 9 dissolved in dichloromethane (30 mL) and tetra-rc-butylammonium fluoride 
(3 mL, 3 mmol, 1.0 M in THF) were stirred overnight at room temperature. The color 
changed from red to green. The product was isolated by filtering the solution through a 
silica gel plug and washing with 1:1 dichloromethane and hexane to give an orange 
solution. The solvent was removed under reduced pressure to provide the red solid, 10 
(0.48 g, 90%). M.P. 61-63 °C. *H NMR (400 MHz, CDC13, ppm) 7.49 (d, J= 8.4, 2H), 
7.38 (d, J= 8.4, 2H), 7.36 (s, 2H), 3.78 (q, J= 14.3, 4H), 1.45 (s, 18H), 1.27 (t, J= 14.3, 
6H). 13C NMR (125 MHz, CDC13, ppm) 154.2, 150.6, 136.1, 132.1, 128.6, 120.3, 114.4, 
90.2, 34.4, 30.2, 30.0. HRMS (EIS) C26H36N30 (+ 1H) calc'd: 406.2858 found: 
406.2856. 
Pluronic-wrapped SWCNTs (11). Raw HiPco SWCNTs (0.09 g) and Pluronic 
F 108NF Prill Poloxamer 338 (donated by the BASF Corporation) (2.25 g) in NANOPure 
water (225 mL) were homogenized for 1 h using a homogenizer shaft driven by a Dremel 
Multipro model 395 motor and model 225 flexible shaft. The SWCNTs were then 
sonicated using a cup-horn sonicator (Cole Parmer Ultrasonic Processor Model CP 750) 
for 10 min at 78% amplitude and the mixture was ultra-centrifuged for 4 h at 29000 rpm. 
The SWCNTs in solution were decanted, and the solid material was discarded. The 
concentration of the resultant material, determined by Beer's law analysis, using an 
extinction coefficient of 0.0305 L/mg at Amax 763 nm, was 42 mg/L. The material was 
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further diluted to 28 mg/L using 1 wt % Pluronic in DI water for ORAC and cell toxicity 
assays. 
OPE-BHT derivatized SWCNTs (12). The pH of 1 wt % (in NANOPure water) 
Pluronic-wrapped SWCNTs 11 (50 mL) was adjusted with enough concentrated HC1 to 
lower the pH to 2. Compound 10 (25 mg, 0.62 mmol) was dissolved in acetonitrile (2 
mL) and then added to the SWCNT solution. The mixture was stirred for 20 min and 
the pH was then adjusted to 10 by adding NaOH (40% aqueous) dropwise. The above 
procedure was repeated to the same SWCNT solution three additional times. The 
mixture was then dialyzed (dialysis bag MWCO 50000) in Pluronic (1 wt % in 
NANOPure water) for 5 d to purify the material, affording 12, a black solution with a 
rust-colored tint. The concentration of the resultant material, determined by Beer's law 
analysis, using an extinction coefficient of 0.0305 L/mg at Xmax 763 nm, was 42 mg/L. 
The material was further diluted to 28 mg/L using 1 wt % Pluronic in DI water for ORAC 
and cell toxicity assays. Raman D/G ratio: 0.45; TGA mass loss: 35%. TGA analysis 
estimates 1/48 SWCNT carbons functionalized with OPE-BHT. 
1 wt % Pluronic in water control (13). 0.4 g of Pluronic was dissolved in 40 
mL of NANOPure water. 
Oxygen Radical Absorbance Capacity (ORAC) Assay.40 All solutions were 
prepared daily in 75 mM phosphate buffer at pH 7.4. Fluorescein sodium salt (FL) was 
prepared at 0.2 |aM from a 4 mM aqueous stock (prepared fresh monthly and stored in the 
dark at 4 °C). a,a'-Azodiisobutyramidine dihydrochloride (AAPH) was prepared at 0.15 
M in water and kept in an ice bath until added to the system. Racemic 6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (trolox) was prepared at 400 in water. 
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The experiments were performed in a black-sided, clear-bottomed 96-well plate. 
In order to account for the background and any fluorescence loss during the overnight 
experiments, phosphate buffer was substituted for AAPH and FL in two wells. 
Therefore, each sample was analyzed in three wells as follows. 
1. Assay = 120 FL + 20 pL sample + 60 ^L AAPH 
2. Control 1 (minus AAPH) = 120 pL FL + 20 pL sample + 60 pL phosphate buffer 
3. Control 2 (minus FL) = 120 pL phosphate buffer + 20 \xL sample + 60 pL AAPH 
In the appropriate wells the FL, sample, and phosphate buffer were added. Each 
experimental run included trolox and phosphate buffer as samples. The plate was then 
incubated at 37 °C for 15 min in a Safire2 plate reader (Tecan Systems Inc). Then the 
ice-cold AAPH was added to the appropriate wells. The fluorescent intensity at 530 nm, 
485 nm excitation, was monitored every min for 6 h. 
The background (control 2) was subtracted from the assay and control 1 well 
results. The assay well results were divided by the control 1 well results. The area under 
the curve (AUC) for the resultant values was determined electronically. Trolox mass 
equivalents (TME) were calculated using eq 2.1.40 
AUCsample-AUCPBS ^ troloxmass = n { E 
AUC,roIox-AUCPBS sample mass 
All PEG-US-SWCNTs solutions were at 83 mg/L, and all Pluronic-wrapped SWCNT 
solutions were at 28 mg/L; solutions were diluted by 10 for the ORAC assay to give 
concentrations of 8.3 and 2.8 mg/L, respectively. The concentration of trolox used in the 
assay was 10 mg/L. Initial SWCNT concentrations were calculated using empirically-
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derived extinction coefficients. Each sample was run a total of nine times with the above 
treatment. Averages and standard deviations were calculated. 
Cytotoxicity of SWCNT Formulations. Human renal epithelial (HRE) and 
HepG2 liver cells were utilized to assay acute cytotoxicity induced by all BHT-
derivatized and non-derivatized SWCNTs. The cells were plated at 1 x 105 cells/well in a 
12-well tissue culture treated plate. The cells were allowed to attach overnight at 37 °C 
in 5% CO2 overnight. The samples were added at a dose concentration of 109 nM (28 
mg/L) for Pluronic-wrapped SWCNTs and 332 nM (83 mg/L) for PEG-US-SWCNTs. 
Triton-X at 1 wt % in water was utilized as the toxic control. After 24 h exposure to the 
SWCNT solutions, the cells were removed from the plate with trypsin. Cell viability was 
assayed utilizing a Beckman Coulter Vi-Cell XR employing a trypan blue permeability 
assay. The viable cell counts were normalized to the phosphate buffered saline (PBS) 
control. 
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2.6 Experimental Contributions 
My contributions to the experimental work in this chapter are as follows: 
synthesis and characterization of pluronic wrapped SWCNTs' purification and 
characterization of the OPE-BHT-derivatized SWCNTs, and assisting in the synthesis of 
ionically and covalently bound amine-BHT PEG-US-SWCNTs. Rebecca Lucente-
Schultz synthesized and characterized the amine BHT, ionic and covalent amine-BHT 
PEG-US-SWCNTs. Meng Lu synthesized the OPE-BHT-derivatized SWCNTs. Valerie 
Moore performed the ORAC and cytotoxicity experiments at The University of Texas 
Health Science Center, Houston. 
68 
Chapter 3 
Single-Walled Carbon Nanotubes as Radioprotectants 
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3.1 Introduction 
Total body exposure to radiation in the form of a nuclear reactor accident, nuclear 
warfare or spaceflight could be deadly to humans. Much research has been done, but 
there is currently no antidote for radiation exposure. Whole-body radiation (WBI) 
1 2 
exposure of only 5 Gy results in death within two weeks of exposure, ' and cause 
gastrointestinal failure, which is usually characterized by nausea, vomiting, anorexia, 
diarrhea, fluid electrolyte imbalance, increased vascular permeability, vascular collapse, 1 ^ 
and infection, collectively referred to as the gastro-intestinal (GI) syndrome. ' 
Sometimes these symptoms are sufficiently severe and prolonged making spontaneous 
recovery unlikely and causing death within only a few days to a few of weeks after 
exposure. 
Exposure to radiation damages DNA molecules,4 either directly or, more 
frequently, through the formation of highly reactive free radicals. Cells that receive a 
lethal dose of radiation die by mitotic cell death (while undergoing division) or by 
apoptosis.5 On the other hand, cells that receive sublethal doses of radiation may be able 
to repair the damage caused from radiation. This sublethal repair process is typically 
accomplished within 4 to 6 h in actively proliferating cells, but other repair processes 
(potentially lethal damage) may continue for as long as 24 h in organized tissues in vivo. 
Organized tissues are restored to normal morphology through regeneration of cells that 
survived radiation, which then repopulate the organ that has depleted of its cells by 
radiation. This process can take days or weeks depending on the extent of radiation 
damage and the rate of cellular proliferation. 
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As discussed in Chapter 2, single walled carbon nanotubes (SWCNTs) are 
extremely potent antioxidants and could be used to lessen the effects of radiation. In 
addition, modified SWCNTs could also serve as a protective barrier, temporarily 
sheltering drugs from premature destruction within the body until they reach the final 
destination of the cell. Capitalizing on the fact that nanotubes are powerful antioxidants 
and effective nanovectors, we examined the ability of nanotubes alone or loaded with 
molecules of interest to protect mice from 12 Gy of whole body irradiation or to mitigate 
the effects of this radiation.6 
3.2 Results and Discussion 
The stem cell crypts in the small intestine (as shown in Figure 3.1) are the tissue 
most sensitive to radiation; the loss of these stem cells is the major cause of death when 
one is exposed to radiation. 
crypts 
muscularis 
n 
Figure 3.1. Section of the jejunum in the small intestine highlighting the crypts. 
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After the reduction of the stem cells, there is a loss of the lining in the small intestines, 
and death by GI syndrome follows. Normally, epithelial cells of the villi are being 
constantly lost and replaced with new cells generated by stem cells in the intestinal crypts. 
This rapidly proliferating tissue is very sensitive to ionizing radiation leading to a rapid 
regenerative response within 2 to 4 d after being exposed to radiation. Based on the 
dynamics of cell loss and regeneration following radiation, H. R. Withers developed the 
first in situ quantitative assay in mice to measure the effects of radiation on survival of 
o 
epithelial stem cells in the GI tract. This assay has become widely accepted as the most 
reliable and accurate clonal technique for studying the effects of radiomodulating agents, 
including radioprotectors. With this assay >100 different SWCNT formulations were 
assessed for the protection or mitigation of ionizing radiation in mice. 
A healthy mouse typically has -160 crypts. A section of a healthy mouse 
intestine is shown in Figure 3.2A. Once exposed to 12 Gy of radiation, within 3 d the 
number of crypts quickly decreases to -15 when no antidote is given as shown in Figure 
3.2B. 
. A B 
Figure 3.2. Image of the jejunum in the small intestine of a mouse. A. The mouse was 
exposed to no radiation B. 3 d after the mouse was exposed to 12 Gy of radiation. 
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In order to reduce the effect of radiation, different nanovector formulations were 
prepared to reduce cellular damage, enhance cell arrest, and induce cell repair. These 
nanovectors were administered to mice using iv, ip and gavage routes at MD Anderson 
Cancer Center in order to study their efficacy in vivo. 
3.2.1 Experiment 1 
We began our in vivo experiments based on the radical scavenging work 
presented in Chapter 2, by administering pristine SWCNTs covalently functionalized 
with BHT (OPE-BHT SWCNTs, 1, as shown in Figure 3.3), PEG-US-SWCNTs loaded 
with amine-BHT (ionic BHT SWCNTs, 2, general structure shown in Figure 3.4), 
Pluronic-wrapped SWCNTs (3) 30 min prior to exposure to 12 Gy of WBI radiation via 
iv administration. The OPE-BHT SWCNTs (1) gave promising results of 23.6 ± 2.8 
surviving crypts in comparison to the control group's (the control group was exposed to 
12 Gy of WBI, and no antidote was given) 16.1 ± 0.6 surviving crypts as shown in Table 
3.1, entries 9 and 2 respectively; this represents an increase of 47 %. 
Pluronic-wrapped 
Figure 3.3. OPE-BHT SWCNTs (1). 
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Figure 3.4. General PEGylated US-SWCNTs sequestering different molecules where 
R = (one or more of the following) butylated hydroxytoluene (BHT), amine derivative of 
butylated hydroxytoluene (amine-BHT, structure shown in Figure 3.5), butylated 
hydroxylanisole (BHA, structure shown in Figure 3.5), diacid BHT (structure shown in 
Figure 3.5), PEI (polyethylene imine), cystamine, glutathione, misoprostol, flagellin, 
caffeic acid, catechin, epidermal growth factor (EGF), protein 53 (p53), D-methionine, 
bismuth subsalicylate, Neuprex, Talactoferrin (TLF) which will all be discussed later in 
the chapter. 
W / / -OH 
H2 
o 
BHT amine BHT diacid BHT 
OH OH 
BHA 
Figure 3.5. Structures of BHT, amine BHT, diacid BHT, and BHA. 
3.2.1.2 Description of Tables 
The treatment column in the Tables list the compound numbers in bold, methods 
of treatment and time of administration. The treatment methods in this project are either, 
i.v. (intravenously, in the tail vein of the mouse), i.p. (intraperitoneally, given in the body 
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cavity of the mouse), or gavage (force feeding the mouse). The time of administration 
varies greatly throughout this project which will be described later in detail, but the 
minus sign before any time means that administration of the compound was given at that 
time before irradiation and no minus sign describes that the treatment was given after 
radiation. The description column is a brief description of the agent administered to the 
mice. As described above, we determined the efficacy of each treatment by the number 
of surviving crypts in the jejunum. The average number of surviving crypts for 8 mice is 
given with the standard deviation. The range is for all mice in that treatment group. The 
p-value was determined using the student t-test and any P-value less than 0.05 was 
considered significant. A control group consisting of 8 mice, were each given WBI and 
no chemical treatment was done for the control group. Finally, a group of 8 mice were 
exposed to no radiation. The grouping of the mice changed during this project, and will 
be described later in detail. 
Experiment 1 
Treatment Description Number of Surviving Crypts P-Value 
Mean ± SE Range 
l No Radiation Control 161.0 ± 1.4 159-165 — 
2 WBI only (12 Gy) Control 16.1 ± 0 . 6 14-19 — 
3 1 40 mg/L(-30 min) 0.2 mL i.v. 
+ WBI 
OPE BHT SWCNTs 15.8 ± 0 . 9 13-20 0.7356 
4 2 (-30 min) 0.2 mL i.v. + WBI Ionic BHT US-SWCNTs 13.6 ± 1.0 11-17 0.0535 
5 3 (-30 min) 0.2 mL i.v. + WBI Pluronic Wrapped 
SWCNTs 
20.0 ±6 .2 7-61 0.5448 
6 1 80 mg/L(No WBI) 0.2 mL i.v. OPE BHT SWCNTs 160.0 ± 2 . 5 155-167 0.7402 
7 2 (No WBI) 0.2 mL i.v. Ionic BHT US-SWCNTs 164.0 ± 3 . 7 156-172 0.5096 
8 3 (No WBI) 0.2 mL i.v. Pluronic Wrapped 
SWCNTs 
162.0 ± 2 . 0 158-167 0.7679 
9 1 80 mg/L(-30 min) 0.2 mL i.v. 
+ WBI 
OPE Pluronic SWCNTs 23.6 ± 2 . 8 13-35 0.0218 
10 2 (-30 min) 0.2 mL i.v. + WBI Ionic BHT US-SWCNTs 15.9 ±2 .2 11-29 0.9031 
11 3 (-30 min) 0.2 mL i.v. + WBI Pluronic Wrapped 
SWCNTs 
14.9 ±2 .5 9-26 0.6088 
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Table 3.1. All mice received 12 Gy of radiation except entries 1, 6, 7, and 8. Entry 9 
was statistically significant. 
3.2.2 Experiment 2 
In order to verify the experiment 1 results, as described in Table 3.1, and increase 
the efficacy of this treatment, the formulation concentration of 1 was increased from 80 
mg/L to 160 and 320 mg/L as shown in Table 3.2, entries, 4, 5, 7, and 8. But, 
unfortunately, none of the samples significantly protected the crypts. Since the SWCNTs 
are being concentrated by this increase in delivery concentration, we hypothesized that 
this process could cause bundling of the SWCNTs, leading to a lower surface area for 
quenching of radicals produced during WBI of the mice. 
Experiment 2 
Trea tment Description 
Number of Surviving Crypts P-Value 
Mean ± SE Range 
l No Trea tment Control 161. 0 ± 3 . 2 154-168 
2 WBI only (12 Gy) Control 10.5 ± 1.9 4-20 
3 1 80 mg/L (No WBI) OPE BHT Pluronic 
SWCNTs 
159.0 ± 2 . 3 155-165 0.59 
4 1 160 mg/L (No WBI) OPE BHT Pluronic 
SWCNTs 
161.0 ± 5 . 3 145-169 0.91 
5 1 320 mg/L (No WBI) OPE BHT Pluronic 
SWCNTs 
164.0 ± 4 . 5 155-168 0.61 
6 1 80 mg/L(-30 min) 0.2 mL i.v. 
+ WBI 
OPE BHT Pluronic 
SWCNTs 
15.8 ±2 .5 4-27 0.12 
7 1 160 mg/L(-30 min) 0.2 mL 
i.v. + WBI 
OPE BHT Pluronic 
SWCNTs 
12.6 ± 1.0 8-17 0.35 
8 1 320 mg/L(-30 min) 0.2 mL 
i.v. + WBI 
OPE BHT Pluronic 
SWCNTs 
12.6 ±2 .2 4-24 0.48 
Table 3.2. All mice received 12 Gy of radiation except entries 1, 3, 4, and 5. None of 
the results were statistically significant. 
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3.2.14 Experiment 14 
In order to develop a formulation that could be administered after exposure to 
radiation and would mitigate the effects of the radiation, the work was then focused on 
the delivery of agents after exposure to radiation. Administration after radiation exposure 
was a requirement for DARPA funding since one would not always be aware that they 
are about to be exposed to radiation, for example in a nuclear attack, meaning 
administration of a treatment after radiation exposure would be necessary. Ionic diacid 
BHT PEI PEG-US-SWCNTs (4) were chosen for Experiment 3 in order to increase the 
number of BHT molecules associated with the SWCNTs. Polyethylene imine (PEI) was 
first added to the US-SWCNTs followed by addition of diacid BHT which will assoicatae 
with the PEI. This was tested along with OPE-BHT SWCNTs functionalized 2x's to 
again increase the amount of BHT (5). Both of these agents were administered 1 h after 
WBI, both i.v. and i.p. Unfortunately, as shown in Table 3.3, none of these compounds 
showed any significant mitigation of radiation damage to the crypts. 
Experiment 3 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l No Treatment (No WBI) Control 158.0 ± 2 . 8 152-164 — 
2 WBI only (12 Gy) Control 13.5 ± 2 . 0 7-24 — 
3 4 ( 1 h) 0.2 mL i.p. + WBI Ionic diacid BHT PEI-PEGylated US-
SWCNTs 
13.9 ±2 .1 9-27 0.8994 
4 4 ( 1 h) 0.2 mL i.v. + WBI Ionic diacid BHT PEI-PEGylated US-
SWCNTs 
12.3 ± 1.5 7-21 0.6246 
5 5 ( 1 h) 0.2 mL i.v. + WBI OPE BHT Pluronic SWCNTs 11.9 ± 1.4 7-18 0.5167 
6 5 ( 1 h) 0.2 mL i.v. + WBI OPE BHT Pluronic SWCNTs 11.0 ± 1.9 8-21 0.3734 
Table 3.3. All mice received 12 Gy of radiation except entry 1. None of the results were 
statistically significant. 
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3.2.14 Experiment 14 
We then investigated other agents for the protection of the crypt cells after 
radiation exposure. Using SWCNTs as nanovectors, carriers of drugs or other moieties, 
for administration of cystamine (6) and glutathione (7), and these were delivered by i.v. 
administration. Both cystamine and glutathione are known to act as radical scavengers, 
and glutathione and other thiols are known to be involved in DNA repair.9 These 
formulations were administered both 30 min before and 30 min after WBI, as shown in 
Table 3.4. No protection from or mitigation of radiation damage was observed. 
Ex periment 4 
Trea tment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l No Treatment (No WBI) Control 164.0 ± 1.7 159-166 — 
2 WBI only (12 Gy) Control 12.5 ± 1.3 9-19 — 
3 6 (-30 min) 0.2 mL i.v. + WBI Cystamine PEGylated US-
SWCNTs 
10.8 ± 1.9 5-20 0.4532 
4 6 48 mg/L (30 min) 0.2 mL i.v. 
+ WBI 
Cystamine PEGylated US-
SWCNTs 
8.3 ± 1.6 3-13 0.0576 
5 7 (-30 min) 0.2 mL i.v. + WBI Glutathione PEGylated US-
SWCNTs 
13.5 ± 1.2 10-19 0.5687 
6 7 (30 min) 0.2 mL i.v. + WBI Glutathione PEGylated US-
SWCNTs 
6.7 ± 0.4 5-8 0.0051 
Table 3.4. All mice received 12 Gy of radiation except entry 1. None of the results were 
statistically significant. 
3.2.5 Experiment 5 
From here, the search for new radical scavengers was continued. Several 
different radical scavenging SWCNT formulations were synthesized; SWCNTs with 
covalently bound amifostine (8), BHT PEGylated US-SWCNTs (10), butylated 
hydroxyanisole (BHA)-PEGylated US-SWCNTs (11), and with polyethylene imine 
(PEI)-PEGylated US-SWCNTs (12). Amifostine was chosen because it is currently used 
in clinical settings for radioprotection of tissue in cancer patients.10'11 BHT and BHA are 
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both known to act as radical scavengers. We also began investigating administration of 
the formulations administered by gavage instead of i.v. or i.p. This would ease the 
distribution and administration of a large number of antidotes in the event of a nuclear 
disaster. All of these new formulations were administered either i.v. or gavage 30 min 
after radiation exposure and the results were compared. As shown in Table 3.5, there was 
no significant mitigation of radiation damage using these formulations. 
Experiment 5 
Trea tment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l No Trea tment (No WBI) Control 163.6 ± 3 . 0 150-177 
2 WBI only (12 Gy) Control 14.6 ± 3 . 7 2-28 
3 8 (30 min) 0.2 mL i.v. + WBI Covalent Amifostine PEG-US-
SWCNTs 
13.0 ± 3.1 12-32 0.7407 
4 9 (30 min) 0.2 mL i.v. + WBI BHA PEI-PEG-US-S WCNTs 10.5 ± 3.1 4-31 0.4060 
5 10 (30 min) 0.2 mL i.v. + WBI BHT PEG-US-SWCNTs 9.9 ± 2.1 3-31 0.2787 
6 11 (30 min) 0.2 mL i.v. + WBI BHA PEG-US-SWCNTs 9.3 ± 1.8 4-21 0.211 
7 12 (30 min) 0.2 mL i.v. + WBI PEI PEG-US-SWCNTs 13.4 ± 2.1 8-23 0.7897 
8 13 (30 min) 0.2 mL i.v. + WBI PEG-PEI-US-SWCNTs 9.4 ± 1.6 3-17 0.2104 
9 14 (30 min) 0.2 mL i.v. + WBI Glutathione PEG-US-SWCNTs 13.8 ± 3 . 2 3-32 0.8603 
10 8 (30 min) 0.2 mL gavage + 
WBI 
Covalent Amifostine PEG-US-
SWCNTs 
11.7 ± 2.0 4-19 0.5176 
11 9 (30 min) 0.2 mL gavage + 
WBI 
BHA PEI-PEG-US-SWCNTs 5.5 ± 0 . 6 3-8 0.0281 
12 10 (30 min) 0.2 mL gavage + 
WBI 
BHT PEG-US-SWCNTs 13.6 ± 3.1 5-27 0.8373 
13 11 (30 min) 0.2 mL gavage + 
WBI 
BHA PEG-US-SWCNTs 6.9 ± 2 . 0 1-19 0.0858 
14 12 (30 min) 0.2 mL gavage + 
WBI 
PEI PEG-US-SWCNTs 10.0 ± 1.8 4-19 0.2774 
15 13 (30 min) 0.2 mL gavage + 
WBI 
PEG-PEI-US-SWCNTs 10.8 ± 2 . 4 3-23 0.3893 
16 14 (30 min) 0.2 mL gavage + 
WBI 
Misoprostol PEG-US-SWCNTs 12.7 ± 2 . 6 7-25 0.6878 
Table 3.5. All mice received 12 Gy of radiation except entry 1. None of the results were 
statistically significant. 
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3.2.14 Experiment 14 
In Experiment 6, the Pluronic wrapped SWCNTs were revisited and higher 
concentrations of ionic BHT SWCNTs, up to 1000 mg/kg, were used. These 
nanomaterials were given either 2 or 6 h after WBI. These times were chosen because of 
funding from DARPA requiring administration 12 h after WBI, but due to the 
overwhelming need for a radiation antidote, these earlier time points were first 
investigated. Unfortunately, even at higher concentrations there was no significant 
mitigation of radiation damage to the crypts using these formulations. 
Experiment 6 
Treatment Description 
Number of Surviving Crypts P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 17.3 ± 1.4 8-34 
- -
2 2(1000 mg/L) (2 h) 0.25 mL 
i.v. + WBI 
Ionic BHT 16.8 ± 4 . 3 10-38 0.08917 
3 2 (500 mg/L) (2 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 16.2 ± 3 . 6 7-32 0.7226 
4 2 (61 mg/L) (2 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 15.4 ± 1.3 10-22 0.4217 
5 2 (24 mg/L) (2 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 20.25 ±4 .4 10-44 0.4072 
6 3 (54 mg/L) (2 h) 0.25 mL i.v. 
+ WBI 
Pluronic wrapped SWCNTs 13.9 ± 2 . 0 8-25 0.1879 
7 3 (32 mg/L) (2 h) 0.25 mL i.v. 
+ WBI 
Pluronic wrapped SWCNTs 19 ± 1.6 14-25 0.4862 
8 2 (1000 mg/L) (6 h) 0.25 mL 
i.v. + WBI 
Ionic BHT 17 ± 2 . 5 14-22 0.9367 
9 2 (500 mg/L) (6 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 16.5 ± 2 . 7 9-22 0.8124 
10 2 (61 mg/L) (6 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 16.9 ± 1.8 8-24 0.8651 
11 2 (24 mg/L) (6 h) 0.25 mL i.v. 
+ WBI 
Ionic BHT 18 ± 2.8 8-29 0.8048 
12 3 (54 mg/L) (6 h) 0.25 mL i.v. 
+ WBI 
Pluronic wrapped SWCNTs 18.6 ± 1.8 14-28 0.5966 
13 3 (32 mg/L) (6 h) 0.25 mL i.v. 
+ WBI 
Pluronic wrapped SWCNTs 11.6 ± 1.5 6-19 0.0249 
Table 3.3. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
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3.2.14 Experiment 14 
In Experiment 7, we sought to determine if the time of administration made a 
difference in protection from radiation damage. Treatment times of 2h or 6 h after WBI, 
and a combination of both 2 h and 6 h after WBI were investigated. Pluronic wrapped 
SWCNTs that were shortened using tip sonication were used for the treatment at two 
different concentrations. Even with multiple administrations and different time points, 
there was no significant mitigation of damage to the crypts and it was not possible to 
determine a treatment time that was best for reducing the effects of radiation. 
Experiment 7 
Trea tment Description 
Number of Surviving Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 9.9 ± 1.7 5-18 ~ 
2 15 (12 mg/kg) (2 h) 0.2 mL i.v. 
+ WBI 
Pluronic Wrapped SWCNTs 8.3 ± 1.3 4-14 0.467 
3 15 (6 mg/kg) (2 h) 0.2 mL i.v. 
+ WBI 
Pluronic Wrapped SWCNTs 13.3 ±1 .1 8-17 0.120 
4 15 (12 mg/kg) (6 h) 0.2 mL i.v. 
+ WBI 
Pluronic Wrapped SWCNTs 9.1 ± 1.5 1-14 0.749 
5 15 (6 mg/kg) (6 h) 0.2 mL i.v. 
+ WBI 
Pluronic Wrapped SWCNTs 12.9 ± 2 . 5 5-26 0.346 
6 15 (12 mg/kg) (2 h and 6 h) 0.2 
mL i.v. + WBI 
Pluronic Wrapped SWCNTs 12.8 ± 2 . 0 5-19 0.285 
7 15 (6 mg/kg) (2 h and 6 h) 0.2 
mL i.v. + WBI 
Pluronic Wrapped SWCNTs 10.8 ± 1.6 4-17 0.719 
Table 3.7. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
3.2.8 Experiment 8 
Since there were no significant reproducible results with the i.v. administration, 
the focus was changed to gavage administration and more administration time points 
were added. A combination of 6, 12, and 24 h after WBI administration of SWCNTs was 
81 
investigated. In order to protect the SWCNTs as they moved through the digestive tract 
of the mouse, the SWCNTs were coated with pectin, psyllium husk, or whey protein as 
shown in Table 3.8. Pectin is a dietary fiber that passes through the small intestine 
intact,12 serving as a protective barrier for our SWCNTs. Psyllium husk is another 
dietary fiber that once placed in water can swell and adsorb the SWCNTs and shield the 
SWCNTs as they pass through the digestive tract. Whey protein is a collection of 
globular proteins and amino acids that is able to easily suspend the SWCNTs. Another 
type of SWCNT was used, Carbolex SWCNTs, with the hope of increasing the number of 
SWCNT in solution. With all these formulations for protection of the SWCNTs through 
the digestive tract, there was no significant mitigation of radiation damage to the crypts. 
However, the work produced new methods for suspending SWCNTs in water. 
Experiment 8 
Treatment Description 
Number of Surviving Crypts P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 13.1 ± 0 . 8 10-17 
2 16 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% Pectin 13.9 ± 1.0 10-18 0.5714 
3 17 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
Carbolex SWCNTs in 2 
wt% Pectin 
16.1 ± 2 . 7 7-28 0.2971 
4 18 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
SWCNTs in 1 wt% 
Psyllium Husk 
16.4 ± 2.1 10-30 0.1757 
5 19 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
Carbolex SWCNTs in 1 
wt% psyllium husk 
14.8 ± 2 . 4 5-25 0.5333 
6 20 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% whey 
protein 
16.4 ± 2 . 3 7-26 0.2037 
7 21 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
Carbolex SWCNTs in 2 
wt% whey protein 
12.1 ± 1.6 8-22 0.5726 
8 2 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
Ionic BHT PEG-US-
SWCNTs 
10.0± 1.8 6-22 0.1363 
9 22 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
Carbolex SWCNTs in 2 
wt% Pectin Decant 
10.6± 1.2 6-15 0.1026 
10 23 (6, 12, and 24 h) 0.1 mL 
gavage + WBI 
SWCNTs in 1 wt% SDS 
decant 
12.0± 1.3 9-20 0.4602 
11 24 (6, 12, and 24 h) 0.1 mL 
i.v. + WBI 
Carbolex SWCNTs in 2 
wt% Pectin Decant 
12.1 ± 1.6 7-21 0.5748 
12 25 (6, 12, and 24 h) 0.1 mL 
i.v. + WBI 
Carbolex SWCNTs in 1 
wt% Pectin Decant 
11.8 ± 1.6 7-18 0.4587 
13 26 (6, 12, and 24 h) 0.1 mL 
i.v. + WBI 
Carbolex SWCNTs in 1 
wt% Pectin 
13.9 ± 1.5 7-20 0.6657 
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Table 3.8. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
3.2.9 Experiment 9 
With the new methods for solubilizing SWCNTs in the formulations developed in 
Experiment 8, these solubilizing agents were combined with a drug treatment as shown in 
Table 3.9. An additional time point of administration at 48 h was also added in this 
experiment. A combination of the different SWCNT wrappers with glutathione, 
amifostine, and misoprostol was used. Misoprostol is a radioprotective prostaglandin that 
can initiate cell repair.13 Even with these new formulations, no significant mitigation of 
radiation damage to the crypts was noted. 
Experiment 9 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 17.9 ± 1.6 11-38 — 
2 27 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
2 wt% whey protein + 
misoprostol + glutathione + 
amifostine 
14.1 ± 0 . 8 11-18 0.125 
3 28 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
1 wt% psyllium husk + 
misoprostol + glutathione + 
amifostine 
16.0 ± 1.4 10-23 0.4613 
4 29 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
2 wt% pectin + misoprostol + 
glutathione + amifostine 
13.2 ± 1.3 10-21 0.0748 
5 30 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 2 wt% whey protein 
+ misoprostol 
11.4 ± 0 . 6 9-15 0.0107 
6 31 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 1 wt% psyllium husk 
+ misoprostol 
8.7 ±0 .8 4-12 0.0008 
7 32 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
Carbolex SWCNTs in 2 wt% 
pectin + misoprostol 
12.1 ± 1.2 7-17 0.028 
8 33 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 2 wt% whey protein 
+ glutathione 
15.7 ± 2.5 10-29 0.4384 
9 34 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 1 wt% psyllium husk 
+ glutathione 
15.1 ± 3 . 2 7-34 0.3961 
10 35 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
Carbolex SWCNTs in 2 wt% 
pectin + glutathione 
15.7 ± 1.0 12-19 0.386 
11 36 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 2 wt% whey protein 
+ amifostine 
15.1 ±2.1 11-25 0.321 
12 37 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 1 wt% psyllium husk 
+ amifostine 
17.9 ± 2.8 9-28 1.000 
13 38 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
Carbolex SWCNTs in 2 wt% 
pectin + amifostine 
15.5 ±2 .2 11-28 0.3972 
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14 39 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 2 wt% whey protein 
+ misoprostol + glutathione + 
amifostine 
17.4 ± 2 . 5 7-29 0.8627 
15 40 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
SWCNTs in 1 wt% psyllium husk 
+ misoprostol + glutathione + 
amifostine 
15.5 ± 2 . 5 5-24 0.4138 
16 41 (6, 12, 24, 48 h) 0.1 mL 
gavage +WBI 
Carbolex SWCNTs in 2 wt% 
pectin + misoprostol + glutathione 
+ amifostine 
14.9 ±2 .1 7-27 0.2794 
Table 3.9. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
3.2.10 Experiment 10 
In Experiment 10, Flagellin, a 60 kD protein, which has been shown in the 
literature to protect mice from gastrointestinal and hematopoietic acute radiation 
syndromes and confer improved survival via a single injection before radiation 
exposure,14 was tested. Caffeic acid and catechin, which are both components of wine 
that have been shown to have very high radical scavenging properties15 were also 
administered. Epidermal growth factor (EGF), which stimulates cell regeneration and 
growth, was also investigated in this experiment. From this experiment the lone positive 
result was that whey protein wrapped SWCNTs given at 15 min and 2 h time points 
showed promising results in mitigating the radiation damage to the crypts as shown in 
Table 3.10 entry 19. Nonetheless, the effect was minimal. 
Experiment 10 
Treatment Description Number of Surviving Crypts P-Value 
Mean ± SE Range 
1 WBI only (12 Gy) Control 19.4 ± 1.5 10-34 — 
2 42 (-30 min) 0.2 mL i.v. + 
WBI 
Flagellin 13.2 ± 1.0 7-16 0.012 
3 43 (-30 min) 0.2 mL i.v. + 
WBI 
PEG-US-SWCNTs + Flagellin 14.4 ± 2 . 6 7-30 0.0882 
4 1 (-30 min) 0.2 mL i.v. + OPE BHT pluronic SWCNTs 13.2 ± 1.7 7-22 0.02 
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Experiment 10 
Treatment Description Number of Surviving Crypts P-Value 
Mean ± SE Range 
WBI 
5 44 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + caffeic 
acid 
14.6 ± 2 . 9 6-33 0.121 
6 45 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + catechin 13.6 ± 1.3 7-18 0.0205 
7 46 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + caffeic 
acid + catechin 
9.9 ± 1.4 7-18 0.0005 
8 47 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + EGF 11.7 ± 3.2 0-32 0.0217 
9 48 (15 min) 0.2 mL i.v. + 
WBI 
EGF only 14.0 ± 0 . 8 11-17 0.0232 
10 43 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + 
Flagellin 
12.0 ± 1.4 8-20 0.0047 
11 49 (15 min) 0.2 mL i.v. + 
WBI 
Flagellin wrapped SWCNTs 13.2 ± 1.8 7-23 0.0214 
12 42 (15 min) 0.2 mL i.v. + 
WBI 
Flagellin 15.7 ± 1.7 8-25 0.1523 
13 50 (15 min) 0.2 mL i.v. + 
WBI 
PEGylated US-SWNTs + p53 11 .6± 1.9 7-24 0.005 
14 44 (15 min, 2 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + caffeic 
acid 
12.2 ± 1.3 7-18 0.0055 
15 45 (15 min, 2 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + catechin 14.0 ± 3 . 0 2-31 0.0844 
16 46 (15 min, 2 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + caffeic 
acid + catechin 
13.5 ± 1.5 10-23 0.0209 
17 51 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs Pectin + caffeic acid 11 .7± 0.7 9-15 0.002 
18 52 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in whey protein + 
caffeic acid 
19.2 ± 3 . 4 9-40 0.9691 
19 20 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in whey protein 25.0 ± 1.5 19-28 0.0264 
20 53 (15 min, 2 h) 0.1 mL 
gavage + WBI 
Pectin + whey protein + caffeic 
acid + catechin 
22.5 ± 2.9 14-39 0.2978 
21 54 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in pectin + whey protein 
+ caffeic acid + catechin 
19.7 ± 2 . 3 10-32 0.8884 
22 20 (No WBI) 0.1 mL 
gavage 
SWCNTs in whey protein 162.2 ± 2 . 8 154-179 0.0001 
23 WBI only (12 Gy) Control 19.4 ± 1.5 10-34 
Table 3.10. All mice received 12 Gy of radiation except entry 22. Entry 19 was 
statistically significant. 
3.2.11 Experiment 11 
With the lone promising result in Experiment 10, administering the drug and 
SWCNT formulations just 15 min after radiation exposure was evaluated. As shown in 
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Table 3.11, there were no significant success using this treatment plan. This suggests that 
there may be an error in the statistical method of determining if a given result is 
significantly important. 
Experiment 11 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) control 16.9± 1.1 10-26 -
2 55 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
2 wt % whey protein + 
misoprostol + glutathione + 
amifostine 
16.9 ± 2.1 11-30 1.0 
3 56 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
1 wt % psyllium husk + 
misoprostol + glutathione + 
amifostine 
16.6 ± 2 . 8 10-27 0.9044 
4 57 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
2 wt % Pectin + misoprostol 
+ glutathione + amifostine 
16.1 ± 1.8 9-25 0.7189 
5 58 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein + misoprostol 
17.9± 2.4 12-29 0.6689 
6 59 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 1 wt % psyllium 
husk + misoprostol 
18.5 ± 1.4 12-23 0.4006 
7 60 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % pectin + 
misoprostol 
15.5 ± 1.9 11-27 0.5187 
8 61 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein + glutathione 
15.4 ± 2 . 0 6-25 0.4851 
9 62 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 1 wt % psyllium 
husk + glutathione 
14.2 ± 1.7 7-21 0.1991 
10 63 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % pectin + 
glutathione 
17.9 ± 2 . 2 7-27 0.6612 
11 64 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein + amifostine 
18.9 ± 1.9 14-27 0.3518 
12 65 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 1 wt % psyllium 
husk + amifostine 
12.0 ± 1.2 9-17 0.0138 
13 66 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % pectin + 
amifostine 
15.6 ± 1.8 12-25 0.5501 
14 67 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein + misoprostol + 
glutathione + amifostine 
17.4 ±1 .1 12-21 0.7842 
15 68 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 1 wt % psyllium 
husk + misoprostol + 
glutathione + amifostine 
17.5 ±2 .1 13-31 0.7767 
16 69 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % pectin + 
misoprostol + glutathione + 
amifostine 
21.4 ± 1.6 16-31 0.0304 
17 2 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + 
ionic BHT 
21.6 ± 3.3 14-43 0.1049 
18 70 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + 
ionic BHT + whey protein 
14.8 ± 1.4 7-20 0.3000 
19 71 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + 
ionic BHT + pectin 
17.5 ± 2.1 10-28 0.7790 
20 72 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + 
misoprostol + glutathione + 
amifostine 
18.0 1.7 14-29 0.5820 
21 73 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + 
cystamine 
15.5 ± 1.9 11-27 0.5187 
22 74 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
PEGylated US-SWNTs + D-
Methionine 
16.0 ± 1.8 11-22 0.6701 
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Experiment 11 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
23 75 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein + D-Methionine 
21.6 ± 2 . 4 16-36 0.0541 
24 76 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
D-Methionine 17.9 ± 1.0 14-22 0.5783 
25 20 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWNTs in 2 wt % whey 
protein 
15.0 ± 2.1 7-25 0.4024 
26 WBI only (12 Gy) control 16.9 ±1 .1 10-26 
Table 3.11. All mice received 12 Gy of radiation. Entry 16 was statistically significant. 
3.2.12 Experiment 12 
Having found no efficacy for formulations with the other drugs, we returned to 
our promising result in Experiment 10 with whey protein-wrapped SWCNTs. In 
Experiment 12, we repeated the conditions that gave that result. In addition, we also 
increased both the amount of whey protein and SWCNTs in various formulations and 
gave it to the mice both 15 min and 2 h after WBI, and we looked at the effectiveness of 
whey protein-wrapped SWCNTs at different doses of WBI. A different drug, 
Talactoferrin (TLF),16 which is a recombinant form of human lactoferrin was used. None 
of the new formulations had efficacy, and even the repeat of the promising whey protein 
and SWCNTs formulation from Experiment 10 showed no mitigation of radiation 
damage to the crypts, further suggesting a batch effect as the source of error. 
At this point, it became clear that the statistical analysis that were being done 
were inadequate. Help was sought from Dr. Jeffery Morris, a biostatistician at MD 
Anderson Cancer Center. Extra control groups were added to the studies in order to 
determine if the results were statistically meaningful. A brief description of his analysis 
follows: 
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The square root of the crypt counts was first taken, since it is well known that this is a 
variance stabilizing transformation for count data, and makes the data more Gaussian to 
be better modeled using standard statistical techniques. 
Let ytijk be the square root of the crypt count for slice k from mouse j from block i 
for a mouse given treatment t. To analyze these data, we fit the following linear mixed 
model: 
(Eq 3.1) 
where ji, represents the overall mean across all blocks, mice, and slices for treatment t, b, 
represents the block effect for block i. Its interpretation is the difference between the 
mean value for that block, and the overall mean in the data set. We assume that this 
block effect is random, being normally distributed with mean of 0 and variance of o*b 
Inclusion of this factor in the model adjusts for any systematic effects of the block, which 
appeared to be a significant issue in these data. 
We assume that my is the random mouse effect, representing the difference 
between the mouse's mean crypt counts and the block mean, and is assumed to be a mean 
zero normal distribution with variance cr2^. Finally, .v,^  is the random slice effect, 
representing the difference between the given slice crypt count and the mean crypt count 
for the mouse, and assumed to be a mean zero normal with variance a2s. 
We estimated the above mixed model using PROC MIXED in SAS (Cary, NC), 
and used Dunnett's Test to compare each treatment to the control, and used Bonferroni 
correction to compare the active treatments (i.e. not control) to each other, with p<0.05 
treated as significant. 
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Using this new statistical approach, the rest of the data were analyzed to better 
understand the significance of each experiment. It eliminated the uncertainty that was 
created using the old statistical analysis where we only used one control block per 
experiment and not a control group within each block of mice (a block consists of mice 
that all received the same treatment). From this point forward we ran blocks containing a 
total of 8 mice, where 6 mice received chemical treatment and 2 mice received no 
chemical treatment, but they were all irradiated at the same time, and there were usually 
two of these blocks per treatment. 
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Experiment 12 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 13.6± 1.8 4-23 — 
2 20 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% whey 
protein 
8.6 ± 0 . 8 6-12 0.0763 
3 21 (15 min, 2 h) 0.1 mL 
gavage + WBI 
Carbolex SWCNTs in 2 wt% 
whey protein 
7.6 ± 0 . 9 5-12 0.0371 
4 77 (15 min, 2 h) 0.1 mL 
gavage + WBI 
2 wt% whey protein 9.2 ± 1.1 5-14 0.1251 
5 78 (15 min, 2 h) 0.1 mL 
gavage + WBI 
5 wt% whey protein 9.6± 0.9 6-14 0.1523 
6 79 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in 5 wt% whey 
protein 
8.8 ± 0 . 8 5-13 0.0837 
7 80 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs (2x) in 2 wt% whey 
protein 
10.2 ± 1.9 6-20 0.2622 
8 81 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs (2x) in 5 wt% whey 
protein 
9.5 ± 1.4 5-15 0.1565 
9 82 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in 1 0 w t % T L F 1.9 ± 1.3 6-15 0.3327 
10 83 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in 1.8 wt% whey 
protein + 0.2 wt% TLF 
10.5 ± 1.7 5-19 0.2893 
11 84 (15 min, 2 h) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% TLF 13.5 ± 1.5 8-20 0.9652 
12 85 (15 min, 2 h) 0.1 mL 
gavage + WBI 
10 wt% TLF 14.0 ± 2 . 9 8-32 0.9103 
13 20 (15 min) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% whey 
protein 
14.8 ± 0 . 4 14-16 0.73 
14 20 (15 min, 2, 4, 6, 8h) 0.1 
mL gavage + WBI 
SWCNTs in 2 wt% whey 
protein 
16.5 ± 2 . 7 9-31 0.3834 
15 20 (5 min, 1 h) 0.1 mL 
gavage + WBI 
SWCNTs in 2 wt% whey 
protein 
10.8 ± 1.8 7-22 0.33380 
16 WBI only (11 Gy) Control (11 Gy) 37.0 ± 1.0 28-46 — 
17 20 (15 min, 2 h) 0.1 mL 
gavage + 11 GyWBI 
SWCNTs in 2 wt% whey 
protein 
30.4 ± 1.9 23-41 0.0288 
18 WBI only (13 Gy) Control (13 Gy) 6.4 ± 0 . 8 3-11 — 
19 20 (15 min, 2 h) 0.1 mL 
gavage + 13 Gy WBI 
SWCNTs in 2 wt% whey 
protein 
5.1 ± 0 . 8 3-10 0.2782 
20 WBI only (12 Gy) Control (12 Gy) 14.8 ± 1.4 7-20 0.3000 
21 86 (15 min, 2 h) 0.1 mL 
gavage + WBI 
Bismuth subsalicylate 
SWCNTs 
13.9 ± 1.0 12-18 0.504 
22 87 (15 min, 2 h) 0.1 mL 
gavage + WBI 
Bismuth subsalicylate 15.6 ± 1.9 9-25 0.5203 
Table 3.12. Entries 1-15, 21, and 22 all received 12 Gy of radiation, 16-17 received 11 
Gy of radiation, and 18-19 received 13 Gy of radiation. None of the results were 
statistically significant. 
3.2.13 Experiment 13 
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In Experiment 13, formulations using bismuth subsalicylate, which is used to treat 
discomforts of the stomach and gastrointestinal tract, and Neuprex, a drug made by 
XOMA17 that is a recombinant fragment of BPI (bactericidal/permeability-increasing 
protein) which could kill bacteria in the jejunum leading to recovery from radiation 
exposure, were tested. The only formulation that showed promise in this experiment was 
Neuprex given alone via gavage administration, Table 3.13, entry 8. 
Experiment 13 
Treatment Description Number of Surviving Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 12.8 ± 1.3 7-27 -
2 88 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
Bismuth subsalicylate in 2 
wt% whey protein 
14.0 ± 2 . 3 7-26 0.6232 
3 89 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
SWNTs wrapped in 2 wt% 
whey protein + bismuth 
ubsalicylate 
15.4 ± 0 . 9 11-19 0.1935 
4 90 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
PEGylated US-SWNTs + 
bismuth subsalicylate 
11.4 ± 1.6 6-19 0.4987 
5 91 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
PEGylated US-SWNTs + 
bismuth subsalicylate in 2 
wt % whey protein 
13.1 ± 2 . 2 6-24 0.8954 
6 92 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
PEGylated US-SWNTs + 
Neuprex 
13.8 ± 3.1 8-35 0.7073 
7 93 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
SWNTs wrapped in 2 wt% 
whey protein + Neuprex 
12.0 ± 1.4 7-19 0.6937 
8 94 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
Neuprex 18.6 ± 1.4 13-24 0.009 
9 95 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
Neuprex in 2 wt % whey 
protein 
13.9 ± 2 . 5 7-25 0.672 
10 96 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
US-SWNTs + bismuth 
subsalicylate 
13.8 ± 1.8 9-24 0.6703 
11 97 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
US-SWNTs + bismuth 
subsalicylate in 2 wt % whey 
protein 
17.5 ± 3 . 4 7-36 0.1283 
12 98 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
SWNTs wrapped in 2 wt% 
whey protein + probiotic 
9.4 ± 0.8 6-13 0.0816 
13 99 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
2 wt% whey protein + 
probiotic 
10.1 ± 1.4 5-16 0.2245 
Table 3.13. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
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3.2.14 Experiment 14 
In Experiment 14 the Neuprex administration was repeated and additional dosing 
methods were studied; unfortunately, this more complete study indicated that Neuprex is 
ineffective. TLF, glutathione and amifostine at a higher concentration were again tested. 
A few formulations with an elevated dose of amifostine showed promise; administration 
of amifostine in Table 3.14 entries 7 and 8, gave an increase in surviving crypts 
compared to the control group (entry 1), of 33% and 57%, respectively. 
Experiment 14 
Trea tment Description 
Number of Surviving Crypts P-Value 
Mean ± SE Range 
l W B I only (12 Gy) Control 11.7± 1.0 — 
2 94 (15 min, 2 h) 0.2 mL i.v. + 
WBI 
Neuprex 11.6± 1.3 7-19 0.971 
3 92 (15 min, 2 h) 0.2 mL i.v. + 
WBI 
PEG-US-SWCNTs + 
Neuprex 
13.5 ± 1.6 8-20 0.328 
4 85 (15 min, 2 h) 0.2 mL i.v. + 
WBI 
TLF 16.9± 1.4 11-20 0.0078 
5 100 (15 min, 2 h) 0.2 mL i.v. + 
WBI 
PEG-US-SWCNTs + TLF 10.4 ± 0 . 7 7-12 0.4 
6 94 (15 min, 2 h, 4h, 6 h) 0.2 mL 
i.v. + WBI 
Neuprex 7.9 ± 1.0 5-12 0.025 
7 37 (15 min, 30 min, 2 h, 4h, 6 h) 
0.1 mL gavage + WBI 
SWCNTs in 1 wt% 
psyllium husk + amifostine 
17.5 ± 1.5 13-25 0.003 
8 38 (15 min, 30 min, 2 h, 4h, 6 h) 
0.1 mL gavage + WBI 
SWCNTs in 2 wt% pectin 
+ amifostine 
18.4 ± 3 . 4 11-38 0.023 
9 94 (15 min, 30 min, 2 h, 4h, 6 h) 
0.1 mL gavage + WBI 
Neuprex 13.4 ± 2 . 4 8-28 0.452 
10 37 (15 min, 30 min, 6 h) 0.1 mL 
gavage + WBI 
SWCNTs in 1 wt% 
psyllium husk + amifostine 
15.8 ± 2 . 8 6-26 0.105 
11 101 (15 min, 30 min, 6 h) 0.1 
mL gavage + WBI 
SWCNTs in 1 wt% 
psyllium husk + amifostine 
(x2) 
13.1 ± 1.8 9-25 0.458 
12 102 (15 min, 30 min, 6 h) 0.1 
mL gavage + WBI 
PEG-US-SWCNTs + 
glutathione + amifostine 
(x2) 
17.4 ± 2 . 5 9-33 0.019 
13 103 (15 min, 30 min, 6 h) 0.1 
mL gavage + WBI 
PEG-US-SWCNTs + 
glutathione (x2) 
12.4 ± 1.7 3-19 0.714 
14 94 (15 min, 2 h) 0.1 mL gavage 
+ WBI 
Neuprex 12.6 ± 1.0 8-17 0.562 
15 a. 94 b. 89 (15 min 1 h, 2 h, 6 h) 
0.1 mL gavage switching 
between two drugs + WBI 
a. Neuprex b. SWCNTs in 
2 wt% whey protein + 
bismuth subsalicylate 
10.1 ± 2 . 3 9-25 0.133 
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Table 3.14. All mice received 12 Gy of radiation. Entries 4, 7, 8, and 12 were 
statistically significant. 
3.2.15 Experiment 15 
In Experiment 15, attention focused on amifostine, given at earlier times of 15 
min, 30 min, and 1 h. Even with these early times, there were no statically significant 
results. 
Experiment 15 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 14.1 ± 9-30 — 
2 104 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + whey protein 11.4 ± 1.6 8-21 0.2754 
3 105 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + whey protein + 
PEG-US-SWCNTs 
13.1 ± 1.7 7-23 0.7000 
4 36 (15 min, 30 min,l h) 0.1 mL 
gavage + WBI 
Amifostine + whey protein + 
raw SWCNTs 
12.9 ± 1.2 10-18 0.5996 
5 106 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + psyllium husk 11.8± 1.2 8-17 0.3151 
6 107 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + psyllium husk 
+ PEG-US-SWCNTs 
15.8 ± 2.1 9-25 0.5424 
7 37 (15 min, 30 min, 1 h) 0.1 mL 
gavage + WBI 
Amifostine + psyllium husk 
+ raw SWCNTs 
14.1 ± 2 . 2 8-28 0.9880 
8 108 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine in water 14.9 ± 2 . 0 8-24 0.7634 
9 109 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + PEG-US-
SWCNTs 
15.6 ± 1.6 9-21 0.5316 
10 110 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + pectin 12.1 ± 1.57 9-21 0.4280 
11 111 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + pectin + PEG-
US-SWCNTs 
13.1 ± 1.26 8-18 0.6808 
12 38 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + pectin + raw 
SWCNTs 
14.5 ±0 .91 10-18 0.8506 
13 94 (15 min, 30 min,l h) ) 0.1 
mL gavage + WBI 
Neuprex 14.5 ± 1.22 11-21 0.8570 
14 85 (15 min, 2 h) 0.2 mL i.v. + 
WBI 
TLF 15.5 ± 3.1 8-27 0.6688 
Table 3.15. All mice received 12 Gy of radiation. None of the results were statistically 
significant. 
3.2.16 Experiment 16 
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In Experiment 16, the amount of amifostine administered to the mice was further 
1 ft 
increased. The mice were given at 500 mg/kg via gavage. Nanoribbons were also 
investigated as a new method of delivery of amifostine, and alone as a radical scavenger. 
Both mitigating radiation damage, by administering the formulations 15 min, 30 min, and 
1 h after radiation exposure, and protecting the mice from damage by administering the 
formulations 30 min or 1 h before exposure to radiation, were tested. Again the 
mitigation efforts were unsuccessful, but the mice were protected by orally administering 
them with amifostine 30 min before irradiation. The increase in surviving crypts was 
dramatic, from 16.2 ± 0.9 in our control group, entry 1 to 86.9 ± 5.8 in the group treated 
gavage with amifostine sequestered in PEG-US-SWCNTs, Table 3.16, entry 9. This is an 
increase of greater than 500%. 
Experiment 16 
Treatment Description 
Number of Surviving 
Crypts 
P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 16.2 ± 0 . 9 11-21 — 
2 WBI only (12 Gy) Control 16.2 ± 0 . 9 12-19 
3 107 (15 min, 30 min,l h) 0.1 
mL gavage + WBI 
Amifostine + psyllium husk + 
PEG-US-SWCNTs 
16.1 ± 1.9 10-22 0.9484 
4 107 (15 min, 30 min,l h) 
0.1 mL gavage + WBI 
Amifostine + psyllium husk + 
PEG-US-SWCNTs 
16.7 ± 0 . 6 15-20 0.6810 
5 112 (15 min, 30 min,l h ) 
0.1 mL gavage + WBI 
PEG Nanoribbons 14.4 ± 1.5 9-22 0.2616 
6 113 (15 min, 30 min,l h ) 
0.1 mL gavage + WBI 
Amifostine + PEG 
Nanoribbons 
21.2± 2.4 13-36 0.0382 
7 105 (-30 min) 0.1 mL 
gavage + WBI 
Amifostine + whey protein + 
PEG-US-SWCNTs 
78.1 ±6 .1 57-102 0.0001 
8 107 (-30 min) 0.1 mL 
gavage + WBI 
Amifostine + psyllium husk + 
PEG-US-SWCNTs 
69.8 ± 12.0 47-107 0.0001 
9 109 (-30 min) 0.1 mL 
gavage + WBI 
Amifostine + PEG-US-
SWCNTs 
86.9 ± 5 . 8 66-113 0.0001 
10 105 (-1 h) 0.1 mL gavage + 
WBI 
Amifostine + whey protein + 
PEG-US-SWCNTs 
62.5 ±7 .2 27-95 0.0001 
11 107 (-1 h) 0.1 mL gavage + 
WBI 
Amifostine + psyllium husk + 
PEG-US-SWCNTs 
51.0 ± 5.4 36-75 0.0001 
12 109 (-1 h) 0.1 mL gavage + 
WBI 
Amifostine + PEG-US-
SWCNTs 
77.8 ± 6 59-108 0.0001 
13 112 (-1 h) 0.1 mL gavage + 
WBI 
PEG Nanoribbons 9.0 ±0 .71 6-12 0.0001 
14 113 (-1 h) 0.1 mL gavage + 
WBI 
Amifostine + PEG 
Nanoribbons 
78.1 ± 9 . 9 31-112 0.0001 
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Table 3.16. All mice received 12 Gy of radiation. Entries 6-14 were statistically 
significant. 
3.2.17 Experiment 17 
Capitalizing on this dramatic result of an effective oral administration of 
amifostine in nanovectors, the best nanomaterial carrier for the drug was sought. Both 
positive and negative controls were run to compare our treatment with less desirable 
known treatments, such as i.p. administration of amifostine. With this experiment it was 
determined that the nanomaterials did not increase the efficacy of amifostine. After an 
indepth literature search of the thousands of compounds tested for radiation protection, it 
was found that amifostine given orally is not effective on larger animals,19 which was 
even unknown to our collaborators (both of which have been working in this field for 
over 30 years). This would mean that oral administration of amifostine would not work 
as a radioprotectant to humans and did not warrant any further testing with this 
compound. 
Experiment 17 
Trea tment Description Number of Surviving Crypts P-Value 
Mean ± SE Range 
l WBI only (12 Gy) Control 14.75 
2 114 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine control 62.2 ± 4.0 49-77 0.0001 
3 115 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine control - made 
fresh 
75.4 ±5.1 63-109 0.0001 
4 113 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + PEG 
Nanoribbons 
72.7 ±6 .1 37-98 0.0001 
5 109 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + PEG-US-
SWCNTs 
61.2 ± 3.9 46-76 0.0001 
6 116 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + pluronic 
wrapped SWCNTs decant 
73.8 ± 3 . 8 58-91 0.0001 
7 117 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + pluronic 
wrapped SWCNTs 
64.7 ± 4 . 3 52-79 0.0001 
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Experiment 17 
Treatment Description 
Number of Surviving Crypts P-Value 
Mean ± SE Range 
8 118 (-30 min) 0.1 mL gavage 
+ WBI 
Glutathione + PEG-US-
SWCNTs 
12.9 ± 1.3 9-18 0.7954 
9 119 (-30 min) 0.1 mL gavage 
+ WBI 
Glutathione control 11.8 ± 1.2 8-17 0.0007 
10 120 (-30 min) 0.1 mL gavage 
+ WBI 
Cystamine + PEG-US-
SWCNTs 
17.3 ±3 .1 9-32 0.8512 
11 121 (-30 min) 0.1 mL gavage 
+ WBI 
Cystamine Control 23.6 ± 3 . 2 12-42 0.0687 
12 122 (-30 min) 0.1 mL gavage 
+ WBI 
PEI-SWCNTs 12.7 ± 1.8 6-23 0.3851 
13 123 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + PEI-SWCNTs 87.9 ± 6.4 63-115 0.0001 
14 124 (-30 min) 0.1 mL gavage 
+ WBI 
Cysteamine + PEG-US-
SWCNTs 
18.7 ± 3 . 4 11-35 0.6364 
15 125 (-30 min) 0.1 mL gavage 
+ WBI 
Cysteamine Control 18.2 ± 1.9 12-25 0.847 
16 126 (-30 min) 0.1 mL gavage 
+ WBI 
Amifostine + BHT-acid + 
PEG-US-SWCNTs 
73.0 ± 4 . 6 56-91 0.0001 
17 127 (15 min) 0.1 mL gavage 
+ WBI 
Amifostine + psyllium husk + 
PEG-US-SWCNTs 
12.7 ± 1.0 9-18 0.5168 
18 109 (15 min) 0.1 mL gavage 
+ WBI 
Amifostine + PEG-US-
SWCNTs 
13.1 ± 1 10-18 0.144 
19 114 (15 min) 0.1 mL gavage 
+ WBI 
Amifostine control 14.4 ± 1.7 8-21 0.1524 
20 114 (-30 min) 0.1 mL i.p. + 
WBI 
Amifostine control (3.8 
mg/dose) 
69.5 ± 3 . 9 55-91 0.0001 
21 114 (-30 min) 0.1 mL i.p. + 
WBI 
Amifostine control (12.5 
mg/dose) 
148.4 ± 3 . 6 133-161 0.0001 
Table 3.17. All mice received 12 Gy of radiation. Entries 2-7, 9, 13, 16, and 20-21 were 
statistically significant. 
3.3 Conclusions 
In conclusion, over 100 different formulations were screened for the protection or 
mitigation of radiation damage due to exposure to WBI in over 1000 mice. 
Unfortunately, we were not able to find a formulation that was successful, since we later 
learned that oral administration of amifostine is not effective at minimizing the effects of 
radiation on larger animals. We did find that our nanomaterials in 100 different 
formulations given multiple times to mice either i.v., i.p., or gavage, does not promote 
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any visual signs of toxicity to the mice up to 3.5 d after administration. Our 
nanomaterials could be useful drug carriers for not only radiation protection but for other 
medicinal purposes such as cancer chemotherapy, traumatic brain injury, and spinal cord 
injury just to name a few. The search for new agents that could be used as 
radioprotectants should continue because there is an overwhelming need to have an 
antidote to radiation exposure, especially in the event of a nuclear reactor accident, 
nuclear warfare or spaceflight requirements. Moreover, though our study here to identify 
a radioprotectant or radiomitigator was unsuccessful, it led to formulations that are 
showing very encouraging efficacy in cancer chemotherapy which will be discussed in 
Chapter 5. 
3.4 Experimental 
Female C3Hf/KamLaw mice 3-4 months old were used, having 8 mice per 
treatment block, which later changed to 2 blocks per treatment containing 8 mice per 
block, where 6 mice received treatment and the other 2 did not, but they all received 
radiation together. Unless stated otherwise, the mice were irradiated whole body 12 Gy 
(WBI) using 300 kVp X-rays at a dose rate of 1.84 Gy/min (+ 0.045 min) as single dose 
XRT. Depending on the treatment method, the mice either received chemical treatment 
before or after radiation exposure. All mice were euthanized 3 d and 14 h after WBI by 
CO2 inhalation. A 2 cm section of the jejunum was removed and fixed in neutral buffer 
formalin. Tissue transverse sections were cut at a thickness of 4 pm and stained with 
H&E. The number of surviving crypts per tissue cross-section was scored 
microscopically at 100X magnification. Surviving crypts were characterized as 
containing at least 10 non-Paneth epithelial cells by Kathy 
Materials. All chemicals were purchased from Sigma-Aldrich and used without 
further purification unless otherwise stated. Flagellin was purchased from InvivoGen. 
Misoprostol was donated by Pfizer. Amifostine was purchased from AB Chem. 
Psyllium husk was purchased from Traditional Medicinals. Whey protein was purchased 
from Designer Whey. Neuprex was donated by XOMA. Dialysis bags (50,000 MWCO) 
were purchased from CelluSep HI. Telactoferrin was donated by Agennix. Pluronic was 
donated by BASF. NanoPure water was obtained from a Barnstead water purification 
system and had a resistivity of 18 megaQ-cm or greater. SWCNTs (HPR 187.4) were 
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obtained from the HiPco laboratory at Rice University ' unless otherwise stated. 
Carbolex SWCNTs were purchased from CarboLex, Inc. Sonication was done using a 
bath sonicator, Cole parmer ultrasonic cleaner 08849-00, unless otherwise stated. Cup 
sonication was done using a Cole Parmer Ultrasonic Processor Model CP 750 and tip 
sonication was done using a Misonix Sonicator 3000 with a microtip. Homogenization 
was done using a homogenizer shaft driven by a Dremel Multipro model 395 motor and 
model 225 flexible shaft. The wrist-arm shaker used was a Burrell wrist action shaker 
and the platform shaker was Innova 2000 platform shaker. All solutions were 
administered within 24 h of preparation, and were each vortexed before administration to 
the mice. 
US-SWCNTs.22 US-SWCNTs were synthesized using a modified procedure 
where the moist filter cake of US-SWCNTs was transferred to a scintillation vial and 
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pulverized with a Teflon stir rod over light heat on a hot plate resulting in a fine, dry 
powder that was dried in a vacuum desiccator overnight. 
PEGylated US-SWCNTs. An oven dried 100 mL round bottom flask equipped 
with a stir bar was charged with US-SWCNTs (0.063 g, 5.2 mequiv C) and anhydrous 
DMF (50 mL). The mixture was stirred vigorously for 15 min under a nitrogen 
atmosphere. _/V,7V-dicyclohexylcarbodiimide (DCC, 1.08 g, 5.2 mmol) was added 
followed by methoxy polyethylene glycol amine (PEG, 0.50 g, 0.1 mmol, MW 5000) and 
4-dimethylaminopyridine (DMAP, 11 mg, 0.09 mmol). The mixture was stirred for 12 h 
and purified by dialysis (dialysis bag MWCO 50000) first in DMF for 1 d to remove 
water-insoluble organic byproducts, then for 4 d in flowing deionized water for further 
purification and replacement of the organic solvent by water. The product was repeatedly 
filtered through several layers of Kimwipes™ to remove remaining particulates. 
Continuous Flow Setup for Aqueous Dialysis.23 A deionized (DI) water supply 
was split into five separate lines using polypropylene T-joints and Nalgene tubing (80 
mm. i.d.). Each line was fed to the bottom of five separate 1 L beakers and the beakers 
were placed in a plastic tray (102 cm x 61 cm x 7.6 cm) fitted with three drains at one 
end; the other end was slightly elevated to promote drainage. The water source was 
turned on and the beakers were allowed to continually overflow. The flow rate was 
adjusted to prevent overflowing the tray. 
OPE-BHT derivatized SWCNTs (1). Prepared using the procedure described in 
Chapter 2. In order to produce a higher concentration, the SWCNTs were concentrated 
by blowing a constant stream of nitrogen over the solution until the desired concentration 
was achieved. 
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Ionic BHT SWCNTs (2). Prepared using the procedure described in Chapter 2. 
Pluronic wrapped SWCNT (3). Prepared Raw HiPco SWCNTs (0.09 g) and 
Pluronic F 108NF Prill Poloxamer 338 (2.25 g) in NANOPure water (225 mL) were 
homogenized for 1 h. The SWCNTs were then sonicated using a cup-horn sonicator for 
10 min at 78% amplitude and the mixture was ultra-centrifuged for 4 h at 29000 rpm. 
The SWCNTs in solution were decanted, and the solid material was discarded. 
Ionic diacid BHT PEI-PEGylated US-SWCNTs (4). In a 25 mL beaker 
equipped with a stir bar was added PEI-PEGylated US-SWCNTs (8 mL, 0.065 mmol). 
This was followed by dropwise addition of diacid BHT (0.021, 0.065 mmol) dissolved in 
a minimal amount of DMF. This was then allowed to stir at room temperature for 12 h 
followed by dialysis in water for 5 d. 
OPE-BHT derivatized SWCNTs (5). Prepared using procedure described in 
Chapter 2, except once the first functionalization was complete the functionalization was 
repeated in the same manner. 
Cystamine PEGylated US-SWCNTs (6). In a 25 mL beaker equipped with a 
stir bar was added PEGylated US-SWCNTs (50 mg, 4.16 mmol) in anhydrous DMF (50 
mL). To this were added cystamine (0.063, 0.416 mmol) and DCC (0.80 g, 4.16 mmol). 
The solution was stirred at room temperature for 12 h followed by dialysis (50000 
MWCO) in water for 5 d. 
Glutathione PEGylated US-SWCNTs (7). In a 25 mL beaker equipped with a 
stir bar was added PEGylated US-SWCNTs in water (6.5 mL, 0.063 mmol). This was 
followed by dropwise addition of glutathione (0.0194, 0.063 mmol) dissolved in a 
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minimal amount of DMF. The solution was stirred at room temperature for 12 h 
followed by dialysis (50000 MWCO) in water for 5 d. 
Covalent Amifostine PEG-US-SWCNTs (8). To a 100 mL round bottom flask 
equipped with a stir bar was added PEGylated US-SWCNTs (5 mL, 0.416 mequiv C) in 
anhydrous DMF. 7V,JV -dicyclohexylcarbodiimide (DCC, 0.218 g, 0.208 mmol) was 
added followed by amifostine (0.022 g, 0.103 mmol) and a few pellets of 4-
dimethylaminopyridine (DMAP, 11 mg, 0.09 mmol). The mixture was stirred for 12 h 
and purified by dialysis (dialysis bag MWCO 50000) first in DMF for 1 d to remove 
water-insoluble organic byproducts, then for 5 d in flowing deionized water for further 
purification and replacement of the organic solvent by water. 
BHA PEI-PEG-US-SWCNTs (9). In a 25 mL beaker equipped with a stir bar 
was added PEI-PEGylated US-SWCNTs in water (4 mL, 0.0225 mmol). This was 
followed by dropwise addition of butylated hydroxyanisole (BHA, 0.001, 0.0055 mmol) 
dissolved in a minimal amount of methanol. The solution was stirred at room 
temperature for 12 h followed by dialysis (50000 MWCO) in water for 5 d. 
BHT PEG-US-SWCNTs (10). In a 25 mL beaker equipped with a stir bar was 
added PEGylated US-SWCNTs in water (4 mL, 0.0203 mmol). This was followed by 
dropwise addition of butylated hydroxytoluene (BHT, 0.001, 0.0051 mmol) dissolved in 
a minimal amount of methanol. The solution was stirred at room temperature for 12 h 
followed by dialysis (50000 MWCO) in water for 5 d. 
BHA PEG-US-SWCNTs (11). In a 25 mL beaker equipped with a stir bar was 
added PEGylated US-SWCNTs in water (4 mL, 0.024 mmol). This was followed by 
dropwise addition of BHA (0.001, 0.006 mmol) dissolved in a minimal amount of 
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methanol. The solution was stirred at room temperature for 12 h followed by dialysis 
(50000 MWCO) in water for 5 d. 
PEI PEG-US-SWCNTs (12). In a 25 mL beaker equipped with a stir bar was 
added PEGylated US-SWCNTs in water (15 mL, 0.190 mmol). This was followed by 
dropwise addition of polyethylene imine (PEI, 0.095 g, 0.190 mmol) dissolved in a 
minimal amount of water. The solution was stirred at room temperature for 12 h 
followed by dialysis (50000 MWCO) in water for 1 d. 
PEG-PEI-US-SWCNTs (13). In a 50 mL oven dried round bottomed flask 
equipped with a stir bar was added US-SWCNTs (8 mg, 0.666 mmol) in anhydrous DMF 
(10 mL). The solution was sonicated in a bath sonicator (Cole Parmer Ultrasonic cleaner, 
model #08849-00) until the US-SWCNTs were dispersed. This was followed by addition 
of PEG-PEI (4000 MW, 0.2287 g, 0.066 mmol), DCC (0.137 g, 0.666 mmol), and 
DMAP (few pellets). The solution was stirred at room temperature for 12 h followed by 
dialysis (50000 MWCO) in water for 5 d. 
Misoprostol PEG-US-SWCNTs (14). In a 25 mL beaker equipped with a stir 
bar was added PEGylated US-SWCNTs in water (4 mL, 0.023 mmol). This was 
followed by dropwise addition of misoprostol (0.006, 0.016 mmol) dissolved in a 
minimal amount of methanol. The solution was stirred at room temperature for 12 h 
followed by dialysis (50000 MWCO) in water for 5 d. 
Pluronic Wrapped SWCNTs Shortened (15). Pluronic wrapped SWCNTs (3, 
10 mL) were shortened by tip sonication for 30 min after centrifugation. 
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SWCNTs in 2 wt% Pectin (16). SWCNTs (70 mg) were added to a 250 mL 
glass jar. To this was added pectin (450 mg) and NanoPure water (225 mL). The 
solution was homogenized for 1 h followed by cup sonication for 10 min. 
Carbolex SWCNTs in 2 wt% Pectin (17). Carbolex SWCNTs (70 mg) were 
added to a 250 mL glass jar. To this was added pectin (450 mg) and NanoPure water 
(225 mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
SWCNTs in 1 wt% Psyllium Husk (18). SWCNTs (70 mg) were added to a 250 
mL glass jar. To this was added psyllium husk (250 mg) and NanoPure water (225 mL). 
The solution was homogenized for 1 h followed by cup sonication for 10 min. 
Carbolex SWCNTs in 1 wt% Psyllium Husk (19). Carbolex SWCNTs (70 mg) 
were added to a 250 mL glass jar. To this was added psyllium husk (250 mg) and 
NanoPure water (225 mL). The solution was homogenized for 1 h followed by cup 
sonication for 10 min. 
SWCNTs in 2 wt% Whey Protein (20). SWCNTs (70 mg) were added to a 250 
mL glass jar. To this was added whey protein (450 mg) and NanoPure water (225 mL). 
The solution was homogenized for 1 h followed by cup sonication for 10 min. 
Carbolex SWCNTs in 2 wt% Whey Protein (21). Carbolex SWCNTs (70 mg) 
were added to a 250 mL glass jar. To this was added whey protein (450 mg) and 
NanoPure water (225 mL). The solution was homogenized for 1 h followed by cup 
sonication for 10 min. 
Carbolex SWCNTs in 2 wt% Pectin Decant (22). Carbolex SWCNTs (70 mg) 
were added to a 250 mL glass jar. To this was added pectin (450 mg) and NanoPure 
water (225 mL). The solution was homogenized for 1 h followed by cup sonication for 
103 
10 min. The resulting solution was centrifuged at 29000 rpm for 4 h and the supernatant 
was decanted and the solid containing material was discarded (about 20 mL were 
discarded). 
SWCNTs in 1 wt% SDS Decant (23). Carbolex SWCNTs (70 mg) were added 
to a 250 mL glass jar. To this was added sodium dodecyl sulfate (SDS, 2.25 g) and 
NanoPure water (225 mL). The solution was homogenized for 1 h followed by cup 
sonication for 10 min. The resulting solution was centrifuged at 29000 rpm for 4 h, the 
supernatant was decanted and the solid containing material was discarded (about 20 mL 
were discarded). 
Carbolex SWCNTs in 2 wt% Pectin Decant (24). Carbolex SWCNTs (70 mg) 
were added to a 250 mL glass jar. To this was added pectin (4.50 g) and NanoPure water 
(225 mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
The resulting solution was centrifuged at 29000 rpm for 4 h, the supernatant was 
decanted and the solid containing material was discarded (about 20 mL was discarded). 
Carbolex SWCNTs in 1 wt% Pectin Decant (25). Carbolex SWCNTs (70 mg) 
were added to a 250 mL glass jar. To this was added pectin (2.25 g) and NanoPure water 
(225 mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
The resulting solution was centrifuged at 29000 rpm for 4 h, the supernatant was 
decanted and the solid containing material was discarded (about 20 mL was discarded). 
Carbolex SWCNTs in 1 wt% Pectin (26). Carbolex SWCNTs (70 mg) were 
added to a 250 mL glass jar. To this was added pectin (2.25 g) and NanoPure water (225 
mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
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2 wt% Whey Protein + Misoprostol + Glutathione + Amifostine (27). To a 
solution of 2 wt% whey protein in water (4 mL) were added misoprostol (0.056 mg), 
glutathione (14.28 g), and amifostine (200 mg). The solution was sonicated in a bath 
sonicator for 10 min and placed on a wrist-arm shaker for 2 d. 
1 wt% Psyllium Husk + Misoprostol + Glutathione + Amifostine (28). To a 
solution of 1 wt% psyllium husk in water (4 mL) were added misoprostol (0.056 mg), 
glutathione (14.28 mg), and amifostine (200 mg). The solution was sonicated in a bath 
sonicator for 10 min and placed on a wrist-arm shaker for 2 d. 
2 wt% Pectin + Misoprostol + Glutathione + Amifostine (29). To a solution of 
2 wt% pectin (4 mL) in water was prepared. To this were added misoprostol (0.056 mg), 
glutathione (14.28 mg), and amifostine (200 mg). The solution was sonicated in a bath 
sonicator for 10 min and placed on a wrist-arm shaker for 2 d. 
SWCNTs in 2 wt% Whey Protein + Misoprostol (30). To a solution of 
SWCNTs in 2 wt% whey protein in water (20, 4 mL) was added misoprostol (0.056 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNT in 1 wt% Psyllium Husk + Misoprostol (31). To a solution of 
SWCNTs in 1 wt% psyllium husk in water (18, 4 mL) was added misoprostol (0.056 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
Carbolex SWCNTs in 2 wt% Pectin + Misoprostol (32). To a solution of 
Carbolex SWCNTs in 2 wt% pectin (17, 4 mL) in water was added misoprostol (0.056 
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mg). The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNTs in 2 wt% Whey Protein + Glutathione (33). To a solution of 
SWCNTs in 2 wt% whey protein (20, 4 mL) in water was added glutathione (14.28 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNTs in 1 wt% Psyllium Husk + Glutathione (34). To a solution of 
SWCNTs in 1 wt% psyllium husk in water (18, 4 mL) was added glutathione (14.28 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
Carbolex SWCNTs in 2 wt% Pectin + Glutathione (35). To a solution of 
Carbolex SWCNTs in 2 wt% pectin in water (17, 4 mL) was added glutathione (14.28 
mg). The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNTs in 2 wt% Whey Protein + Amifostine (36). To a solution of 
SWCNTs in 2 wt% whey protein in water (20, 4 mL) was added amifostine (200 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNTs in 1 wt% Psyllium Husk + Amifostine (37). To a solution of 
SWCNTs in 1 wt% psyllium husk in water (18, 4 mL) was added amifostine (200 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
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Carbolex SWCNTs in 2 wt% Pectin + Amifostine (38). To a solution of 
Carbolex SWCNTs in 2 wt% pectin in water (17, 4 mL) was added amifostine (200 mg). 
The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
SWCNTs in 2 wt% Whey Protein + Misoprostol + Glutathione + Amifostine 
(39). To a solution of SWCNTs in 2 wt% whey protein in water (20, 4 mL) were added 
misoprostol (0.056 mg), glutathione (14.28 mg), and amifostine (200 mg). The solution 
was sonicated in a bath sonicator for 10 min and placed on a wrist-arm shaker for 2 d. 
SWCNTs in 1 wt% Psyllium Husk + Misoprostol + Glutathione + Amifostine 
(40). To a solution of SWCNTs 1 wt% psyllium husk (18, 4 mL) were added misoprostol 
(0.056 mg), glutathione (14.28 mg), and amifostine (200 mg). The solution was 
sonicated in a bath sonicator for 10 min and placed on a wrist-arm shaker for 2 d. 
Carbolex SWCNTs in 2 wt% Pectin + Misoprostol + Glutathione + 
Amifostine (41). To a solution of Carbolex SWCNTs in 2 wt% pectin in water (17, 4 
mL) were added misoprostol (0.056 mg), glutathione, (14.28 mg) and amifostine (200 
mg). The solution was sonicated in a bath sonicator for 10 min and placed on a wrist-arm 
shaker for 2 d. 
Flagellin (42). Flagellin at a concentration of 100 |j,g/mL in lx PBS was used 
without any modification. 
PEG-US-SWCNTs + Flagellin (43). Flagellin (0.400 mL, 100 jig) was added to 
PEGylated US-SWCNTs (0.017, 366 mg/L) and lx PBS (1.58 mL). The sample was 
placed on a wrist arm shaker at 4 °C for 4 d. 
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PEGylated US-SWCNTs + Caffeic Acid (44). A stock solution of caffeic acid 
was made by adding caffeic acid (0.876 g) to a vial equipped with a stirbar. To this was 
added saturated NaOH (0.5 mL) and water (6 mL). NaOH was continued to be added 
dropwise until pH 9 was reached and all the caffeic acid was dissolved. The pH was 
lowered to pH 7 by dropwise addition of 6 M HC1. The final volume was increased to 12 
mL with water. 2 mL of this stock solution was slowly added to PEGylated US-
SWCNTs in water (1 mL, 366 mg/L). The solution was placed on the wrist-arm shaker 
for 3 d. 
PEGylated US-SWCNTs + Catechin (45). Catechin (0.02 lg) was added to 2 
mL of water and heated with a heat gun until all the catechin was dissolved. PEGylated 
US-SWCNTs in water (1 mL, 366 mg/L) were added dropwise to a stirring solution of 
catechin. The solution was placed on the wrist-arm shaker for 3 d. 
PEGylated US-SWCNTs + Caffeic acid + Catechin (46). 2 mL of the caffeic 
acid stock solution described in 44 was added to a vial equipped with a stirbar. To this 
was added catechin (0.021 g) and was heated with a heat gun until all the catechin was 
dissolved. The solution was allowed to cool to room temperature and then PEGylated 
US-SWCNTs in water (1 mL, 366 mg/L) were added dropwise. The solution was placed 
on the wrist-arm shaker for 3 d at room temperature. 
PEGylated US-SWCNTs + EGF (47). Epidermal Growth Factor (EGF, 80 pL) 
was added to PEGylated US-SWCNTs in water (0.234 mL, 366 mg/L) and PBS (1.65 mL, 
lx). The sample was placed on a wrist arm shaker in a cold room for 4 d. 
EGF only (48). EGF (80 pL) was added to lx PBS (1.92 mL). The sample was 
placed on a wrist arm shaker at 4 °C for 4 d. 
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Flagellin wrapped SWCNTs (49). Flagellin (0.400 mL, 100 pg) was added to 
pluronic wrapped SWCNTs in water (0.067) and lx PBS (1.43 mL). The sample was 
placed on a wrist arm shaker at 4 °C for 4 d. 
PEGylated US-SWCNTs + p53 (50). Protein 53 (p53, 0.053 mL) was added to 
PEGylated US-SWCNTs in water (0.002, 366 mg/L) and lx PBS (1.92 mL). The sample 
was placed on a wrist arm shaker at 4 °C for 4 d. 
SWCNTs Pectin + Caffeic Acid (51). SWCNTs wrapped in 2 wt% pectin in 
water (0.5 mL) were diluted with water (0.5 mL) and stirred vigorously. To this was 
added 2 mL of the stock solution of caffeic acid as described in 44. The solution was 
sonicated for 20 min in a bath sonicator and placed on the wrist-arm shaker for 3 d. 
SWCNTs in Whey Protein + Caffeic Acid (52). SWCNTs wrapped in 2 wt% 
whey protein in water (1 mL) were stirred vigorously, and to this was added 2 mL of the 
stock solution of caffeic acid as described in 44. The solution was sonicated for 20 min 
in a bath sonicator and placed on the wrist-arm shaker for 3 d. 
Pectin + Whey Protein + Caffeic Acid + Catechin (53). Catechin (0.021 g) was 
added to a stock solution of caffeic acid (2 mL) as described in 44. The solution was 
slowly heated with a heat gun until all the catechin was in solution. The solution was 
allowed to slowly cool to room temperature and a solution of 1 wt% whey protein and 1 
wt% pectin in water (1 mL) was added dropwise to the stirring solution of caffeic acid 
and catechin. The solution was sonicated for 20 min in a bath sonicator and placed on the 
wrist-arm shaker for 3 d. 
SWCNTs in Pectin + Whey Protein + Caffeic Acid + Catechin (54). SWCNTs 
wrapped in 2 wt% pectin in water (1 mL) were diluted with water (1 mL). To this was 
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added 1 wt% whey protein in water (1 mL). The mixtures was sonicated in a bath 
sonicator until a homogeneous solution was seen. In a separate vial, 2 mL of the caffeic 
acid stock solution as described 44 was added followed by addition of catechin (0.021 g). 
The solution was heated with a heat gun until all the catechin was dissolved. The 
solution was allowed to slowly cool to room temperature and the SWCNTs with pectin 
and whey protein were slowly added. The solution was sonicated for 20 min in a bath 
sonicator and placed on the wrist-arm shaker for 3 d. 
2 wt % Whey Protein + Misoprostol + Glutathione + Amifostine (55). To a 2 
wt% solution of whey protein in water (3.66 mL) was added glutathione (0.33 mL), 
amifostine (0.200 g), and misoprostol (0.05 mL). The solution was sonicated for 10 min 
and then placed on a wrist-arm shaker for 4 d. 
1 wt % Psyllium Husk + Misoprostol + Glutathione + Amifostine (56). To a 1 
wt% solution of psyllium husk in water (3.66 mL) was added glutathione (0.33 mL), 
amifostine (0.200 g), and misoprostol (0.05 mL). The solution was sonicated for 10 min 
and then placed on a wrist-arm shaker for 4 d. 
2 wt % Pectin + Misoprostol + Glutathione + Amifostine (57). To a 2 wt% 
solution of pectin in water (3.66 mL) was added glutathione (0.33 mL), amifostine (0.200 
g), and misoprostol (0.05 mL). The solution was sonicated for 10 min and then placed on 
a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Whey Protein + Misoprostol (58). To a 2 wt% solution of 
SWCNTs in whey protein (20, 4 mL) was added misoprostol (0.05 mL). The solution 
was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
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SWCNTs in 1 wt % Psyllium Husk + Misoprostol (59) To a 1 wt% solution of 
SWCNTs in psyllium husk in water (18, 4 mL) was added misoprostol (0.05 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Pectin + Misoprostol (60). To a 2 wt% solution of 
SWCNTs in pectin in water (16, 4 mL) was added misoprostol (0.05 mL). The solution 
was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Whey Protein + Glutathione (61). To a 2 wt% solution of 
SWCNTs in whey protein in water (20, 3.66 mL) was added glutathione (0.33 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 1 wt % Psyllium Husk + Glutathione (62). To a 1 wt% solution of 
SWCNTs in psyllium husk in water (18, 3.66 mL) was added glutathione (0.33 g). The 
solution was sonicated for 10 min and was placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Pectin + Glutathione (63). To a 2 wt% solution of 
SWCNTs in pectin in water (16, 3.66 mL) was added glutathione (0.33 g). The solution 
was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Whey Protein + Amifostine (64). To a 2 wt% solution of 
SWCNTs in whey protein in water (20, 3.66 mL) was added amifostine (0.200 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 1 wt % Psyllium Husk + Amifostine (65). To a 1 wt% solution of 
SWCNTs in psyllium husk in water (18, 3.66 mL) was added amifostine (0.200 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d at room 
temperature. 
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SWCNTs in 2 wt % Pectin + Amifostine (66). To a 2 wt% solution of 
SWCNTs in pectin in water (16, 3.66 mL) was added amifostine (0.200 g). The solution 
was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Whey Protein + Misoprostol + Glutathione + Amifostine 
(67). To a solution of SWCNTs in 2 wt% whey protein in water (20, 3.66 mL) were 
added glutathione (0.33 mL), amifostine (0.200 g), and misoprostol (0.05 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 1 wt % Psyllium Husk + Misoprostol + Glutathione + 
Amifostine (68). To a solution of SWCNTs in 1 wt% psyllium husk in water (18, 3.66 
mL) were glutathione (0.33 mL), amifostine (0.200 g), and misoprostol (0.05 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Pectin + Misoprostol + Glutathione + Amifostine (69). To 
a solution of SWCNTs in 2 wt% pectin (16, 3.66 mL) were added glutathione (0.33 mL), 
amifostine (0.200 g), and misoprostol (0.05 mL). The solution was sonicated for 10 min 
and then placed on a wrist-arm shaker for 4 d. 
PEGylated US-SWCNTs + Ionic BHT + Whey Protein (70). Ionic BHT 
SWCNTs in water (2, 2 mL) was added to a vial. To this was added a solution 2 wt% 
whey protein in water (2 mL). The solution was sonicated for 10 min and then placed on 
a wrist-arm shaker for 4 d. 
Ionic BHT SWCNTs + Pectin (71). Ionic BHT SWCNTs in water (2, 2 mL) 
was added to a vial. To this was added a solution of 2 wt% pectin in water (2 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
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PEGylated US-SWCNTs + Misoprostol + Glutathione + Amifostine (72). To 
PEGylated-US-SWCNTs (3.66 mL, 633 mg/L) was added glutathione (0.33 mL), 
amifostine (0.200 g), and misoprostol (0.05 mL). The solution was sonicated for 10 min 
and then placed on a wrist-arm shaker for 4 d. 
PEGylated US-SWCNTs + Cystamine (73). To PEGylated-US-SWCNTs in 
water (3.66 mL, 633 mg/L) was added cystamine (0.030 g) and water (0.33 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
PEGylated US-SWCNTs + D-Methionine (74). To PEGylated-US-SWCNTs in 
water (3.33 mL, 633 mg/L) was added D-Methione (0.66 g). The solution was sonicated 
for 10 min and placed on a wrist-arm shaker for 4 d. 
SWCNTs in 2 wt % Whey Protein + D-Methionine (75). To SWCNTs in 2 
wt% whey protein (20, 3.33 mL) was added D-methione (0.66 g). The solution was 
sonicated for 10 min and then placed on a wrist-arm shaker for 4 d. 
D-Methionine (76). D-methionine (0.66 mL) was dissolved in water (3.33 mL) 
and sonicated for 10 min. The sample was placed on a wrist-arm shaker for 4 d. 
2 wt% Whey Protein (77). A solution of 2 wt% whey protein in water (4 mL) 
was sonicated for 5 min and placed on a wrist-arm shaker for 4 d. 
5 wt% Whey Protein (78). A solution of 5 wt% whey protein in water (4 mL) 
was sonicated for 5 min and placed on a wrist-arm shaker for 4 d. 
SWCNTs in 5 wt% Whey Protein (79). SWCNTs (70 mg) were added to a 250 
mL glass jar. To this was added whey protein (11.05 g) and NanoPure water (225 mL). 
The solution was homogenized for 1 h followed by cup sonication for 10 min. 
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SWCNTs (2x) in 2 wt% Whey Protein (80). SWCNTs (140 mg) were added to 
a 250 mL glass jar. To this was added whey protein (450 mg) and NanoPure water (225 
mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
SWCNTs (2x) in 5 wt% Whey Protein (81). SWCNTs (140 mg) were added to 
a 250 mL glass jar. To this was added whey protein (11.05 g) and NanoPure water (225 
mL). The solution was homogenized for 1 h followed by cup sonication for 10 min. 
SWCNTs in 10 wt% TLF (82). SWCNTs (10 mg) were added to a 25 mL glass 
jar. To this was added Talactoferrin (TLF, 10 mg). The solution was homogenized in an 
ice bath for 1 h followed by tip sonication in an ice bath for 10 min. The solution was 
placed on a platform shaker at 4 °C for 3 d. 
SWCNTs in 1.8 wt% Whey Protein + 10 wt% TLF (83). SWCNTs in a 1.8 
wt% solution of whey protein (20, 9 mL) was added to TLF (1 mL, 10 wt%). The 
solution was homogenized for 45 min in an ice batch and placed on a platform shaker at 
4 °C for 3 d. 
SWCNTs in 2 wt% TLF (84). SWCNTs (0.02 g) were added to a 100 mL glass 
jar. To this was added TLF (11.2 mL), whey protein (0.56 g) and NanoPure water (44.8 
mL). The solution was homogenized for 1 h in an ice bath followed by tip sonication for 
10 min in an ice bath and was then placed on a platform shaker at 4 °C for 3 d. 
10 wt% TLF (85). TLF (3 mL) was diluted to a 10 wt % solution using water. It 
was then placed on the platform shaker at 4 °C for 3 d. 
Bismuth Subsalicylate SWCNTs Protein (86). SWCNTs (140 mg) were added 
to a 250 mL glass jar. To this was added bismuth subsalicylate (200 mL) and NanoPure 
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water (20 mL). The solution was homogenized for 1 h followed by cup sonication for 10 
min and wrist arm shaking for 3 d. 
Bismuth Subsalicylate (87). A solution bismuth subsalicylate in water (15 
mg/mL) was prepared. The solution was sonicated for 10 min followed by 3 d of wrist-
arm shaking. 
Bismuth Subsalicylate in 2 wt% Whey Protein (88). To a solution of 5 wt% 
whey protein in water (1.6 mL) was added bismuth subsalicylate (2.4 mL). The solution 
was sonicated for 10 min followed by 3 d of wrist-arm shaking. 
SWCNTs Wrapped in 2 wt% Whey Protein + Bismuth Subsalicylate (89). To 
a solution of SWCNTs in 2 wt% whey (20, 1.6 mL) was added bismuth subsalicylate 
(2.4 mL). The solution was sonicated for 10 min followed by 3 d of wrist-arm shaking. 
PEGylated US-SWCNTs + Bismuth Subsalicylate (90). To a solution of 
PEGylated US-SWCNTs (1.6 mL, 356 mg/L) was added bismuth subsalicylate (2.4 mL). 
The solution was sonicated for 10 min followed by 3 d of wrist-arm shaking. 
PEGylated US-SWCNTs + Bismuth Subsalicylate in 2 wt % Whey Protein 
(91). To a solution of PEGylated US-SWCNTs (1.6 mL, 356 mg/L) was added bismuth 
subsalicylate (2.4 mL) and whey protein (0.08 g). The solution was sonicated for 10 min 
followed by 3 d of wrist-arm shaking. 
PEGylated US-SWCNTs + Neuprex (92). To a solution of PEGylated US-
SWCNTs (1 mL, 461 mg/L) was added Neuprex (1 mL). The solution was sonicated for 
10 min followed by 3 d of wrist-arm shaking. 
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SWCNTs wrapped in 2 wt% Whey Protein + Neuprex (93). To a solution of 
PEGylated US-SWCNTs (1 mL, 461 mg/L) was added Neuprex (1 mL) and whey protein 
(0.08 g). The solution was sonicated for 10 min followed by 3 d of wrist-arm shaking. 
Neuprex (94). To 1 mL of Neuprex (2mg/mL) was added water (1 mL). The 
solution was placed on the wrist-arm shaker for 3 d at 4 °C. 
Neuprex in 2 wt % Whey Protein (95). To a solution of 2 wt% whey protein in 
water (1.6 mL) was added Neuprex (1 mL). The solution was sonicated for 10 min 
followed by 3 d of wrist-arm shaking. 
US-SWCNTs + Bismuth Subsalicylate (96). To a solution of PEGylated US-
SWCNTs in water (1.6 mL, 356 mg/L) was added bismuth subsalicylate (2.4 mL). The 
solution was sonicated for 10 min followed by 3 d of wrist-arm shaking. 
US-SWCNTs + Bismuth Subsalicylate in 2 wt % Whey Protein (97). To a 
solution of US-SWCNTs in water (1.6 mL, 356 mg/L) was added bismuth subsalicylate 
(2.4 mL) and whey protein (0.08 g). The solution was sonicated for 10 min followed by 
3 d of wrist-arm shaking. 
SWCNTs wrapped in 2 wt% Whey Protein + Probiotic (98). To a solution of 
SWCNTs wrapped in 2 wt% whey protein in water (20, 4 mL) was added cultured 
probiotic (2 capsules). The solution was sonicated for 10 min followed by 3 d of wrist-
arm shaking. 
2 wt% Whey Protein + Probiotic (99). To a 2 wt% solution of whey protein in 
water (4 mL) was added cultured probiotic (2 capsules). The solution was sonicated for 
10 min followed by 3 d of wrist-arm shaking. 
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PEG-US-SWCNTs + TLF (100). To a solution of PEG-US-SWCNTs in water 
(3.75 mL, 633 mg/L) was added TLF (1.25 mL). The solution was sonicated for 10 min 
followed by 3 d of wrist-arm shaking. 
SWCNTs in 1 wt% Psyllium Husk + Amifostine (x2) (101). To a solution of 
SWCNTs in 1 wt% psyllium husk in water (18, 3 mL) was added amifostine (0.225 g). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 2 d. 
PEG-US-SWCNTs + Glutathione + Amifostine (x2) (102). To a solution of 
PEGylated US-SWCNTs in water (3 mL, 633 mg/L) was added amifostine (0.225 g) and 
glutathione (0.021 g). The solution was sonicated for 10 min and then placed on a wrist-
arm shaker for 2 d. 
PEG-US-SWCNTs + Glutathione (x2) (103). To a solution of PEGylated US-
SWCNTs in water (3 mL, 633 mg/L) was added glutathione (0.042 g). The solution was 
sonicated for 10 min and then placed on a wrist-arm shaker for 2 d. 
Amifostine + Whey Protein (104). Amifostine (0.170 g) and whey protein 
(0.068) were added to water (3.4 mL). The solution was sonicated for 10 min and then 
placed on a wrist-arm shaker for 2 d. 
Amifostine + Whey Protein + PEG-US-SWCNTs (105). Amifostine (0.170 g) 
and whey protein (0.068) were added to PEGylated US-SWCNTs in water (3.4 mL, 533 
mg/L). The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 
2 d . 
Amifostine + Psyllium Husk (106). Amifostine (0.170 g) and psyllium husk 
(0.034) were added to water (3.4 mL). The solution was sonicated for 10 min and then 
placed on a wrist-arm shaker for 2 d. 
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Amifostine + Psyllium Husk + PEG-US-SWCNTs (107). Amifostine (0.170 g) 
and psyllium husk (0.034) were added to PEGylated US-SWCNTs in water (3.4 mL, 633 
mg/L). The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 
2d . 
Amifostine in Water (108). Amifostine (0.170 g) was dissolved in water (3.2 
mL) and was sonicated for 10 min and then placed on a wrist-arm shaker for 2 d. 
Amifostine + PEG-US-SWCNTs (109). Amifostine (0.170 g) was added to 
PEGylated US-SWCNTs in water (3.2 mL, 633 mg/L). The solution was sonicated for 
10 min and then placed on a wrist-arm shaker for 2 d. 
Amifostine + Pectin (110). Amifostine (0.170 g) and pectin (0.068) were added 
to water (3.4 mL). The solution was sonicated for 10 min and then placed on a wrist-arm 
shaker for 2 d. 
Amifostine + Pectin + PEG-US-SWCNTs (111). Amifostine (0.170 g) and 
pectin (0.068 g) were added to PEGylated US-SWCNTs in water (3.2 mL, 633 mg/L). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 2 d. 
PEG Nanoribbons (112). An oven dried 100 mL round bottom flask equipped 
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with a stir bar was added nanoribbons (0.050 g, 4.2 mmol of carbon) and anhydrous 
DMF (50 mL). The mixture was bath sonicated for 30 min under a nitrogen atmosphere. 
DCC (412 mg, 2 mmol) was added followed by 10,000 MW PEG (366 mg, 0.04 mmol), 
and a few pellets of DMAP. The mixture was stirred overnight and purified by dialysis 
(MWCO 50000) in DMF for 1 d and water for 5 d. The solution of PEG-NR was then tip 
sonicated for 15 min. 
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Amifostine + PEG Nanoribbons (113). Amifostine (0.112 g) was added to 
PEGylated nanoribbons in water (2.25 mL). The solution was sonicated for 10 min and 
then placed on a wrist-arm shaker for 3 d. 
Amifostine Control (114). Amifostine (0.187 g) was added to water (1.5 mL). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Amifostine Fresh (115). Amifostine (0.187 g) was added to water (1.5 mL). The 
solution was sonicated for 10 min on the day of administration. 
Amifostine + Pluronic wrapped SWCNTs Decant (116). To a solution of 
Pluronic wrapped SWCNTs decant in water (3, 1.5) was added amifostine (0.187 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 2 d. 
Amifostine + Pluronic wrapped SWCNTs (117). Pluronic wrapped SWCNTs 
in water (3 without centrifugation, 1.5 mL) were place in a small vial. To this was added 
amifostine (0.187 g). The solution was sonicated for 10 min and then placed on a wrist-
arm shaker for 3 d. 
Glutathione + PEG-US-SWCNTs (118). PEGylated US-SWCNTs in water (1.5 
mL, 300 mg/L) were place in a small vial. To this was added glutathione (0.269 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Glutathione Control (119). Glutathione (0.269 g) was added to water (1.5 mL). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Cystamine + PEG-US-SWCNTs (120). PEGylated US-SWCNTs in water (1.5 
mL, 300 mg/L) were place in a small vial. To this was added cystamine (0.075 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
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Cystamine Control (121). Cystamine (0.075 g) was added to water (1.5 mL). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
PEI-SWCNTs (122). To US-SWCNTs (5 mg) was added a 1 wt% of 
triethanolamine in water (5 mL). The solution was sonicated in a bath sonicator for 5 
min and then a 1 wt% solution of PEI (10000 MW, 5 mL) was added. The solution was 
sonicated for another 5 min and 5% sodium borohydride in 2 M sodium hydroxide (3.5 
mL) was added. HC1 (6 M) was added dropwise until no gas evolved. The solution was 
neutralized with 2 M NaOH until a neutral pH was reached. The solution was then 
dialyzed (50000 MWCO) in water for 5 d. 
Amifostine + PEI-SWCNTs (123). PEI-SWCNTs in water (1.5 mL, 269 mg/L) 
were placed in a small vial. To this was added amifostine (0.188 g). The solution was 
sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Cysteamine + PEG-US-SWCNTs (124). PEGylated US-SWCNTs in water (1.5 
mL, 300 mg/L) were placed in a small vial. To this was added cysteamine (0.075 g). 
The solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Cysteamine (125). Cysteamine (0.075 g) was added to water (1.5 mL). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Amifostine + BHT-Acid + PEG-US-SWCNTs (126). To a solution of ionic 
BHT SWCNTs in water (2, 1.5 mL, 278 mg/L) was added amifostine (0.187 g). The 
solution was sonicated for 10 min and then placed on a wrist-arm shaker for 3 d. 
Amifostine + Psyllium Husk + PEG-US-SWCNTs (127). PEGylated US-
SWCNTs in water (1.5 mL, 300 mg/L) were placed in a small vial. To this was added 
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psyllium husk (0.015 g) and amifostine (0.187 g). The solution was sonicated for 10 min 
and then placed on a wrist-arm shaker for 3 d. 
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3.6 Experimental Contributions 
My contributions to the experimental work in this chapter are the following: 
experimental design and synthesis of about 85 % of all the formulations listed in this 
chapter. Katherine Price, Jacob Berlin, Dmitry Kosynkin, Meng Lu, and Rebecca 
Lucente-Schultz assisted with the synthesis. Audra Doades and Kathy Mason at MD 
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Anderson Cancer Center performed all the mouse experiments. Kathy Mason at MD 
Anderson Cancer Center counted all the crypts for analysis. Jeffery Morris at MD 
Anderson Cancer Center developed the routine and performed all of the statistical 
analysis on the procedures that used two controls per block of 8 mice. 
Chapter 4 
Fluorescent Single-Walled Carbon Nanotubes 
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4.1 Introduction 
With the growing research dealing with single-walled carbon nanotubes 
(SWCNTs) in many areas of science, imaging of these molecules is essential. Several 
different methods of imaging SWCNTs have been explored to date. Fluorescence is a 
common and inexpensive way to image SWCNTs, and can be investigated in two 
different ways with SWCNTs. 
SWCNTs have an inherent fluorescence because of their extended conjugation 
which allows for direct imaging using a fluorescent microscope.1 This has been shown to 
be a viable tool in the tracking of SWCNTs both in vivo and in vitro. But once the 
SWCNTs are covalently functionalized, their fluorescence quickly diminishes due to 
disruption of the extended conjugation with sp3 bonds, thereby eliminating this option for 
functionalized SWCNTs. In fact, one addend covalently attached will quench 
fluorescence over 90 nm of SWCNTs.2 Because many SWCNTs used for biological and 
other materials applications are heavily functionalized, complementing their inherent 
through appended fluorophores is essential. 
One difficulty in attaching fluorescent tags to the SWCNTs is that the extended n-
system of the SWCNTs can quench much of the appendage's fluorescence making 
imaging difficult. In this chapter, we further examine the attachment of fluorescent 
molecules to SWCNTs through both covalent and non-covalent bonds. 
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4.2 Results and Discussion 
Fluorescein and fluorescein isothiocyanate (FITC) were the fluorescent tags used 
in this work with SWCNTs. These fluorescent tags are inexpensive and can be easily 
attached to the SWCNTs. 
Sequestration of FITC in PEG-US-SWCNTs 
As discussed in Chapter 2, hydrophobic molecules can be sequesterd by PEG-
SWCNTs. FITC has very low water solubility, making it a good fluorescent molecule to 
be sequestered by PEG-US-SWCNTs. As shown in Figure 4.1, FITC was sequestered by 
the PEG-SWCNT matrix. After one month of dialysis the fluorescence was still retained 
and can be imaged in vitro. With our collaborator, Valerie Moore at the University of 
Texas Health Science Center, Houston, SWCNTs were imaged using a confocal 
microscope in both liver and microphage cells. As shown Figure 4.2, FITC/PEG-US-
SWCNTs are internalized by both liver and macrophage cells while still retaining their 
fluorescence. 
Figure 4.1. Sequestration of FITC in PEG-US-SWCNTs to give FITC/PEG-US-
S WCNTs, 1. 
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Figure 4.2. Confocal microscopy of FITC-PEG-US-SWCNTs in A) liver cells and B) 
macrophage cells. The SWCNTs are internalized and evenly distributed throughout the 
cytoplasm. 
PEI/FITC/PEG-US-SWCNTs and Fl/PEI/PEG-US-SWCNTs 
It has been shown that wrapping DNA with polyethylene imine (PEI), directs the 
DNA to the nucleus of cells when the wrapped DNA is exposed to cells in vitro. 
Addition of PEI to FITC/PEG-US-SWCNTs was investigated to yield PEI/FITC/PEG-
US-SWCNTs by an acid base complexing as shown in Figure 4.3. In Figure 4.4a, the 
SWCNTs are fluorescent after water dialysis, and preliminary results from Valerie Moore 
indicated that the PEI/FITC/PEG-US-SWCNTs associate with the nucleus of the cells 
(Figure 4.4b). It has not been confirmed if it is simple association or internalization of 
the nanovectors in the nucleus, but this will be further investigated. 
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Figure 4.3. Addition of PEI to FITC/PEG-US-SWCNTs to give PEI/FITC/PEG-US-
SWCNTs (2). 
A B 
Figure 4.4. a) PEI/FITC/PEG-US-SWCNTs under UV irradiation (365 nm) using two 
hand lamps, b) Association of PEI/FITC/PEG-US-SWCNTs with the nucleus of 
macrophage cells. 
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Using the same ionic association, PEI was added to PEG-US-SWCNTs, where the 
primary amines of the PEI can associate with the carboxylic acids on the US-SWCNTs, 
leaving many open amines for the association with fluorescein. Fluorescein (Fl) is a 
water soluble molecule that can associate with the PEI/PEG-US-SWCNT matrix through 
ionic interactions to give Fl/PEI/PEG-US-SWCNTs (4) as shown in Figure 4.5. Water 
dialysis was used for only 1 d. Prolonged dialysis was avoided since Fl is water soluble 
and after multiple days of dialysis the fluorescence of Fl/PEI/PEG-US-SWCNTs 
significantly decreases. 
Figure 4.5. Addition of PEI and Fl to PEG-US-SWCNTs to yield Fl/PEI/PEG-US-
SWCNTs, 4. 
MeO. 
'O 
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PEI-US-SWCNTs 
With the encouraging results of cell nucleus association with PEI-PEG-US-
SWCNTs, a method to covalently attach PEI to US-SWCNTs was sought. As shown in 
Figure 4.6, PEI was attached to US-SWCNTs using reductive amination to yield PEI-US-
SWCNTs (6). These PEI-US-SWCNTs were then associated with F1 to give Fl/PEI-US-
SWCNTs (7). These Fl/PEI-US-SWCNTs are soluble in both water and PBS, making in 
vitro testing possible. 
Figure 4.6. Covalent attachment of PEI to US-SWCNTs through reductive amination to 
give PEI-US-SWCNTs (6), which were associated with F1 to give Fl/PEI-US-SWCNTs 
(7). 
130 
Cystamine-FITC-SWCNTs 
Another method of attaching of a fluorescent tag to SWCNTs is through a 
cleavable linker. Cystamine, a cleavable disulfide linker, was initially investigated to 
attach FITC as a proof of concept for cleaving other drugs from the SWCNTs. As shown 
in Figure 4.7, FITC was covalently attached to cystamine, to yield FITC-cystamine (8), 
which was then attached to PEG-US-SWCNTs. It was found that the SWCNTs quench 
much of the FITC fluorescence, as shown in Table 4.1 entry 1, the fluorescence intensity 
was 202. But, after addition of dithiothreitol (DTT), which is known to cleave disulfides, 
the fluorescence increased to 637 (entry 2) and after filtering the SWCNTs away from the 
cleaved FITC derivative (10), the fluorescence increased to greater than 1000 (entry 3). 
This cleavable fluorescent matrix could be used for in vitro applications and as a 
chemical sensor in the oil industry. 
For in vitro work, when the FITC is attached to the US-SWCNTs through the 
cystamine linker, the matrix would not fluoresce, but for example, if the SWCNTs were 
to enter the cancer cells that are at a lower pH than other cells, then the disulfide would 
be cleaved and the fluorescence would be detected. This would be a good indication that 
the SWCNTs actually entered the cells and were not just associated with the cells. 
Another application of FITC-cystamine-PEG-US-SWCNTs is for use as chemical 
sensors in oilfield applications. One danger in oil and gas drilling is the unexpected 
exposure to hydrogen sulfide. This system could potentially sense hydrogen sulfide 
down hole, since the presence of hydrogen sulfide would cleave the disulfide, releasing 
the FITC, and sensing the presence of hydrogen sulfide. This is an example of a nano 
chemo-sensor for oilfield applications. 
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Figure 4.7. Synthesis of a cleavable fluorescent tag to PEG-US-SWCNTs. 
Description Fluorescence Intensity 
1 FITC-PEG-US-SWCNTs (9) 202 
2 Reaction with DTT (10+11) 637 
3 Filtrate after addition of DTT (12) > 1000 
4 DTT in water 4.0 
5 Water 1.0 
Table 4.1. Fluorescence intensity of FITC-PEG-US-SWCNTs (9), after reaction with 
DTT (10 and 11), filtrate after reaction with DTT (12), DTT and water control. 
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4.3 Conclusions 
In conclusion several different methods of attaching FITC and Fl covalently and 
non-covalently to SWCNTs were developed. These systems have been shown to work in 
vitro with liver and macrophage cells. These methods could be broadened to attach other 
molecules, for example drugs or payloads, in the manner as FITC and Fl. Further 
development of these fluorescent SWCNT matrixes is warranted for in vitro applications 
and for use as a chemical sensor in downhole oilfield applications. 
4.4 Experimental 
General. All chemicals were purchased from Sigma-Aldrich and used without 
further purification unless otherwise stated. SWCNTs (Lot# HPR 187.4) were obtained 
from the HiPco laboratory at Rice University.4'5 Dialysis bags (50000 MWCO) were 
purchased from CelluSep HI. Sonication was done using a bath sonicator, Cole Parmer 
ultrasonic cleaner 08849-00. Thermogravimetric analysis was performed using a heating 
rate of 10 °C/min under argon. Raman spectroscopy was performed on a Renishaw 
Raman microscope using a 633 nm He-Ne laser, taking the median of five scans. XPS 
analysis was carried out on a PHI Quantera SXM Scanning X-ray Microprobe with a pass 
energy of 26.00 eV, 45° takeoff angle and a 100 pm beam size. Samples were evacuated 
prior to XPS analysis at room temperature and 0.1 mm Hg for 12 h. 
Continuous Flow Setup for Aqueous Dialysis.6 A deionized (DI) water supply 
was split into five separate lines using polypropylene T-joints and Nalgene tubing (80 
mm. i.d.). Each line was fed to the bottom of five separate 1 L beakers and the beakers 
were placed in a plastic tray (102 cm x 61 cm * 7.6 cm) fitted with three drains at one 
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end; the other end was slightly elevated to promote drainage. The water source was 
turned on and the beakers were allowed to continually overflow. The flow rate was 
adjusted to prevent overflowing the tray. 
US-SWCNTs (5).7 US-SWCNTs were synthesized using a modified procedure 
where the moist filter cake of US-SWCNTs was transferred to a scintillation vial and 
pulverized with a Teflon stir rod over light heat on a hot plate resulting in a fine, dry 
powder that was dried in a vacuum desiccator overnight. The Raman diamondoid-to-
graphitic (D/G) ratio was 1.7 and the thermogravimetric analysis (TGA) mass loss was 
53%. The X-ray photoelectron spectroscopy (XPS) atomic concentrations were: C l s 
66%, Ols 32%, S2p 1.5% similar to previously described heavily carboxylated 
nanotubes.7 
PEGylated US-SWCNTs (3).6 To an oven dried 100 mL round bottom flask 
equipped with a stir bar was added US-SWCNTs (0.063 g, 5.2 mmol) and anhydrous 
DMF (50 mL). The mixture was stirred vigorously for 15 min under a nitrogen 
atmosphere. N,N'-dicyclohexylcarbodiimide (DCC, 1.08 g, 5.2 mmol) was added 
followed by methoxy polyethylene glycol amine (PEG, 0.50 g, 0.1 mmol, MW 5000) and 
4-dimethylaminopyridine (DMAP, 11 mg, 0.09 mmol). The mixture was stirred for 12 h 
and purified by dialysis (dialysis bag MWCO 50000) first in DMF for 1 d to remove 
water-insoluble organic byproducts, then for 4 d in flowing deionized water for further 
purification and replacement of the organic solvent by water. TGA mass loss was 76%. 
The X-ray photoelectron spectroscopy (XPS) atomic concentrations were: C=65.9%, 
N=3.4%, 0=30.3%. 
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FITC/PEG-US-SWCNTs (1). In a 25 mL beaker equipped with a stir bar was 
added PEGylated US-SWCNTs in water (15 mL, 0.749 mmol, 594 mg/L). In a separate 
vial FITC (0.029 g, 0.075 mmol) was dissolved in 1 mL of DMF. The FITC was added 
dropwise to the PEGylated US-SWCNTs while stirring vigorously. This mixture was 
allowed to stir for 12 h followed by continuous water dialysis (50000 MWCO) from 5 d -
30 d. 
PEI/FITC/PEG-US-SWCNTs (2). In a 25 mL beaker equipped with a stir bar 
was added FIT/PEG-US-SWCNTs in water (1, 20 mL, 0.719 mmol, 432 mg/L). To this 
was added dropwise a solution of polyethylene imine (PEI, 0.092 g, 0.046 mmol) 
dissolved in a minimal amount of water. The mixture was stirred for 12 h followed by 
dialysis (50000 MWCO) in water for 1 d. 
Fl/PEI/PEG-US-SWCNTs (4). To a solution of PEG-US-SWCNTs (15 mL, 
0.0699 mmol) was added PEI (2000 MW, 0.14 g, 0.0699 mmol). The solution was 
allowed to stir for 12 h followed by 5 d of water dialysis (50000 MWCO). The solution 
was then placed in a 25 mL beaker and Fl (0.023 g, 0.0699 mmol) dissolved in water (2 
mL) was added dropwise. The solution was allowed to stir for 12 h, followed by 1 d of 
water dialysis (50000 MWCO). 
PEI-US-SWCNTs (6). To US-SWCNTs (5, 5 mg) was added a 1 wt% of 
triethanolamine in water (5 mL). The solution was sonicated in a bath sonicator for 5 
min followed by addition of a 1 wt% solution of PEI (10000 MW, 5 mL). The mixture 
was sonicated for 5 min and 5% sodium borohydride in 2 M sodium hydroxide (3.5 mL) 
was added. HC1 (6 M) was then added dropwise until no more H2 gas evolved. The 
solution was neutralized with 2 M NaOH until a neutral pH was reached. The solution 
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was then dialyzed (50000 MWCO) in water for 5 d. TGA (20 °C/min, Ar, up to 850 °C) 
mass loss was 63%. The X-ray photoelectron spectroscopy (XPS) atomic concentrations 
were: C=67.2%, N=18.0%, 0=14.8%. 
Fl/PEI-US-SWCNTs (7). To a solution of PEI-US-SWCNTs (6, 10 mL, 0.046 
mmol, 55 mg/L) was added fluorescein (0.015g, 0.046) in water (1 mL) dropwise. The 
solution was stirred for 12 h and then dialyzed (50000 MWCO) in water for 5 d. 
Cystamine-FITC (8). Synthesized using a known procedure.8 Briefly, 
cystamine was dissolved in a mixture of MeOH (5 mL), water (2 mL) and 
triethanolamine (TEA, 0.040 mL) in a 50 mL roundbottom flask equipped with a stir bar. 
In a separate vial, FITC (0.051 g, 0.131 mmol) was dissolved in MeOH (5 mL) and TEA 
(0.050 mL). The FITC solution was added dropwise to the stirring solution of cystamine. 
The reaction was allowed to stir for 12 h. The product was concentrated to 5 mL under 
vacuum and was then precipitated in a 10:1 solution of acetonitrile:MeOH. The 
precipitate was filtered and washed with the acetonitrile:MeOH solution 3x. The solvent 
was removed under vacuum. 1H NMR (400 MHz, MEOD) 52.86 (t, 2H), 2.98 (t, 2H), 
3.10 (t, 2H), 3.33 (t, 2H), 6.60 (m, 2H), 6.64 (m, 2H), 7.12 (d, 2H), 7.25 (d, 2H), 7.96 (d, 
1H). 
Cystamine-FITC-PEG-US-SWCNTs (9). US-SWCNTs (15 mg, 1.25 mmol) 
were placed in an oven dried 50 mL round bottom flask with anhydrous DMF (15 mL). 
The solution was sonicated for 30 min until all US-SWCNTs were dispersed. To this was 
added PEG (5000 MW, 0.125 g, 0.025 mmol), DCC (0.208 g, 1,25 mmol), and DMAP 
(few pellets, cat.). The solution was stirred for 12 h, and 10 mL of the solution was 
transferred into an over-dried 50 mL flask with cystamine-FITC (0.045 g, 0.083 mmol). 
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To this were added DCC (0.172 g, 0.833 mmol) and DMAP (few pellets, cat.). The 
solution was stirred for 12 h. 
Cleavage of Disulfide (10, 11). To a solution of FITC-Cystamine-PEG-
SWCNTs (9, 15 mL, 1.25 mmol) was added DTT (0.013 g, 0.083 mmol). The solution 
was allowed to stir for 2 h. After this time the solution was filtered over a Teflon 
membrane and was analyzed for fluorescence. 
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4.6 Experimental Contributions 
My contributions to the experimental work in this chapter are the following: 
synthesis and characterization of all compounds. Dmitry Kosynkin, Jacob Berlin, B. 
Katherine Price, and Jay Lomeda assisted with the synthesis and characterization. 
Chapter 5 
Biodistribution and Long-Term Toxicity of 
PEGylated Hydrophilic Carbon Clusters and Paclitaxel 
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4.1 Introduction 
Too often, viable anticancer agents are dropped from further investigation due to 
their poor pharmaceutical characteristics. These poor characteristics include water 
insolubility, high protein binding, instability and lack of transport to the intracellular 
compartment. A classic example of a powerful anticancer agent with poor water 
solubility is paclitaxel (PTX, shown in Figure 5.1). To overcome this, PTX is solublized 
in a form of polyethoxylated castor oil called Cremophor EL. However, the use of 
cremophor as the excipient for PTX is well-known to cause significant allergic reactions, 
including hypersensitivity. Consequently, patients are heavily pre-medicated with 
antihistamines and corticosteroids in order to prevent potentially life threatening 
hypersensitivity reactions.1 
Figure 5.1. Structure of paclitaxel (PTX), a water insoluble chemotherapy drug. 
SWCNTs have unique properties that make them promising candidates for 
biological applications as discussed in Chapter 1. Addends to SWCNTs can be used to 
sequester payloads and deliver them to the site, organ, or cell of interest. In particular, 
highly oxidized hydrophilic carbon clusters (HCC, Note: In Chapter 1 these materials 
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were referred to US-SWCNTs. The name has now been changed to HCCs, which we 
think is a more suitable description since no radial breathing modes (RBMs)3"5 are 
present in the HCCs) when functionalized with polyethylene glycol (PEG), are stable in 
biological media.6 The PEG groups that act as solubilizing tentacles can also absorb a 
hydrophobic molecule away from an unfavorable, aqueous environment and into a more 
favorable, organic PEG-HCC matrix. Thus, PEG-HCCs can be used as vectors to deliver 
hydrophobic molecular cargo, such as PTX. In addition, PEG-HCCs could serve as a 
protective barrier, theoretically sheltering the drug or payload from premature destruction 
within the body before it reaches the final destination in the cell. Due to SWCNT's rapid 
cellular uptake,7"13 HCCs with addends and drug sequestration could be useful for drug 
delivery in a Trojan Horse-like application. Thus, utilizing PEG-HCCs as novel drug 
carriers is of interest in anticancer and drug development.14 
5.2 Results and Discussion 
SWCNTs were heavily oxidized2'15 as discussed in Chapter 1 to form HCCs that 
were then PEGylated to produce PEG-HCCs, which are soluble in phosphate buffered 
saline (PBS),6 for delivery in clinical applications. Thee HCCs were 30-100 nm in length 
and 1 nm in diameter and possess many oxidative groups on their defective sidewalls. 
The PEG-HCCs at a concentration of 200 mg/L were loaded with PTX (1 mg/mL), 
a water insoluble drug, which becomes solubilized when loaded into the PEG-HCC 
matrix as shown in Figure 5.2. 
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Figure 5.2 Sequestration of PTX in the PEG-HCC matrix. 
The maximum loading concentration of PTX in the PEG-HCCs to date is 12 
mg/mL. As shown in Figure 5.3, it is visually apparent if PTX is precipitating, because 
as shown in C, when the PTX is overloaded the solution becomes a milky white color. 
A B C D 
Figure 5.3. A. HCCs in PBS. B. PEG-HCCs in PBS. C. PTX/PEG-HCC where PTX is 
overloaded. D. PTX/PEG-HCC where the PTX is predominantly sequestered and thereby 
in solution 
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The complete solubilization of PTX using PEG-HCCs was confirmed with in 
vitro experiments with a 96 well plate of four different cell lines, OSC-19, SQCCY1 
(head and neck cancer cells), and A549, HI975 (lung cancer cells). PTX/PEG-HCCs 
have the same cell killing ability as does Taxol (PTX/Cremphor EL) at the same 
concentration of PTX, in all cell lines studied, confirming that all of the PTX is in 
solution and is still accessible while in the PEG-HCC matrix (see Figure 5.4). In 
comparison, when PTX is not fully solublized and is then administered to cells, its cell 
killing ability is greatly decreased. 
A. OSC-19 Cells B. SQCCY1 Cells 
— PTX/Cremophor 
- • -PTX/PEG-HCC 
— PEG-HCC 
0 1 2 3 
Log Concentration of PTX (nM) 
A549 Cells 
0 1 2 3 
Log Concentration of PTX (nM) 
o% 
• PTX/Cremophor 
- PTX/PEG-HCC 
- 1 0 1 2 3 
Log Concentration of PTX (nM) 
D. H1975 Cells 
- 1 0 1 2 3 
Log Concentration of PTX (nM) 
Cell Type A549 OSC-19 SQCCY1 H1975 
PTX/Cremophor IC50 [nM] 1.77±0.37 1.94±0.11 2.88±0.43 1.69±1.00 
PTX/PEG-HCC IC50 [nM] 1.69±0.31 1.87±0.06 2.68±0.53 1.63±0.97 
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Figure 5.4. Four different cancer cell lines were studied for the efficacy of PTX/PEG-
HCC (blue line with circles) and PTX/Cremophor (red line with triangles) at killing 
cancer cells: A. OSC-19 with PEG-HCC control showing that the PEG-HCCs do not kill 
the cells and B. SQCCY1 (head and neck cancer cell lines), C. A549 and D. HI975 
(breast cancer cell lines) with. Each graph represents an individual trial, while the table 
presents the IC50 data for an average of three trials (96 wells/trial). 
5.2.1 Single Dose Study of PEG-HCCs 
Since these PEG-HCCs showed promise in the delivery of a water insoluble 
cancer-therapy drug, PTX, it is important to test the fate of these PEG-HCCs as 
nanocarriers. In vivo toxicity studies were conducted with PEG-HCCs. Nude mice (3 
mice per group) were administered a single, tail-vein injection of PEG-HCCs at a 
concentration of either 200 mg/L, 500 mg/L, or 1000 mg/L (concentration is determined 
for the core of the HCC using UV-Vis). After a single dose injection, all mice were 
observed daily for 5 d, and none of the mice visually exhibited any acute toxicities. After 
5 d the mice were euthanized, a terminal blood sample was collected, and the major 
organs including the heart, lungs, spleen, kidneys, liver, and brain were removed and 
examined for gross toxicity, by Dr. Garbriela Raso, a Pathologist at MD Anderson 
Cancer Center. At all tested concentrations, no abnormalities were seen in any of the 
organs, warranting a longer-term toxicity experiment. 
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5.2.2 Longer Term Exposure 
With the promising results in the short-term toxicity experiments, a longer term 
toxicity experiment was warranted. PEG-HCCs at a concentration of 200 mg/L were 
investigated for longer term toxicity experiments since this was the concentration of 
PEG-HCCs used for the in vitro studies. Nude mice (5 mice per group) received a 200 
(iL tail vein injection of PEG-HCCs once per week, for up to 10 weeks. All animals were 
observed daily, and as shown in Figure 5.5, the weight of the mice slowly increased over 
the 10 week period as expected, and there were no visual signs of fatigue or discomfort in 
any of the mice studied. 
Time (weeks) 
Figure 5.5 Average weight change of mice over the 10 week period. The mice gradually 
gained weight as expected. 
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After weeks 1, 2, 4, 6, 8, and 10, five mice per group were euthanized and a 
terminal blood sample was taken from each mouse. The blood was screened for aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK 
PHOS), and bilirubin that are all indicators of liver function, and all values were within 
normal limits. Sodium, potassium, and chloride were all measured, concluding there is a 
proper balance of electrolytes in all of the mice which is necessary for normal cell and 
organ functions. Creatinine and blood, urea, nitrogen (BUN) levels are indicative of 
kidney function, and were all found to be within normal limits. The measure of glucose 
is a way to determine if the metabolism pathways are functioning correctly, and with all 
the mice, the levels were consistent with healthy mice. The final chemistry in the blood 
analyzed was calcium which is an indication of cardiac function, and again all levels 
were within normal limits. Table 5.1 shows the chemistry data for the terminal blood 
samples in comparison to normal limits in healthy nude mice. 
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Time sodium potassium chloride creatinine BUN glucose calcium Bilirubin AST ALT alk phos 
(weeks) (mEg/L) (mEg/L) (mEg/L) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (mg/dl) (U/L) (U/L) (U/L) 
1 Normal 147-167 5 - 9 104-120 0.5-0.8 19-34 106-278 9 - 1 2 0.3-0.8 69-191 26-120 44- 118 
2 1 150.7 8.2 107.1 <0.20 29.1 164 11.6 0.1 89 48 107 
3 1 151 8.1 108.2 <0.20 23.5 211 11.7 0.2 64 29 93 
4 1 153.7 7.82 110.2 <0.20 31 123 12.2 0.2 107 41 106 
5 1 152.5 9.95 109.3 0.21 30.1 327 12.6 0.2 77 42 78 
6 1 151.6 7.96 109 <0.20 22.2 193 11.7 0.1 83 43 103 
7 2 153.8 7.2 114.7 <0.20 20.9 233 10.9 0.2 128 33 65 
8 2 154.7 8.39 113.5 0.22 26.6 239 11.6 0.1 57 27 71 
9 2 152.4 8.77 110.6 0.22 19.2 308 11.6 0.2 77 29 77 
10 2 152.5 7.6 113.5 <0.20 23.3 248 11.7 0.2 127 41 85 
11 4 152.4 7.71 113.2 <0.20 27.8 177 10.6 0.2 97 42 71 
12 4 153.9 7.75 113.9 <0.20 28.4 178 10.9 0.2 95 53 78 
13 4 152.5 8.26 111.9 <0.20 24.1 190 10.6 0.2 84 44 65 
14 4 150.2 8.79 113.7 <0.20 29.3 215 10.5 0.2 195 115 79 
15 6 153.5 8.1 111.8 0.23 14.9 217 10.9 0.2 151 78 48 
16 6 152 9.8 115.1 0.21 19.9 217 11.5 0.1 281 98 61 
17 6 152.5 7.73 112.3 <0.20 16.5 234 10.6 0.2 142 47 37 
18 6 154.1 7.79 113.3 <0.20 16.3 244 10.8 0.1 84 30 64 
19 6 153.1 7.74 112.5 <0.20 15.2 205 10.2 0.2 82 39 63 
20 8 149.4 7.49 112.8 <0.20 18.1 255 10.9 0.1 58 24 46 
21 8 149.9 6.9 114.2 <0.20 19.2 159 10 0.1 97 40 32 
22 8 149.2 7.97 114.8 <0.20 14.5 254 10.7 0.1 69 30 35 
23 8 149.3 6.92 112 <0.20 17.9 198 10.3 0.1 62 25 54 
24 8 147.9 7.26 111.1 <0.20 17.8 215 10.7 0.1 75 29 56 
25 10 153.4 7.86 112.9 <0.20 15.8 202 10.3 0.1 63 26 43 
26 10 152.7 7.13 112.4 <0.20 16.8 174 10.3 0.1 69 27 25 
27 10 153.7 7.24 113 <0.20 17.8 201 10.3 0.1 58 22 48 
28 10 152.5 8.28 111.8 <0 20 18.7 233 10.2 0.1 55 23 49 
29 10 150.4 9.47 111 <0.20 15.3 296 11.1 0.1 59 21 30 
Table 5.1. Chemistry of terminal blood samples. Entry 1 is the normal limits for mice. 
All values are within normal limits. 
Hematological tests were done for all mice as shown in Table 5.2. White blood 
cells (WBC) and red blood cells (RBC) are used a measure a body's immune system and 
its ability to carry oxygen and blood. Hemoglobin and hematocrit counts measure the 
ability of the RBCs to carry oxygen throughout the body. All of these were within 
normal limits for healthy nude mice, as shown in Table 5.2. Platelet counts are important 
for blood clotting, because too little could cause major bleeding, whereas too much could 
cause internal blood clotting. WBC differential count consisting of segmented 
neutrophils (Segs), monocytes or macrophages (Monos), basophils (Basos), lymphocytes 
(lymphs), and eosinophils (Eos) is a breakdown of the different types of WBC. All 
hematology values were within normal limits. 
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Time 
(weeks) 
WBC 
(X103/ML) 
RBC 
(X106/ML) 
Hemoglobin 
(g'dL) 
Hematocrit (%) 
Platelet 
Count 
(X103/JJL) 
MCV(fL) MCH (pg) MCHC (g'dL) 
WBC Differntial Count 
Segs 
(%) 
Monos 
(%) 
Basos 
(%) 
Lymphs 
<%) Eos (%) 
1 
2 
Normal 
1 
3 .0 -14 .2 
4.99 
5 .0 -9 .5 
9.12 
10.9-16.3 
15.2 
38.5-45.1 
49.6 
1084- 1992 
1574 
48 .0 -56 .0 
54.4 
11.9-19.0 
16.6 
25 .9 -35 .1 
30.6 35.4 5.5 0.8 51.3 3.4 
3 1 8.39 9.05 15.5 51.5 1612 56.9 17.1 30 40.5 3.3 0.5 50.7 2.4 
4 1 6.73 9.01 16 52.9 1738 58.8 17.7 30.2 30.3 3.7 0.6 61 2.3 
5 1 5.22 8.58 14.6 48 1400 55.9 17 30.4 35.2 3.2 0.8 51.4 5.3 
6 1 6.75 8.82 14.9 50.5 1390 57.3 16.9 29.5 35 15 47 2 
7 2 4.76 8.97 14.5 47.5 1086 52.9 16.1 30.5 51 6 — 37 6 
8 2 5.59 9.11 15 50.5 1477 55.5 16 5 2 9 7 31.2 2.8 0.4 60.7 3.9 
9 2 5.12 8.6 14.5 46.3 1203 53 8 16.8 31.3 28 2.2 0.7 60.4 6.2 
10 2 5.15 9.04 13.4 48.3 1143 53.4 14 8 27.7 30 6 — 57 7 
11 2 5.28 9.56 15.3 52.3 1394 54.6 16 29.3 35.2 2.4 0.4 57.5 3.2 
12 4 5.2 8.64 14 44.9 1442 52 16.2 31.2 35.2 1.8 0.3 55.6 4 
13 4 5.05 8.99 14.6 45.4 1216 50.5 16.2 32.1 43.7 2.9 0.5 44.9 6.4 
14 4 4.04 8.99 13.6 44.2 1452 49.1 15.1 30.8 27.1 1.8 0.6 60.6 7.7 
15 4 4.89 8.3 14 44.6 1205 53.7 16.9 31.5 34.2 2.9 0.5 54.9 5.8 
16 6 8.17 8.57 13.1 44.3 1265 51.7 15.3 29.7 25 2.1 0.5 62.2 7.9 
17 6 6.76 8.82 13.5 44.4 1049 50.3 15.3 30.4 32.4 2.9 0.4 51.7 11 
18 6 5.07 8.38 13.3 44.7 1832 53.4 15.9 29.8 35 8 — 48 8 
19 6 4.7 8.46 13.4 44.5 1515 52.6 15.8 30.1 33 7 — 50 10 
20 8 5.34 8.22 12.5 41.8 1693 50.8 15.2 29.9 25.9 5.9 1.1 61.3 4.4 
21 8 10.04 7.65 11.7 40 1210 52.3 15.3 29.3 36.9 2.7 0.6 54.2 3.6 
22 8 5.41 8.29 12.6 41.6 1890 50.1 15.2 30.2 42 5 — 47 5 
23 8 5.6 8.79 13.5 43 1425 49 15.4 31.4 30.9 4.1 0.8 55 7.9 
24 8 4.56 8.69 13.5 44.1 1825 50.8 15.6 30.7 37.4 4.1 0.8 48.9 7.4 
25 10 7.96 9.38 14.1 46.3 1608 49.3 15 30.4 45 9 — 42 4 
26 10 9.46 8.19 12.1 40.6 2506 49.6 14.8 29.8 65.1 1 0.7 27.9 3 
27 10 11.56 9.38 13.8 47.4 2286 50.5 14.7 29.1 44 13 — 38 5 
28 10 8.44 8.92 13.1 43.7 1968 48.9 14.6 29.9 30 20 — 46 3 
29 10 8.56 8 81 13.1 45.1 2377 51.2 14.8 28.9 27 11 — 41 20 
Table 5.2. Hematology of terminal blood samples. Entry 1 is the normal limits for mice. 
All values are within normal limits. 
Major organs including the heart, lungs, spleen, kidneys, liver, and brain were 
removed after 1, 2, 4, 6, 8, and 10 weeks and were examined for gross toxicity. For all 
mice examined, no gross toxicity was apparent in the brain, kidneys, or spleen. It was 
difficult to examine the lungs for toxicity, because they were not inflated with saline prior 
to placing them in formalin. SWCNTs were seen in the liver inside of Kuppfer 
(macrophage) cells, but besides the macrophage, the organs appeared normal. In the 
week 10 mice, some lesions were seen in the liver. It was difficult to determine the 
presence of SWCNTs in the spleen because of many dark features inherent to the spleen. 
Samples of lungs, spleen, kidneys, brain, and liver for 1 week, and 10 week mice are 
shown in Figures 5.6-5.9. 
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Figure 5.6. Samples of each organ of the 1 week mice A. Lungs. B. Spleen C. Kidney. D. 
Brain. E. Liver. All organs appear normal. The scale bars are 200 jim. 
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/ / 
i 
200 Mm 
Figure 5.7. A closer image of the liver in the 1 week mice showing the SWCNTs inside 
the Kuppfer cells. Arrows point to the SWCNTs inside the Kuppfer cells. Scale bar is 
200 jam. 
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Figure 5.9. A closer image of the liver in the 10 week mice showing the SWCNTs inside 
the Kuppfer cells. Arrows point to the SWCNTs inside the Kuppfer cells. 
5.2.3 Radiolabeling PEG-HCCs and PTX/PEG-HCCs 
Another component of longer-term toxicity is biodistribution of the nanomaterials. 
The biodistribution of PEG-HCCs with and without PTX was determined using 111 In as a 
tracker in both healthy and orthotopically-implanted tumor mice. Indium was chosen 
1 f\ 17 
because of its half-life of 2.8 d and ease to attach to the PEG HCCs. ' As shown in 
Scheme 5.1 diethylene triamine pentaacetic acid (DTPA) was used to functionalize HCCs 
in order to complex with i n In . DTP A isothiocyanate was coupled to an amino, azido 
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functionalized PEG oligomer. The resulting product was joined to an amino, alkynyl 
i n
 # 
functionalized 6,000 MW PEG chain using click chemistry. Treatment with Na2S and 
Ca(OH)2 removed any Cu bound to the DTP A.19 The conjoined polymer was then 
90 
coupled to the HCCs using standard peptide coupling conditions, and small molecule 
contaminants were removed using a size exclusion column. The purified DTPA-PEG-
HCCs were mixed with 11'in, and any unbound 11'in was removed by second size 
exclusion column to yield '"in-DTPA-PEG-HCCs. 
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Scheme 5.1. Synthesis of1 1 'In-DTPA-PEG-HCCs. 
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To determine the binding efficiency of 11 'in to the DTPA-PEG-HCCs and PEG-
HCCs, the HCCs were challenged with EDTA. As shown in Figure 5.8 11 'in + DTPA-
PEG-HCCs showed 89% bound ' " i n whereas, a control with unfiinctionalized ' " i n + 
PEG-HCCs (Figures 5.10 and 5.11) treated under the same conditions showed only 17% 
bound " ' in . Once the indium is added to either the PEG-HCCs or DTPA-PEG-HCCs, it 
is purified through a 10 DG GE Healthcare column. The remaining solution is developed 
on a TLC plate with ammonium acetate and EDTA as the solvent. All bound indium 
stays at the base line with the PEG-HCCs or DTPA-PEG-HCCs and any unbound, or 
loosely bound indium is complexed by the EDTA in the developing solvent and moves 
with the solvent front. The TLC plate is then read with BioScan, which determines the 
amount of activity (counts) at each spot on the TLC plate and the binding efficiency is 
determined. The peak around 150 mm is the indium that was complexed off by the 
EDTA, whereas the peak around 80 mm is bound to either the DTPA-PEG-HCCs or 
PEG-HCCs. This confirms that the DTPA is strongly chelating the indium, as expected. 
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Figure 5.10. Binding experiment of inIn-DTPA-PEG-HCC challenged with EDTA. The 
binding efficiency is 89 %. 
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Figure 5.11. Binding experiment of 11'in + PEG-HCC with no DTP A challenged with 
EDTA. The binding efficiency is 17%. 
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5.2.4 Biodistribution of PEG-HCCs and PTX/PEG-HCCs 
27 nude mice were administered 200 pL of l uIn-DTPA-PEG-HCC at a 
concentration of 200 mg/L via tail vein injections. Three mice were euthanized at each of 
the following time points: 0 (no treatment control), 0.5, 1, 3, 6, 18, 24, 48, 72, 96, and 
120 h, and a terminal blood sample was taken along with the heart, lungs, spleen, kidneys, 
liver, brain, and tongue, and the radioactivity of each sample was determined using a 
gamma counter. As shown in Figures 5.12 - 5.19 mIn-DTPA-PEG-HCCs accumulate in 
the spleen, liver, and kidneys in comparison to the mIn-DTPA-PEG control that 
accumulates in the kidneys (The y-axis is all figures are normalized to the total organ 
radioactivity count divided by the organ's weight. This value is then divided by the 
initial radioactivity count injected in each mouse. All plots in Figures 5.12-5.19 have the 
same Y-axis scale to ease comparisons. Inserts provide the expanded views). This is 
1 f\ 17 9 1 9 9 
very similar to other SWCNT nanovectors. ' ' ' It is interesting to note that the 
PTX/PEG-HCCs are well distributed in highly vascular organs such as the lungs, liver 
23 
and kidneys (Figures 5.13, 5.15, 5.16). This is known for Taxol® , which suggests that 
the distribution of PTX/PEG-HCCs is similar to Taxol® which could lead to potential 
PEG-HCC targeting. The urine and feces were collected every 24 h, and all samples 
were shown to be quickly excreted through the urine and a smaller amount in the feces 
(Figures 5.20 and 5.21). There was no accumulation in the brain (Figure 5.17), as 
expected. 
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Figure 5.12. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the heart of healthy nude mice. 
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Figure 5.15. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the kidney of healthy nude mice. 
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Biodistribution in Spleen of Healthy Mice 
•20.15 
Figure 5.14. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the spleen of healthy nude mice. 
Biodistribution in Kidneys of Healthy Mice 
0.5 
^0.45 
| 0 4 
g0.35 
o 0.3 
Z 
>P'25 
> 0.2 
So-15 
r 0 / 1 
0.05 
0 
• DTPA-PEG Control 
B DTPA-PEG-HCCs 
• PTX /PEG-HCCs 
- B-i.lt. LiL.ii.^ .fk.^ .fL,.^  
0.5 1 3 6 18 24 48 72 96 120 
Time (h) 
Figure 5.15. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the kidney of healthy nude mice. 
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Figure 5.16. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the liver of healthy nude mice. 
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Figure 5.15. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the kidney of healthy nude mice. 
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Figure 5.18. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the tongue of healthy nude mice. 
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Figure 5.19. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the blood of healthy nude mice. 
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Figure 5.20. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the urine of healthy nude mice. 
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Figure 5.15. Biodistribution of DTPA-PEG used as a control, DTPA-PEG-HCCs and 
PTX/DTPA-PEG-HCCs in the kidney of healthy nude mice. 
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The same biodistribution study was performed using an orthotopic tongue tumor 
mouse model. The 30 mice were injected with 3xl05 OSC-19 head and neck cancer cells 
one week prior to injection of mIn-DTPA-PEG, mIn-DTPA-PEG-HCCs or PTX/ m In-
DTPA-PEG-HCCs. Within 7 days a visual tumor was on the tongue of each mouse as 
shown in Figure 5.22. 
Figure 5.22. Tumor (arrow) on the tongue (orthotopic model) of a nude mouse 7 d after 
injection of 3xl05 OSC-19 cells directly on its tongue. 
The rest of the biodistribution study was performed in the same manner as healthy 
mice. Figures 5.21-5.31 show the distribution of mIn-DTPA-PEG-HCCs and PTX/ m In-
DTPA-PEG-HCCs in orthotopic tongue tumor mouse. The biodistribution is very similar 
to the healthy mice with accumulation in the liver, spleen, and kidneys. The PTX/PEG-
HCC also accumulates in the lungs, as expected from the earlier results. Most 
importantly, as shown in Figure 5.29 the PEG-HCCs are capable of reaching the 
orthotopic tongue tumor. 
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Figure 5.23. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
heart of an orthotopic tongue tumor mice. 
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Figure 5.24. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
lungs of an orthotopic tongue tumor mice. 
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Figure 5.25. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
spleen of orthotopic tongue tumor mice. 
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Figure 5.26. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
kidneys of orthotopic tongue tumor mice. 
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Figure 5.27. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
liver of orthotopic tongue tumor mice. 
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Figure 5.28. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
brain of orthotopic tongue tumor mice. 
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Biodistribution in Tongue of Tumor Mice 
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Figure 5.29. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
tongue of orthotopic tongue tumor mice. 
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Figure 5.30. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
blood of orthotopic tongue tumor mice. 
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Figure 5.31. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
tumor of orthotopic tongue tumor mice. 
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Biodistribution in Feces of Tumor Mice 
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Figure 5.33. Biodistribution of DTPA-PEG-HCCs and PTX/DTPA-PEG-HCCs in the 
feces of an orthotopic tongue tumor mouse. 
4.2.5 Efficacy 
In vivo experiments were performed to determine if PTX/PEG-HCCs were as 
effective at treating a tumor on the tongue of a mouse as PTX/Cremphor (Taxol®), since 
it was shown earlier that the PEG-HCCs are able to reach the tumor and have comparable 
cell-killing ability as PTX/Cremphor in vitro. As shown in Figure 5.34, PTX/PEG-HCC 
at a PEG-HCC concentration of 100 mg/L and PTX concentration of 1 mg/L is 
statistically equivalent to PTX/Cremphor at a PTX concentration of 1 mg/L in tumor 
growth inhibition as compared to the control group. A PEG-HCC concentration of 100 
mg/L was used instead of 200 mg/L, because PTX/PEG-HCCs at 200 mg/L were seen to 
be toxic to the mice after 4 weeks of administration. We are currently investigating why 
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PTX/PEG-HCCs at 200 mg/L is toxic to the mice whereas PEG-HCCs alone at 200 mg/L 
shows no toxicity. 
Days After Cell Injection 
Figure 5.34. In vivo study of PTX/PEG-HCC in comparison to PTX/Cremophor in 
treating a cancerous tumor on the tongue of a mouse. Treatment began on day 10. 
PTX/PEG-HCC has comparable tumor shrinking ability as does PTX/Cremophor. 
4.3 Conclusions 
The data supports the conclusion that PEG-HCCs are viable candidates for use as 
drug delivery agents. We have shown here that PEG-HCCs are able to sequester a water 
insoluble drug, PTX and deliver it to an orthotopic tongue tumor. The PEG-HCCs are 
not toxic given once weekly up to 10 weeks and they accumulate primarily in the liver, 
spleen, and kidneys, without pathological changes. We are currently investigating 
targeting the PTX/PEG-HCCs to the orthotopic tongue tumor and conducting longer-term 
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toxicity experiments using 14C labeled PEG-HCCs to determine how long it takes for the 
PEG-HCCs to be completely eliminated from the animals. 
4.4 Experimental 
General. Unless note otherwise, all chemicals were purchased from Sigma-
Aldrich and used without further purification unless otherwise stated. Paclitaxel was 
purchased from LC Laboratories. Taxol® was purchased from Dabur Oncology PLC. 
i n I n was purchased from PerkinElmer. Dialysis bags (MWCO 50000) were purchased 
from CelluSep HI. SWCNTs (HPR 187.4) were purchased from HiPco Laboratory at 
Rice University.24"26 Sonication was done using a Cole Palmer ultrasonic cleaner 08849-
00. BALB/c (nu-/nu-) mice were used under a protocol approved by MD Anderson 
Cancer Center. HCC concentrations were determined using Beer's law analysis, using an 
extinction coefficient of 0.0104 L/mg at Xmax 763 nm. This concentration is of the HCC 
carbon core only. 
Synthesis of HCCs.2 p-SWCNT (HPR 187.4, 500 mg) were disentangled in 250 
mL oleum (20% fuming) by vigorous stirring for 7 d at a concentration of 2 mg/mL in a 
three neck, 1 L round bottomed flask with all joints sealed with Teflon. After 7 d in a 
separate flask submerged in an ice bath was prepared a mixture of oleum (125 mL) and 
nitric acid (125 mL). The temperature was never allowed to exceed 40 °C. To the 3-
neck flask containing the p-SWCNTs and oleum was added an internal thermometer, and 
the flask was placed in an ice bath. The 1:1 oleum:nitric acid solution was added in small 
portions to the SWCNTs while stirring and never allowing the temperature to exceed 
40 °C. When 40 °C was reached the mixture was allowed to cool until the temperature 
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returned to 10 °C before adding the next portion. The addition process took 
approximately 1 h. The final proportion of oleum:nitric acid is 3:1. The three neck flask 
was then placed in an oil bath, with vigorous stirring and was heated to 65 °C monitored 
using the internal thermometer. Once this temperature was reached, the reaction was 
allowed to proceed for 1.5 h. After this time, the reaction was removed from the oil bath 
and was allowed to cool for 20 min before carefully pouring over 1 L of ice. For ease of 
filtration, the water/HCC solution was allowed to settle for 12 h. The solution was 
decanted, leaving the HCCs at the bottom of the beaker which were then filtrated over 
Teflon. The filtration process is very slow and can take up to several d. Once filtered, 
the black solid (HCCs) was dissolved in a minimal amount of methanol (20 mL). To this 
was continually added ether with subsequent filtering over Teflon until a pH of 6 was 
reached. The HCCs were again filtered over Teflon until a moist filter cake remained 
(the HCCs were never allowed to completely dry). The final evaporation of the ether was 
done by placing the HCCs in a 50 mL beaker and using a hot plate, slowly allowing the 
HCCs to heat while continually pulverizing them with a Teflon stir rod resulting in a fine, 
dry powder that was dried in a vacuum dessicator for 12 h. The Raman diamondoid-to-
graphitic (D/G) ratio was 1.7 and the thermogravimetric analysis (TGA, 10 °C/min, Ar, 
up to 900 °C) mass loss was 53%. The X-ray photoelectron spectroscopy (XPS) atomic 
concentrations were: C l s 66%, Ols 32%, S2p 1.5% similar to previously described 
heavily carboxylated nanotubes.2 
Synthesis of PEG-HCCs. To an oven dried 100 mL round bottom flask 
equipped with a stir bar was added HCCs (0.063 g, 5.2 mequiv C) and anhydrous DMF 
(50 mL). The mixture was vigorously stirred for 15 min under a nitrogen atmosphere. 
172 
N,N'-dicyclohexylcarbodiimide (DCC, 1.08 g, 5.2 mmol) was added followed by 
methoxy polyethylene glycol amine (0.50 g, 0.1 mmol, MW 5000) and 4-
dimethylaminopyridine (DMAP, 11 mg, 0.09 mmol). The mixture was stirred for 12 h 
and purified by dialysis (dialysis bag MWCO 50000) first in DMF for 1 d to remove 
water-insoluble organic byproducts, then for 4 d in flowing deionized water for further 
purification and replacement of the organic solvent by water. The PEG-HCCs were then 
filtered through a PD-10 GE Healthcare column. 
In Vitro ICS0 of PTX/PEG-HCC and PTX/Cremophor. The OSC-19 line was 
obtained from the Laboratory of Gary Clayman, MD. This cell line was established in 
Japan from a metastatic tumor to a cervical lymph node of a patient with well-
differentiated SCC of the tongue. This cell line was grown in vitro in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
L-glutamine, sodium pyruvate, nonessential amino acids and a 2-fold vitamin solution 
(Life Technologies, Inc., Grand Island, NY). The SqCC/Yl human HNSCC line was 
obtained from the Laboratory of Dr. Vali Papadimitrakopoulou at MD Anderson Cancer 
Center. The HI975 human lung adenocarcinoma cell line was obtained from the 
Laboratory of Dr. John Heymach at MD Anderson Cancer Center. The A549 human 
non-small cell lung cancer was obtained from American Type Culture Collection 
(Rockville, MD). HI975 cells and A549 cells were maintained in RPMI 1640 containing 
penicillin-streptomycin (Flow Laboratories, Rockville, MD), nonessential amino acids, 
sodium pyruvate, L-glutamine and 10% fetal bovine serum (FBS). The SqCC/Yl cells 
were maintained in DMEM/F12 low glucose containing penicillin-streptomycin, L-
glutamine and 10% FBS. Adherent monolayer cultures were maintained on plastic and 
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incubated at 37 °C in 5% carbon dioxide and 95% air. The cultures were free of 
Mycoplasma species and were maintained for no longer than 12 weeks after recovery 
from frozen stocks. 
Cells were grown for 24 h in a 96-well plate (2000 cells/well in 100 fiL of 10% 
serum containing media) at 37 °C in 5% carbon dioxide and 95% air before treating with 
drugs. Serial dilutions of known PTX concentrations (500.0, 166.7, 55.6, 18.5, 6.17, 
2.06, 0.69, 0.23, 0.08 nM) were prepared in media from each of the initial drug stock 
solutions (PTX/PEG-HCCs (PTX is 1 mg/mL, PEG-HCCs are 100 mg/L), PEG-HCCs 
(PEG-HCCs are 100 mg/L), and PTX/Cremophor EL (PTX is 6 mg/mL)). For each 
sample, 100 fiL of each dilution was added to six wells. The cells were incubated for 
three days at 37 °C, then MTT solution (25 (iL of 2 mg/mL) was added in each well. 
After incubation for 2 h, the media was removed by careful aspiration to avoid suctioning 
of the cells. Then, 100 |aL of DMSO was added to each well in order to lyse the cells and 
solubilize the colored crystals. Finally, the plates were analyzed using an ELISA plate 
reader at a wavelength of 570 nm to measure optical density (OD) of each well, which 
proportionate to number of viable cells in each well. The percent of viable cells relative 
to control was obtained by dividing the average OD for the treated wells by the OD for 
the control wells. 
Short-Term Toxicity of PEG-HCCs in Healthy Mice. 15 BALB/c (nu-/nu ) 
mice were randomized into 3 mice per group for each PEG-HCC concentration (200 
mg/L, 500 mg/L, and 1000 mg/L) and one control group which received saline. Each 
group received a tail-vein injection of 200 (J.L of PEG-HCCs or saline. After 5 d the mice 
were euthanized using CO2. A terminal blood sample was collected and sent for 
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pathology work. Various organs were also harvested (including heart, liver, lungs, 
kidneys, spleen, and brain) and placed in formalin for histology work. 
Longer-Term Toxicity of PEG HCCs in Healthy Mice. 30 BALB/c (nu-/nu ) 
mice were randomized into 5 mice per group for each time point (1, 2, 4, 6, 8, 10 wk). 
Each group received a tail-vein injection of 200 pL of PEG-HCCs IX per week until 
euthanization. The mice were euthanized using CO2. A terminal blood sample was 
collected and sent for pathology work. Various organs were also harvested (including 
heart, liver, lungs, kidneys, spleen, and brain) and placed in formalin for histology. 
Biodistribution in Healthy Mice. 30 BALB/c (nu-/nu-) mice were randomized to 
be used over the following 10 time points (3 mice per time point): 0.5, 1, 3, 6, 18, 24, 48, 
72, 96 and 120 h. Each animal received a single i.v. injection at a dose of 2 mg/kg PEG-
HCCs. n iIn-DTPA-PEG, luIn-DTPA-PEG-HCC, or PTX/11 'in-DPTA-PEG-HCC 
dissolved in PBS. After injection, each animal was placed in a plastic metabolism cage 
in order to collect the urine and feces. The animals were fed a commercial diet and water 
ad libitum. For each group and time point, 3 animals were euthanized and terminal blood 
samples were collected and various organs were harvested (heart, liver, lungs, kidneys, 
spleen, brain, and tongue) and placed into pre-weighed scintillation vials. Each organ and 
blood sample was weighed and analyzed for 11 'in activity using a gamma counter. Total 
voided urine and excreted feces were collected every 24 h and analyzed for 11 'in activity. 
Biodistribution in Orthotopic Squamous Cell Cancer Mouse Model. 30 
BALB/c (nu-/nu-) mice were randomized to be used over the following 10 time points (3 
mice per time point): 0.5, 1, 3, 6, 18, 24, 48, 72, 96 and 120 h. Each mouse was 
anesthetized using 45 mg/kg Nembutal and 5x10s OSC-19 cells were injected on the 
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tongue of each animal. After 7 d the tumor was visible and the animal received a single 
i.v. injection at a dose of 2 mg/kg PEG-HCCs. "'in-DTPA-PEG, "'in-DTPA-PEG-
HCCs, PTX/11 'in-DTPA-PEG-HCCs were dissolved in PBS for injection. After injection, 
each animal was placed in a plastic metabolism cage in order to collect the urine and 
feces. The animals were fed a commercial diet and water ad libitum. For each group at 
each time point, 3 animals were euthanized and terminal blood samples were collected 
and various organs were harvested (heart, liver, lungs, kidneys, spleen, brain, and tongue) 
and placed into pre-weighed scintillation vials. Each organ and blood sample was 
weighed and analyzed for 11 'in activity using a gamma counter. Total voided urine and 
excreted feces were collected every 24 h and analyzed for 11 'in activity. 
Efficacy of PTX/Cremphor EL and PTX/PEG-HCC in Orthotopic Squamous 
Cell Cancer Mouse Model. 36 nude mice were injected in the tongue with 5xl04 
squamous cell carcinoma OSC-19 cells suspended in serum-free DMEM, as described 
previously. 12 d after the injection, tumor sizes were measured and all of the mice had 
similar sized tumors. The mice were randomized into three groups (9 mice per group). 
Treatments (PBS as a placebo, PTX/PEG-HCCs, (PTX 1 mg/mL, PEG-HCCs 100 mg/L), 
PTX/Cremophor EL (PTX 1 mg/mL, PEG-HCCs PEG-HCCs 100 mg/L)) were 
administered intravenously on days 12, 19 and 26 following cell injection by injecting 
200 (iL into the tail vein of the mice. The mice were examined twice a week for tumor 
size and weight loss. The mice were euthanized using carbon dioxide asphyxiation if they 
lost more than 20% of their preinjection body weight or became moribund. The 
remaining mice were euthanized at 50 d post-cell inoculation. 
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Synthesis of PTX/PEG-HCCs. In a 50 mL round bottom flask equipped with a 
stirbar was added a solution of PEG-HCCs (10 mL, 200 mg/L or 100 mg/L). In a 
separate vial a solution of PTX (10 mg) in methanol (MeOH, 1 mL) was made. The 
solution was sonicated until the PTX was all dissolved. The PTX solution was added 
dropwise to the PEG-HCCs while vigorously stirring. The solution was allowed to stir 
for 10 min and was then bath sonicated for 30 min. The solution was then placed on the 
rotavap with minimal heat until a volume of 9 mL remained as an indication of complete 
removal of the MeOH. The solution was then reconstituted to 10 mL with phosphate 
buffered saline (PBS) resulting in a concentation of 1 mg/mL PTX and an HCC 
concentration of 200 mg/L or 100 mg/L. 
Synthesis of DTPA-PEG. p-SCN-Bn-DTPA (donated by Macrocyclics, 
http://www.macrocyclics.com, 0.059 g, 0.099 mmol) was dissolved in 2 mL of anhydrous 
DMF. To this was added 1 l-azido-2,6,9-trioxaundecan-l-amine (0.022 g, 0.099 mmol). 
The solution was allowed to stir under nitrogen for 12 h, followed by removal of DMF 
under vacuum to yield DTPA-PEG. DTPA-PEG (0.080 g, 0.160 mmol) was dissolved in 
water (8 mL) and tertbutanol (8 mL). To this was added amino, alkynyl functionalized 
PEG (6000 MW, 0.628 g, 0.106 mmol). It was slowly heated with a heat gun until all 
was in solution. To this was added copper sulfate (0.027 g, 0.106 mmol) and the solution 
quickly turned blue in color. This was followed by addition of sodium ascorbate (0.021 g, 
0.106 mmol). The blue color persisted after addition of sodium ascrobate suggesting that 
the DTPA was chelating the copper. The solution was then transferred to a 10000 
MWCO dialysis bag and placed in continuous flow DI water for 24 h. The copper was 
then removed by addition of sodium sulfide (0.025 mL, 0.106 mmol). The solution 
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quickly turned brown in color; this was followed by addition of calcium hydroxide (0.008 
g, 0.106 mmol). The mixture was allowed to stir for 1 h and the insoluble copper was 
filtered away. The same procedure (addition of sodium sulfide followed by addition of 
calcium hydroxide) was repeated a second time and the filtrate was almost colorless 
suggesting complete removal of copper. The water was removed under vacuum. The 
light yellow solid was redissolved in a minimal amount of chloroform (5 mL) and the 
solution was added dropwise to cold ether (50 mL). The mixture was placed in the 
freezer for 1 h and the precipitate was filtered away, leaving a white solid, MALDI-TOF 
MS m/z calcd for C3oH46N80,3S 758, found 759. 
Synthesis of DTPA-PEG-HCCs. In a 100 mL over-dried round bottom flask were 
added HCCs (0.018 g, 1.50 mmol) and anhydrous DMF (20 mL). The solution was 
sonicated for 30 min until the HCCs were well dispersed. To this was added DTPA-PEG 
(0.100 g, 0.015 mmol), DCC (0.310 g, 1.50 mmol), and DMAP (11 mg, 0.09 mmol). The 
solution was stirred under nitrogen for 12 h. It was then placed in a 10000 MWCO 
dialysis bag in DMF for 1 d followed by dialysis in DI water for 4 d. This was then 
filtered through a PD-10 GE Healthcare column. 
inIn-DTPA-PEG-HCCs. DTPA-PEG-HCCs (200 mg/L) were placed in a small 
vial. To this was added 130 jaCi of 11 'in in sodium acetate. The solution was vortexed 
for 1 min and was then allowed to react for 20 min before removal of any unbound 11 'in 
through a PD-10 GE Healthcare column. 
Binding Experiments of indium with PEG-HCCs and DTPA-PEG-HCCs. PEG-
HCCs or DTPA-PEG-HCCs (100 ^L) were placed in a vial. To this was added l l l l n 
(160 juCi) in 0.1 M sodium acetate. The solution was vortexed and allowed to mix for 30 
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min. After this time the sample was purified using a PD-10 GE Healthcare column to 
remove any unbound indium. The remaining solution was developed on a TLC plate 
with ammonium acetate and EDTA. All bound indium stays at the base line with the 
PEG-HCCs or DTPA-PEG-HCCs and any unbound, or loosely bound indium will 
grabbed by the EDTA in the developing solvent and will move with the solvent front. 
The TLC plate was then read with BioScan, which determines the amount of activity at 
each spot on the TLC plate and the binding efficiency is determined. 
PTX/ m In-PEG-HCCs. To a vigorously stirring solution of luIn-PEG-HCCs (10 
mL, 200 mg/L) in a round bottom flask was added PTX (10 mg) in methanol (MeOH, 1 
mL) dropwise. The solution was allowed to stir for 10 min and was then bath sonicated 
for 2 h. The volume was then reduced to 9 mL using a hairdryer while the solution was 
stirring to remove the MeOH. The solution was then reconstituted to 10 mL with PBS 
resulting in a solution of 1 mg/mL PTX and an HCC concentration of 200 mg/L. 
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5.6 Experimental Contributions 
My contributions to the experimental work in this chapter are the following: 
synthesis and characterization of u lIn-DTPA-PEG-HCCs, PTX/niIn-DTPA-PEG-HCCs, 
mIn-DTPA-PEG, PEG-HCCs, PTX/Cremophor. Jacob Berlin, Daniela Marcano, and 
Tam Pham assisted with the synthesis. I also euthanized and collected the terminal blood 
sample and organs from the animals for the toxicity and biodistribution studies. Tam 
Pham, Shaoyu Yan, and Stefania Fiorentino at MD Anderson Cancer Center assisted with 
these animal experiments. Shaoyu performed all tail vein injections. Xiaoxia Wen at 
MD Anderson Cancer Center ran the binding experiments. Daisuke Sano at MD 
Anderson Cancer Center grew and injected the cancer cells on the tongue of the mice. 
Daisuke Sano and Tam Pham ran the in vitro and in vivo efficacy experiments. Gabriela 
Raso at MD Anderson Cancer Center examined all organs for abnormalities. 
Chapter 6 
Nanoengineered Carbon Scaffolds for Hydrogen Storage 
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4.1 Introduction 
Growing concerns regarding the accessibility of hydrocarbon fuels and their 
environmental impact have led to global interest in developing hydrogen-fueled 
vehicles.1 Hydrogen can be an efficient energy carrier and its sole reaction product in a 
fuel cell or internal combustion engine, water, is pollution-free. Like gasoline, hydrogen 
is not a primary fuel; it must be generated from other sources. But unlike gasoline, 
hydrogen can be obtained from a wide variety of renewable energy protocols. 
Problematically, compressed hydrogen gas tanks are heavy and volumetrically large if 
they are to provide the equivalent energy content derivable from conventional liquid 
2 3 • 
gasoline tanks. Moreover, although currently being used in prototypes, ' the use of high 
pressure (5000 psi or 350 atm) hydrogen tanks in consumer automobiles lessens their 
attractiveness. 
Hydrogen that is reversibly bound to a light-weight solid phase support provides 
an attractive alternative to the large volume, weight and pressure tanks currently being 
explored.4 Although hydrogen may be generated onboard a vehicle by reforming 
hydrocarbons or by the catalytic decomposition of a chemical hydride, only fueling with 
hydrogen and the storage of this hydrogen will be considered here. This divides the 
storage of hydrogen into two basic categories, covalent binding (chemisorption) of the 
dissociated hydrogen, usually as a metal hydride, and physical adsorption (physisorption) 
of the hydrogen molecule. In the former case, covalent binding of the hydrogen atom to 
the metal is generally strong, which requires elevated temperatures to release the 
hydrogen. Nanoparticles are used for hydrogen chemisorption because of their high 
surface areas coupled with the ability to have good kinetics for the adsorption and release 
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of hydrogen.5'6 However, the metal nanoparticles tend to be unstable with hydrogen 
depletion and are prone to aggregation, leading to poor cycling. Conversely, the 
undissociated hydrogen molecule can be physisorbed onto a high surface area porous 
structure of lightweight materials; carbon is the most widely explored system, both its 
amorphous form (usually activated) and in sp2-carbon rich systems that include both 
graphite and carbon nanotubes.7 Metal organic frameworks (MOFs) can also provide 
high surface areas for physisorption of hydrogen.8 In general, these materials utilize 
reduced temperatures to adsorb the hydrogen molecule, as the binding of molecular 
hydrogen to the surface is relatively weak. An intermediate case is termed "spillover" in 
which the hydrogen molecule is catalytically dissociated and the atomic hydrogen 
migrates onto a host surface. It is then catalytically recombined for delivery as a 
hydrogen molecule. The dissociation on platinum or similar catalyst takes place at room 
temperature, and the uptake and release of hydrogen is accomplished through a change in 
pressure.9'10 Although this has the desirable property of storing and releasing hydrogen at 
room temperature, the kinetics of uptake tend to be slow, which would lead to extended 
fill times, and the quantity stored has been less than that achieved by physisorption at 
reduced temperatures. 
The use of physisorption rather than chemisorption of hydrogen atoms to a 
surface eliminates the need for high heating to desorb the hydrogen from the solid phase, 
thereby providing for faster kinetics of release. This also produces high energy efficiency 
and essentially complete availability of all stored hydrogen at lower pressures, generally 
in the 1-100 atm range. In addition, it is desirable to have a storage medium that is stable 
upon cycling, that can provide good thermal conductivity to dissipate the heat of 
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adsorption, and that has paths with minimal tortuosity for fast kinetics of uptake. 
Although many solid-phase supports have been prepared, they are neither high density 
nor do they have high thermal conductivity for heat removal during the adsorption step.4 
We show here the fabrication of chemically crosslinked 3-dimensional (3-D) frameworks 
of single-walled carbon nanotube (SWCNT) fibers. These fibers physisorb twice as 
much hydrogen, at low pressures, with respect to their surface areas, than typical 
macroporous carbon materials. 
SWCNT fibers alone do not have sufficient surface area for the storage of 
hydrogen because the SWCNTs are bundled tightly together (Figure 6.1 A). The fibers 
can swell in oleum (20% free SO3, fuming sulfuric acid) (Figure 6.IB), which protonates 
the nanotube surfaces and intercalates between them, overcoming the van der Waals 
attractions of 0.5 eV/nm cohesive interaction between adjacent nanotubes,11"13 and 
causing the fiber diameter to expand. If re-coagulated in water, the fibers repack and 
return approximately to their starting diameter (Figure 6.1 A). The swollen geometry 
could be locked-in by inserting crosslinks that are stable in oleum,11 yielding fibers with 
an expanded geometry and stabilized enlarged pores even after removal of the 
intercalating solvent (Figure 6.1C). It is the interstitial spaces between nanotubes (Figure 
6.1C) that could be tuned by the choice of intercalating acid and crosslinker, providing 
higher surface area for hydrogen adsorption and also a multi-faced environment for the 
hydrogen to assume several points of physisorption contact. 
186 
Figure 6.1. An illustration showing the cross-sectional view of a SWCNT fiber. A. The 
individual tubes in the fiber are packed tightly in the bundle, maximizing the density of 
the fiber. B. A fiber where the SWCNTs have debundled slightly because of oleum 
intercalation, thereby expanding the fiber diameter. C. The SWCNT fiber is locked into 
this slightly debundled form through functionalization with crosslinkers. 
The production of SWCNT fibers is known from previous work.14 SWCNTs can 
be dispersed in oleum to form liquid crystalline dopes and spun into well-aligned fibers 
using conventional spinning techniques much like those for making aramid fibers such as 
Kevlar™.14'15 Because of alignment, SWCNTs in fibers have a considerably better 
packing density than in powders. The SWCNT fibers have densities of about 1.0-1.2 
g/cm3 and they have packing densities of 70-80%, thereby well-addressing the volumetric 
desires for mobile adsorption beds.14'16 The alignment of the SWCNTs in the fibers 
creates a path of low tortuousity for hydrogen diffusion, leading to faster kinetics of 
uptake. Powders tend to be poor thermal conductors due to the lack of connectivity 
between the particles, whereas continuous fibers are better suited to benefit from the high 
uniaxial thermal conductivity of the individual carbon nanotubes. For these reasons, 
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SWCNT-based structures of this type have recently been theorized by Week et al. to be 
thermodynamically stable and good choices for the storage of hydrogen.17 
6.2 Results and Discussion 
The chemistry taking place on the SWCNTs is shown in eq 6.1 where 
methylenedianiline is converted, in situ, into the bis-diazonium salt which can add 
between adjacent nanotubes in the bundled structure of the fiber (Figure 6.1C). This 
particular crosslinker was chosen because its end-to-end distance would provide a 7-9 A 
i n 
spacing which is in the range desired for molecular hydrogen packing and because its 
rigidity would limit its intra-tube attachment. Ring sulfonation on the anilines during 
11 18 20 
oleum functionalizations occurs as described previously. ' 
This creates expansion between the individual SWCNTs, thus providing greater surface 
area for hydrogen adsorption. The functionalization of the SWCNT fibers is confirmed 
using Raman spectroscopy.12'19 The D-band (diamondoid) at 1290 cm"1 is diagnostic for 
3 1 
the sp -hybridized carbons, compared to the G-band (graphitic) at 1594 cm" that is 
diagnostic for the sp -hybridized carbons remaining on the SWCNTs. An increase in the 
(6.1) 
2 
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D/G ratio in Raman spectra of these fibers is indicative of functionalization of SWCNTs. 
After functionalization of the SWCNT fibers, the D/G increases from 0.05 to 0.17 as 
shown in Figure 6.2, confirming covalent functionalization. 
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Figure 6.2. Representative Raman spectrum (633 nm excitation) showing the starting 
SWCNT fiber 1 and crosslinked product 2. The increase in the D band in 2 is indicative 
of sidewall functionalization of the nanotubes that comprise the fiber. 
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Typically, SWCNT fibers have diameters of 40-200 jam,14 therefore, optical 
microscopy can be used to measure the expansion of the fibers after functionalization. 
As shown in Figure 6.3, the starting SWCNT fiber average diameter is 47 (Lim (Figure 
6.3A). When this fiber is expanded in oleum and then is plunged back into water, it 
coalesces back to its near-original average diameter of 47 |im (Figure 6.3B). After oleum 
intercalation and functionalization, this SWCNT fiber retains an average diameter of 65 
|o.m (Figure 6.3C), an increase of approximately 30%. These functionalized fibers remain 
expanded and they do not fall apart even at temperatures as high as 800 °C under 
hydrogen or argon. Though 300-500 °C is typically sufficient to remove all aryl pendants 
from a SWCNT via evolution of an aryl radical,20 in this case, the chelation effect and the 
restricted environments deter loss of the addend from the inner cavities. Desulfonation is 
expected to occur upon heating to these temperatures. However, the cross-linking 
prevents collapse of the scaffold so there is no energy assist from recovery of the van der 
Waals interaction, thus making it even more difficult to drive out the sulfuric acid solvent. 
Figure 6.3. Optical micrographs of a SWCNT fiber before and after functionalization 
with methylenedianiline to build the 3-D nanoengineered structure. A) SWCNT fiber 
before functionalization; average diameter = 47 (im. B) The same SWCNT fiber after 
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expansion in oleum and subsequent re-coagulation in water without having been exposed 
to the crosslinking spacer group; average diameter = 47 pm. C) SWCNT fiber after 
expansion in oleum, functionalization using methylenedianiline in the same solvent, and 
then coagulation into water to remove oleum; average diameter = 65 pm. A 30-40% 
increase in the fiber diameter was maintained through the covalent crosslinking of several 
samples. 
The methylenedianiline-functionalized SWCNT fiber (2) was tested for hydrogen 
adsorption capacity at 2 bar and 77 K; surprisingly there was only 0.03 wt% hydrogen 
uptake. At this stage, the expanded SWCNT fibers were "sticky", consistent with trapped 
sulfuric acid in the pores of the SWCNT fibers. Using thermogravimetric analysis (TGA) 
to heat the functionalized SWCNT fibers to 600 °C under argon, a weight loss of 45 wt% 
was detected (Figure 6.4) which is attributed to the evaporation of intercalated sulfuric 
acid with some desulfonation, and loss of the peripheral addends. 
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Figure 6.4. Thermogravimetric analysis of the functionalized SWCNT fibers heated 
under argon at a heating rate of 10 °C/min to 600 °C and held there for 1 h. A weight loss 
of 45 wt% is attributed to the evaporation of intercalated sulfuric acid and desulfonation 
of the crosslinker. 
The liberation of trapped sulfuric acid and/or sulfonic acid moieties was 
confirmed by the observation of sulfur containing species during thermal desorption mass 
spectroscopy. Thereafter, the functionalized SWCNT fibers were heated either under 
vacuum or an inert atmosphere to remove the trapped acid from the scaffolds and allow 
for the adsorption of hydrogen. The expanded structure of the fibers was kept intact after 
heating as determined by optical diameter measurements. Thus, we can conclude that the 
internal crosslinkers are not destroyed during the heating process. 
In order to determine if the trapped sulfuric acid was causing the poor hydrogen 
adsorption, the functionalized fibers were heated to increasingly higher temperatures and 
the BET surface area was recorded as shown in Table 6.1. When the fibers were heated 
to a minimal temperature of 200 °C, the nitrogen BET surface area was found to be 218 
m2/g whereas when the temperature was significantly increased to 800 °C, the surface 
area increased to 515 m /g, an increase of 130 %. The boiling point of sulfuric acid is 
338 °C, and is given as a rough guide. Even when the fibers are baked under vacuum, 
which will lower the temperature for outgassing, it is more than offset by the strong 
physisorption into the sticky sp2-carbon pores of the expanded lattice. Since the rigid 
framework cannot collapse, there is no recovery of the large tube-tube van der Waals 
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interaction and hence there is no energy of collapse that could otherwise drive out the 
acid upon heating. 
Heating Temperature Surface Area 
200 °C 218 m2/g 
350 °C 347 m2/g 
500 °C 396 m2/g 
650 °C 501 m2/g 
800 °C 515 m2/g 
Table 6.1. Heating of functionalized SWCNT fibers produces higher BET surface areas 
after removal of the sulfuric acid. The conditions involve heating the same sample in a 
BET analyzer under vacuum and holding for 12 h, or for temperatures above 350 °C the 
sample was heated in a furnace for 30 min under argon and 10% hydrogen before 
recording the BET surface area. 
Hypothesizing that the crosslinkers could be preventing the escape of trapped acid 
and blocking hydrogen from penetrating into the fibers, we also used a complementary 
functionalization scheme: decreasing the amount of crosslinker and replacing it with a 
small, non-crosslinking moiety produced from 4-chloroaniline in order to keep the 
SWCNT fibers propped open. After a few experiments, the preferred ratio of crosslinker 
(methylenedianiline) to chloroaniline was found to be 1:9 which kept the SWCNT fibers 
propped open to the same degree by optical microscopy measurements but presumably 
created more space for the trapped acid sulfur species to depart the fiber. Through this 
study we found that it is important to retain some crosslinked SWCNT fibers to maintain 
sample integrity. When the SWCNT fibers were functionalized with only 4-chloroaniline, 
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the fibers retained no structural integrity and they could no longer be handled without 
falling apart. This confirms that simply adding functional groups to the walls of the 
SWCNTs does not lead to a stable expanded structure; crosslinking units are essential. 
Decreasing the amount of crosslinker and replacing it with 4-chloroaniline presumably 
allowed for the trapped sulfuric acid to be removed from the fibers, an assumption which 
was confirmed with a higher hydrogen uptake. 
As shown in Figure 6.5, a variety of nanoengineered SWCNT fiber samples were 
prepared using the oleum functionalization chemistry with methylenedianiline and 
chloroaniline (1:9) and hydrogen uptake measurements were performed after the sulfuric 
acid was thermally removed. Although the physical size differences between hydrogen 
and the larger nitrogen are realized, standardization to common BET methods was sought. 
Hydrogen vs. nitrogen size difference is a problem that we share in common with the 
other researchers making and testing nanoporous materials to store hydrogen. But, it 
behooves us to use the same nitrogen-based BET method which is the most widely used 
measurement technique for surface area. Moreover, since we have obtained the hydrogen 
uptake numbers, and they correlate well with the BET-derived data, the comparisons 
between the two gases appear reasonable in this case. 
Plotting the surface area of the samples against the average hydrogen uptake at 2 
bar and 77 K provides a fitted line slope that is significantly steeper than that typically 
found for surface adsorption onto other macroporous carbon materials. As determined by 
Chahine et al., typical activated carbon materials show a maximum surface excess of ~1 
wt% hydrogen for every 500 m /g of specific surface area at 30-50 bar. Thus for a 
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typically activated carbon with -2500 m2/g, a maximum surface excess of ~5 wt% 
hydrogen is expected according to this so-called "Chahine rule". 
Due to the limited sample quantities produced in these laboratory scale 
experiments (5-20 mg), we needed to use a more accurate volumetric measurement 
system that has an upper pressure limit of ~2 bar (see Experimental Section 6.4.2). 
Hence, the uptake values reported here are expected to be significantly below the 
maximum surface excess values. Yet, on a per specific surface area basis, the sorbed 
amount is nearly a factor of two greater than the amount expected from consideration of 
the Chahine slope (dashed line, Figure 6.5). For comparison purposes, purified laser-
generated SWCNTs which were extensively processed with acid and base washes and 
high temperature treatments in air or CO2 resulted in high surface areas of -800 m /g and 
sorbed ~2 wt% hydrogen at 2 bar and 77 K, and have a maximum surface excess 
hydrogen uptake of ~3 wt%. This suggests that the uptake values reported in Figure 6.5 
should be scaled by an additional 33% to project the saturation surface excess values at 
9 9 
higher pressures. Such an adjustment would make the slope we obtained in Figure 6.5 
substantially steeper than the 1.85 wt % uptake per 500 m /g that we obtained at 2 bar. 
This data demonstrates that when hydrogen is taken up into nm-sized pores that 
are surrounded by sp2-carbon, as in the case for these scaffolded SWCNTs, there is a 
considerable enhancement of hydrogen adsorption. If extrapolated, there would be 3.7 
wt % hydrogen uptake with 1000 m2/g and 7.4 wt% hydrogen uptake at 2000 m2/g using 
only 2 bar of pressure. Thus it appears that the key to designing a carbon-based hydrogen 
adsorption medium is not only relying on the surface area of the material but also on 
engineering the pore size to be optimal for hydrogen adsorption. 
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In order to assess the role of the 7i-electron cloud of the SWCNT fibers in storing 
23 
hydrogen on the scaffold, we heavily functionalized the fibers with fluorine (26 
atomic % fluorine by X-ray photoelectron spectroscopy, XPS) causing the 7r-electron 
cloud to be significantly destroyed. The resulting fibers have a high specific surface area 
of 883 m2/g but the hydrogen adsorption of 2.1 wt % (diamond in Figure 6.5) falls below 
the line derived from the data in the present work, but close to the Chahine slope. 
Therefore, preserving the sp -carbon structure of the individual SWCNT in the fibers 
appears important for the higher storage of hydrogen. 
Our samples are not at all identical. Each expanded scaffold was deliberately 
prepared from a different batch of spun SWCNT fiber; the amount of expansion also 
varied, the functionalization was changed, and the total hydrogen wt% uptake exhibits a 
wide range. Yet, in spite of these many variations, the data points are all remarkably 
consistent in their proximity to the enhanced slope illustrated in Figure 6.5. The one 
thing that is consistent throughout all of these measurements is that the hydrogen is 
enveloped in a 7t-cloud of sp -carbon. But when the Tt-cloud was disrupted as shown by 
the addition of fluorine to the scaffold that converts a large portion of the sp2-carbons to 
sp3-carbons, the enhancement was lost along with the rc-cloud for this control experiment. 
Similar enhanced uptake of hydrogen was reported by the Iijima group15 for isolated 
pockets of hydrogen surrounded by sp -carbons in adjacent nanohorns, and in 
9 4 
calculations by the Seifert and Heine. ' Likewise, the Eklund group observed over a 
factor of two enhancement in binding energy for those hydrogen molecules fully 
intercalated into a carbon nanotube bundle compared to those bound to just a single 
surface of a SWCNT on the outside of the bundle. Therefore, our observed need for high 
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degrees of sp2-carbon atoms in the nanopores corroborates well with the body of 
literature data on the subject. 
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Figure 6.5. Specific surface area determined from nitrogen BET at 77 K versus hydrogen 
uptake at 77 K and 2 bar. The solid line is the fit and extrapolation obtained from our 
samples (triangles). The dashed line correlates to the maximum surface excess values 
typically observed for macroporous carbons. The diamond is the data point obtained 
with the fluorinated fibers. 
Although the work presented here shows the 3-D scaffolds to be superior in 
comparison to unordered SWCNTs, the challenge of removing trapped sulfuric acid still 
leads us to investigate alternative functionalization methods where we might achieve 
197 
higher surface areas and concomitant hydrogen adsorption weights. Finally, with these 
carbon scaffolds in hand, we are using them as platforms for supporting metals in order to 
enhance the uptake of hydrogen at ambient temperatures. 
6.3 Conclusions 
Scaffolds for the storage of hydrogen have been engineered by swelling SWCNT 
fibers and crosslinking the open structures in place, thereby providing a 3-D 
nanoengineered network. These scaffolds double the amount of hydrogen that can be 
adsorbed, per unit surface area, over typical macroporous carbon frameworks. The 
SWCNT scaffolds have the high density needed to pack hydrogen into a small amount of 
space. Work is underway to synthesize the SWCNT fibers with better pore sizes for the 
storage of hydrogen, with the ultimate goal of developing a hydrogen vehicle fuel tank 
that works near ambient temperature and pressure. 
6.4 Experimental 
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General. Purified SWCNTs were obtained from Rice University HiPco 
laboratory. Oleum was purchased from Alfa Aesar. All other starting compounds were 
purchased from Sigma-Aldrich and used without further purification. Thermogravimetric 
analysis was performed using a heating rate of 10 °C/min under argon. Raman 
spectroscopy was performed on a Renishaw Raman microscope using a 633 nm He-Ne 
laser, taking the median of five scans. Optical microscope images were taken using a 
polarizing optical microscope (Zeiss Axioplan-2). Multipoint BET measurements 
recorded in Table 1 were taken using 11 points on a Quantachrome Autosorb-3b BET 
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surface analyzer using nitrogen at 77 K. The BET surfaces areas recorded on this 
instrument were within 10% of the BET surface areas obtained in the Quantachrome 
Autosorb-1 Physisorption system noted below. XPS analysis was carried out on a PHI 
Quantera SXM Scanning X-ray Microprobe with a pass energy of 26.00 eV, 45° takeoff 
angle and a 100 jxm beam size. Samples were evacuated prior to XPS analysis at room 
temperature and 0.1 mm Hg for 12 h and these conditions were also used before testing 
for uptake. The SWCNT fibers were spun according to the previously described 
protocol.14 CAUTION: Oleum is a dangerous and corrosive liquid. The user should wear 
a lab coat, a rubber smock, thick-lined rubber gloves, eye protection and a full-face 
shield. All reactions should be conducted using a well-ventilated hood with the sash 
down and the reaction mixture behind a secondary transparent shield. Likewise, fluorine 
gas is very reactive and corrosive and it should be used only with approved gas fittings 
28 
and manifold as previously described. 
Hydrogen Uptake Measurements. All hydrogen uptake measurements were 
9 9 
recorded at the National Renewable Energy Laboratory using a home-built system that 
records hydrogen uptake at 2 bar and 77 K while simultaneously providing the ability to 
heat-treat and record BET surface areas on the same sample without exposure to air. The 
critical advance in this instrument which allows high precision measurements on very 
small (< 5 mg) samples is the direct control of the temperature and temperature gradients 
across the various zones using copper collars, graphoil gaskets, and a closed-loop 
thermostatted heat exchanger. The BET specific surface areas were measured using a 
Quantachrome Autosorb-1 Physisorption system that had all of the O-rings sealed, and 
electrically actuated valves were replaced with metal-sealed and pneumatically actuated 
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valved systems to improve thermal stability and accuracy to achieve BET measurements 
on small samples. Temperature programmed desorption was performed using a custom 
built system. 
Methylenedianiline Functionalized SWCNT Fibers (2). SWCNT fibers (49 mg, 
4.1 meq C) and 20 mL of oleum (20% free SO3) were placed in a 150 mL crystallization 
dish on an orbital shaker under nitrogen for 30 min. In a separate vial, 
methylenedianiline (0.813 g, 4.1 mmol) was dissolved in oleum (2 mL) and was then 
carefully added to the fiber suspension. Following the addition of the aniline, sodium 
nitrite (0.57 g, 8.2 mmol) and 2,2'-azobis(2-methylpropionitrile) (AIBN, 0.135 g, 0.82 
mmol) were carefully and sequentially added and the fibers were mixed under nitrogen 
on the orbital shaker for 1 h. After 1 h, the reaction mixture was quenched by carefully 
pouring it over ice. The fibers were then filtered over a polycarbonate membrane (0.22 
pm pores), and the filter cake was rinsed several times with water (30 mL), followed by 
methanol (30 mL) and ether (30 mL). Once rinsed, the fibers were dried under vacuum 
(0.1 mm Hg) for 12 h. The Raman D/G ratio was 0.17. 
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1:9 Methylenedianiline and Chloroaniline Functionalized SWCNT Fibers (3). 
SWCNT fibers (24 mg, 2.0 meq C) and 20 mL of oleum (20% free S03) were placed in a 
150 mL crystallization dish under nitrogen, allowing the oleum to intercalate in the 
SWCNT fibers for 30 min on an orbital shaker. In a separate vial, methylenedianiline 
(0.020 g, 0.1 mmol) and 4-chloroaniline (0.115 g, 0.9 mmol) were dissolved in 2 mL of 
oleum and the mixture was then carefully added to the fibers. Following the addition of 
the anilines, sodium nitrite (0.166 g, 2.4 mmol) and 2,2'-azobis(2-methylpropionitrile) 
(AIBN) (0.039 g, 0.12 mmol) were carefully and sequentially added and the mixture was 
shaken under nitrogen for 1 h. The same workup as above afforded the desired fibers. 
The Raman D/G ratio was 0.47. 
Fluorinated SWNT Fibers (4). A similar procedure for fluorination of SWNCTs 
was followed.23 Briefly, SWCNT fibers (18 mg) were placed in a Monel reactor. The 
apparatus was flushed with helium while the system was slowly heated to 70 °C at which 
point fluorine was introduced to the system. Fluorine flowed through the system for 1.5 
h. After this time the flow of fluorine was stopped and the reactor was slowly cooled 
under helium gas flow to room temperature. Once at room temperature, the sample was 
removed and no purification was needed. The Raman D/G ratio was 0.34. XPS: 
C=53.9%, F= 25.9%, 0 = 20.1%. 
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